Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2010

ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN
KINASE SIGNALING AS CANCER THERAPEUTICS
Scott Rothbart
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Medical Pharmacology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/2272

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

© Scott B. Rothbart, 2010
All Rights Reserved

ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN KINASE SIGNALING
AS CANCER THERAPEUTICS
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

by
SCOTT BARRI ROTHBART
Bachelor of Science, University of Florida, 2005
RICHARD G. MORAN, PH.D.
Professor, Department of Pharmacology and Toxicology and the Massey Cancer Center

Virginia Commonwealth University
Richmond, Virginia
September 2010

ii

ACKNOWLEDGEMENTS

It is with sincere gratitude that I recognize those who have supported me throughout my
graduate education and dissertation research. I thank my graduate mentor, Professor Richard G.
Moran for challenging me to critically think both conceptually and analytically. You have
allowed me to explore my curiosities while channeling my enthusiasm into productive
dissertation research. You have also been instrumental in helping me improve my oral and
written communication skills (although I hope to never see 20+ versions of a manuscript again).
Your sideline approach to mentoring in the lab has given me the confidence to work my way
through a scientific question from the experimental design and implementation to the analysis
and presentation. I am grateful for you lending an ear and an opinion in our often-lengthy
discussions over a range of topics, both scientific and personal. I have truly enjoyed my time in
your lab.
I also thank the members of my graduate committee, Drs. Shirley Taylor, Gordon Ginder,
Steve Sawyer, and Dana Selley for contributing to my educational, scientific, and career
development. I am especially grateful to Dr. Shirley Taylor for thoughtfully advising me on
aspects of my dissertation research and for helping me develop my interest in chromatin biology.
I am appreciative of Dr. David Williams and Ninad Walavalkar for enjoyable and educational
discussions as well as technical assistance on protein expression and purification. To my
colleagues, past and present, in the Moran and Taylor labs, thank you for your advice, support,
and friendship. I would especially like to thank Dr. Alexandra Racanelli for contributing
conceptually to portions of my dissertation research. I have great respect for your sense of logic
and scientific reasoning, and I look forward to hearing great things from you as a physicianscientist.
To my family and friends, I thank you all for providing the support system essential to
navigate through the roller coaster ride of graduate school. I thank my parents, David and Janet,
and my brother, Dustin, for being a constant source of relief and inspiration. I would not have
made it this far without your love, laughter, and encouragement. To my wife, Jocelyn, I cannot
begin to describe how thankful I am to you for being by my side throughout this experience. I
know at times it was as challenging for you as it was for me, and I truly appreciate the sacrifices
you have made to see me to this point. You believed in me at times when I did not believe in
myself, and for that, I am grateful. I love you, and I dedicate this dissertation to you.

iii

“Research is to see what everybody else has seen,
and to think what nobody else has thought.”
-

Albert Szent-Györgyi

iv
TABLE OF CONTENTS
Page
Acknowledgements ………………………...……………………………………………….…… ii
List of Tables ……………………………………………………………………………..…….. ix
List of Figures ……………………………...……………………………………………………. x
Abbreviations ……………………………...…………………………………………...……..... xv
Abstract ……………………………………...………………………………………...…….…. xx
Chapter
1

Background and Significance ………………………………………...……...……. 1
Structural, absorptive, and transport characteristics of
naturally occurring folates ………………………………………………...……...…. 1
Folates and one-carbon metabolism ……………………………………………….... 4
Discovery and development of antifolates as cancer therapeutics ...………………... 7
Second-generation antifolates move away from DHFR inhibition ..…………….... 10
Pemetrexed: a multi-targeted antifolate ……...……………………………………. 11
The unusual clinical utility of pemetrexed suggests alternative targets ………...…. 14
Scope of the dissertation …………………………………………………...…….... 16

2

Discovery of AICART as the second folate-dependent target of pemetrexed ... 18
Introduction ……………………………...………………………………………… 18
Thymidylate biosynthesis ……...………………………………………………. 20
De novo purine biosynthesis …………..……………………………………….. 25
Glycinamide ribonucleotide formyltransferase ...………………………………. 28
Aminoimidazolecarboxamide ribonucleotide formyltransferase …………….… 30
Defining the folate-dependent targets of pemetrexed ……………………….…. 35

v
Materials and Methods ……………………………………………..……………… 36
Chemicals and reagents ………………………………………..……………….. 36
Cell culture ………………………………………………………..……………. 38
Cellular end product reversal experiments ………………………..…………… 38
N-Formyl glycinamide ribonucleotide synthesis from 14C-glycine ……...…….. 39
High performance liquid chromatography analysis of ZMP …………..………. 40
Expression and Purification of recombinant human ATIC ………………..…… 42
Total RNA Isolation ………………………………………………..…... 44
cDNA Synthesis ………………………………………………..………. 45
Primer design …………………………………………………..………. 45
Cloning the human ATIC cDNA ……………………………..………... 46
rhATIC Expression …………………………………….......................... 49
rhATIC Purification ………………………………………..................... 49
Production of 10-CHO-H4PteGlu from 5-CHO-H4PteGlu …………..………… 51
AICART activity assay ………………………………….................................... 53
Results ……………………………………………………………………..………. 55
End-product reversal studies define the folate-dependent cellular
targets of antifolates ……………………………………………………..……... 55
Effects of pemetrexed on GART in intact cells …………………………..……. 61
ZMP accumulates to high levels in intact cells following AICART inhibition ... 63
ZMP inhibits cell growth …………………………………………………..…... 69
The dynamics of ZMP accumulation ……………………………………..……. 73
The pemetrexed analog, LCA, is an AICART inhibitor …………….…...…….. 78
Recombinant human AICART is sensitive to substrate inhibition in vitro …..... 80

vi
Discussion ………………………………………………………………..………... 89
Why has AICART inhibition by pemetrexed or its metabolites
not been previously recognized? .......................................................................... 89
Is there biological relevance to the variability of ZMP accumulation
across cell lines? .................................................................................................. 92
Defining the pharmacophore of an AICART inhibitor …………………..…….. 96
Diminution of ZMP following drug washout ……………………………..…… 98
3

Pemetrexed triggers an energy-sensitive metabolic checkpoint
secondary to AICART inhibition …………………………………………….… 101
Introduction ………………………………………………………………………. 101
AMP-activated protein kinase – a cellular energy sensor …………………….. 101
The Energy Charge Hypothesis ………………………………………. 102
Subunit Structure ……………………………………………………... 104
Mechanism of Activation ……………………………………………... 105
Upstream Kinases …………………………………………………….. 106
Downstream targets of AMPK ………………………………………………... 108
PI3K-AKT signaling ………………………………………………….. 108
Signals converging on mTOR ………………………………………… 108
Structural components of mTOR complexes …………………………. 111
Opposing influences of AKT and AMPK on mTORC1 ……………… 113
Signaling downstream of mTORC1 …………………………………... 114
Pharmacological and environmental modulation of AMPK signaling ……….. 118
Materials and Methods …………………………………………………………… 122
Chemicals and reagents ……………………………………………………….. 122
Immunoblotting ……………………………………………………………….. 124

vii
Total Protein Isolation ………………………………………………… 124
SDS-PAGE and Protein Transfer ……………………………………... 124
Antibody Detection …………………………………………………… 125
AMPK activity assays ………………………………………………………… 126
High performance liquid chromatography analysis of ATP ………………….. 128
RNA interference ………………..…………………..…………………..……. 128
Clonogenic survival assays …..…………………..…………..……………….. 130
Assaying for global protein synthesis ……..………………..……………..….. 130
m7GTP-CAP pulldown ..…………………..…………………..……………… 132
Results ……………………………………………………………………………. 133
AMPK is activated by accumulated ZMP following AICART
inhibition by pemetrexed ……………………………………………………... 133
mTORC1 inhibition by pemetrexed is dependent on AMPK activity ……...… 138
LKB1 is not required for AMPK activation in response to pemetrexed ….…... 142
Feedback suppression of AKT is relieved following
pemetrexed-induced mTORC1 inhibition …………………………………….. 152
The effects of AMPK activation by pemetrexed extend beyond
mTORC1 inhibition …………………………………………………………... 159
Discussion ………………………………………………………………………... 167
The requirements for AMPK activation may be cell and substrate-specific …. 168
Antifolate activation of AMPK by ZMP-independent mechanisms ………….. 171
Diverse potential clinical utility of AICART inhibitors ……………………… 173
Diminishing the influence of AKT on AMPK-mediated
mTORC1 inhibition …………………………………………………………... 178
Molecular genetics of tumor sensitivity to AMPK activation ………………... 180

viii

4

Differential therapeutic outcomes of folate-dependent target inhibition
by pemetrexed …………………………………………………………………… 182
Introduction ………………………………………………………………………. 182
The cytotoxicity associated with TS inhibition is apoptotic
and S-phase-specific ..………………………………………………………… 182
Therapeutic effects of AICART inhibition …………………………………… 183
Materials and Methods …………………………………………………………… 186
Chemicals and reagents ……………………………………………………….. 186
DNA content/Cell Cycle Analysis ……………………………………………. 186
Acridine Orange Staining …………………………………………………….. 186
Results ……………………………………………………………………………. 188
Pemetrexed is both a cytotoxic and antiproliferative therapeutic agent ……… 188
The cytotoxicity of pemetrexed requires both an
apoptotic and autophagic response …………………………………………… 194
Discussion ………………………………………………………………………... 202
A complex interplay between autophagy and apoptosis ……………………… 202
Comparison of pemetrexed and raltitrexed illustrates the
significance of a secondary target …………………………………………….. 205
Does p53 influence the therapeutic outcome of AICART inhibition? ……….. 206

5

Perspectives ……………………………………………………………………… 210

Literature Cited ……………………………………………………………………………….. 215
Vita ……………………………………………………………………………………………. 246

ix
LIST OF TABLES
Page
Table 1-1

Inhibitory activity of pemetrexed and its polyglutamates against
folate-dependent enzymes ……………………………………………..…….. 13

Table 2-1

Kinetic constants for several recombinant human enzymes
of folate metabolism …………………………………………………..…….. 22

Table 2-2

ZMP accumulates in human skin fibroblasts devoid of AICART activity ….. 64

Table 2-3

ZMP accumulates in human carcinoma cell lines following exposure to
pemetrexed and thymidine ………………………………………………..…. 69

Table 3-1

Direct targets of AMP-activated protein kinase ……………………………. 109

Table 3-2

Antibody sources and conditions for immunoblotting ……………………... 123

x
LIST OF FIGURES
Page
Figure 1-1

Chemical structures of folic acid and tetrahydrofolate ……………………...... 2

Figure 1-2

Key therapeutic targets of folate metabolism .………………………………... 6

Figure 1-3

Classes of clinically evaluated antifolates and representative compounds
from each class ………………………………………………………………... 9

Figure 2-1

The cytotoxicity of the thymidylate synthase inhibitor raltitrexed is
reversed by addition of thymidine to cell culture media .……………………. 19

Figure 2-2

Crystal structures of thymidylate synthase with fluoropyrimidine (left)
and antifolate (right) inhibitors bound illustrate differences in
modes of inhibition …………...….…………………………………………... 24

Figure 2-3

The folate-dependent steps of de novo purine biosynthesis and
mechanisms of salvage ……...………………………………...…………….. 27

Figure 2-4

Crystal structure of E. coli GART with 5-deaza-H4PteGlu and GAR
supports SAR studies with recombinant mouse GART …………..…………. 31

Figure 2-5

Crystal structure of human AICART/IMPCH bound to ZMP and a
sulfonyl-containing antifolate illustrates that the AICART active site
is formed by homodimerization …………………………………………....... 34

Figure 2-6

FGAR accumulates in CEM cells treated with azaserine .…………………... 41

Figure 2-7

Identification and quantification of ZMP by HPLC ……………………….... 43

Figure 2-8

Recombinant human AICART expression and purification …………..…….. 52

Figure 2-9

Reversal of CEM cell growth inhibition by AICA suggests that the
second target of pemetrexed is AICART, not GART ………………..……… 57

Figure 2-10

Thymidine and hypoxanthine reversal profiles of growth inhibition
induced by pemetrexed in H460 and HCT116 cells ………..............……….. 58

Figure 2-11

HCT116 growth inhibition in the presence of pemetrexed and thymidine is not
rescued any further by increasing the thymidine (A) or hypoxanthine (B)
concentration .……………………..………………………………….……… 60

xi
Figure 2-12

14

Figure 2-13

ZMP accumulation in CEM cells indicates that pemetrexed is
an inhibitor of AICART .………………..…………………………………… 65

Figure 2-14

ZMP does not accumulate in response to methotrexate treatment
in HCT116 cells ………………..…………………...……………………….. 67

Figure 2-15

Expansion of the ZMP pool by AICA in pemetrexed-treated CEM cells
indicates an AICART block……………………………………...…………... 68

Figure 2-16

The secondary growth-inhibitory mechanism of pemetrexed
correlates with ZMP accumulation .…………………………………..……... 71

Figure 2-17

ZMP inhibits growth in CEM cells ………...………………………...……… 72

Figure 2-18

Hypoxanthine dose-dependently prevents the accumulation of ZMP
and growth inhibition by pemetrexed in CEM cells ………….......…………. 74

Figure 2-19

ZMP accumulates as a function of time in HCT116 cells
exposed to pemetrexed .………………………………………..…………….. 75

Figure 2-20

Dynamics of ZMP accumulation in HCT116 cells in response to
pemetrexed withdrawal .………………………………………..……………. 77

Figure 2-21

The reversal pattern of CEM cell growth inhibition by LCA suggests
that the primary target is AICART, with a secondary inhibition
of thymidylate synthase .……………………………………………..……… 79

Figure 2-22

ZMP accumulates dose-dependently in CEM cells exposed to LCA ……..… 81

Figure 2-23

Comparing ZMP accumulation across cell lines in response to
pemetrexed and LCA .………...…………..……………………………..…... 82

Figure 2-24

Km determination for 10-CHO-THF on recombinant human AICART ...….. 85

Figure 2-25

10-CHO-THF inhibits AICART activity at high concentrations .……......….. 86

Figure 2-26

Km determination for ZMP on recombinant human AICART .…...……...…. 87

Figure 2-27

Recombinant human AICART is sensitive to substrate inhibition
by ZMP …………………………………………………………………….... 88

Figure 2-28

Proposed kinetic mechanisms for inhibition of AICART by ZMP .…......….. 91

C-FGAR accumulation in CEM cells suggests that pemetrexed is a
weak inhibitor of GART ……………..………………………..…………….. 62

xii
Figure 2-29

ZMP (500 µM) does not increase the potency of pemetrexed
as an AICART inhibitor .……..……………………………………………… 93

Figure 3-1

Cellular signaling upstream and downstream of mTORC1
and mTORC2 …………………………………………………………...….. 103

Figure 3-2

The most commonly mutated genes upstream of mTORC1 in
human non-small cell lung cancer cell lines .………….…...………………. 107

Figure 3-3

Regulation of CAP-dependent translation initiation .……..………..………. 116

Figure 3-4

Identification and quantification of ATP by HPLC .…..………………..….. 129

Figure 3-5

AICART knockdown in HCT116 cells .……………………………………. 131

Figure 3-6

Pemetrexed induces AMPKα phosphorylation and activity
in HCT116 cells …………………………………………………………..... 134

Figure 3-7

ATP is not depleted in CEM cells treated with pemetrexed .…...…….……. 136

Figure 3-8

AICART knockdown recapitulates effects of pemetrexed
in HCT116 cells .……….......…………………………………………….… 137

Figure 3-9

Downstream effects of pemetrexed-induced activation of AMPK
on mTORC1 signaling …………………………...………………………… 139

Figure 3-10

Inhibition of mTORC1 signaling by pemetrexed is dependent
on AMPK activity .…………………………………………………………. 140

Figure 3-11

Pemetrexed inhibits mTORC1 through activation of AMPKα1
in HCT116 cells .……………….…….…………………………………….. 141

Figure 3-12

Sensitivity of carcinoma cells to pemetrexed with thymidine
and to rapamycin …..……………………………………………………….. 143

Figure 3-13

Sensitivity of LKB1-null cell lines to growth inhibition
by pemetrexed .……………………………………………………………... 145

Figure 3-14

Signaling downstream of mTORC1 is inhibited in LKB1-null cells
following pemetrexed treatment .…………………………………………... 146

Figure 3-15

Inhibition of mTORC1 signaling by pemetrexed is dependent on
AMPK activity, even in the absence of LKB1 ……..……………………….. 148

Figure 3-16

Differential effects of AMPKα T172 phosphorylation in response to
pemetrexed across cell lines……………………………………….………... 149

xiii

Figure 3-17

Differential effects on acetyl-CoA carboxylase S-79 phosphorylation
in response to pemetrexed across cell lines .……………………………….. 150

Figure 3-18

Phosphorylation of eukaryotic elongation factor 2 at T56 is augmented in
response to pemetrexed in cells of wild type (HCT116) and –null
(H460, HELA) LKB1 status following pemetrexed treatment …………….. 151

Figure 3-19

ZMP accumulation and AMPK activation as a function of time in
HCT116 cells exposed to pemetrexed .………….…………………………. 155

Figure 3-20

Repression of mTORC1 signaling to 4E-BP1 is maintained over time
following pemetrexed treatment in HCT116 cells .………………………… 156

Figure 3-21

Repression of mTORC1 signaling to S6K1 partially recovers over time
following pemetrexed treatment in HCT116 and H460 cells .……………... 157

Figure 3-22

Recovery of mTORC1 signaling in response to pemetrexed is concurrent
with release of feedback inhibition of PI3K and AKT
in HCT116 cells .………………………………………………………..….. 158

Figure 3-23

AKT reactivation mediates recovery of mTORC1 signaling after pemetrexed
treatment in HCT116 cells .………………………………………………… 160

Figure 3-24

The cytotoxicity of pemetrexed in HCT116 cells is enhanced
in combination with GSK690693 .…………………………………………. 161

Figure 3-25

The cytotoxicity of pemetrexed in (A) HCT116 and (B) H460 is enhanced
in combination with OSU-03012 .………………………………………….. 162

Figure 3-26

Global translational effects of pemetrexed and rapamycin
in HCT116 cells ……………………………………………………………. 164

Figure 3-27

De novo lipid and cholesterol biosynthesis .………………………………... 176

Figure 3-28

Pemetrexed inhibits nuclear localization of the SREBP-1
transcription factor …………………………………………………………. 177

Figure 4-1

The cytotoxic effect of pemetrexed in HCT116 cells is rescued
in the presence of thymidine and a preformed purine .……………………... 189

Figure 4-2

The cytotoxic effect of pemetrexed in H460 cells is rescued
in the presence of thymidine and a preformed purine .……………………... 190

xiv
Figure 4-3

The effect of pemetrexed in the presence of thymidine is antiproliferative
to HCT116 cells ……………………………………………………………. 191

Figure 4-4

The effect of pemetrexed in the presence of thymidine is antiproliferative
to H460 cells ……………………………………………………………….. 192

Figure 4-5

The antiproliferative effect of LCA is not rescued in the
presence of thymidine ………………………………………….…………... 195

Figure 4-6

Cell cycle analysis of HCT116 cells following pemetrexed exposure
indicates a shift from S-phase accumulation to G1/S arrest in the
presence of thymidine .………………….………………………………….. 196

Figure 4-7

Cell cycle analysis of H460 cells following pemetrexed and thymidine
or LCA exposure indicates a G1/S arrest in these cells ………….....……… 197

Figure 4-8

Acidic vesicles are more prominent in HCT116 and H460 cells treated
with LCA …………………………….…………………………………….. 198

Figure 4-9

LC3-GFP staining pattern following pemetrexed treatment indicates
a commitment to autophagy that is independent of
thymidylate synthase inhibition .……………………………………….…... 200

Figure 4-10

The apoptotic effect of pemetrexed is ablated in the
absence of autophagy ………………………………………………………. 201

Figure 4-11

A proposed model for the involvement of apoptosis and autophagy in
the induction of cell death by pemetrexed .…………..…………………….. 204

xv
ABBREVIATIONS
5-FU

5-fluorouracil

α

alpha

ACC

acetyl CoA carboxylase

AdoMet

S-adenosyl-methionine

AICA

5-aminoimidazole-4-carboxamide

AICAR

5-aminoimidazole-4-carboxamide ribonucleoside

AICART/AICARFT

5-amino-4-imidazolecarboxamide ribonucleotide formyltransferase

AK

adenosine kinase

AKT

protein kinase B

ALL

acute lymphocytic leukemia

AMP

adenosine-5’-monophosphate

AMPK

AMP-activated protein kinase

APRT

adenine phosphoribosyltransferase

ATP

adenosine-5’-triphosphate

AU

absorbance units

β

beta

BSA

bovine serum albumin

=CH+

methenyl

=CH2

methylene

CH3

methyl

CHO

formyl

cm

centimeter

xvi
DDATHF

5,10-dideaza-H4PteGlu, lometrexol

Deptor

DEP-domain-containing mTOR-interacting protein

dFBS

dialyzed fetal bovine serum

DHFR

dihydrofolate reductase

DNA

deoxyribonucleic acid

dUMP

2’-deoxy-uridylate, uridylate

dUTP

2’-deoxyuridine-5-triphosphate

eEF2

eukaryotic elongation factor 2

FBS

fetal bovine serum

FGAR

N-formylglycinamide ribonucleotide

fmol

femptomole

FPGS

folylpoly-γ-glutamate synthetase

FPLC

fast protein liquid chromatography

fZMP

5-formylaminoimidazole-4-carboxamide ribonucleotide

g

grams

GAR

Glycinamide ribonucleotide formyltransferase

GART/GARFT

glycinamide ribonucleotide formyltransferase

H2PteGlu

dihydrofolate

H4PteGlu

5,6,7,8-tetrahydrofolate

HGPRT

hypoxanthine-guanine phosphoribosyltransferase

HPLC

high-performance liquid chromatography

Hx

hypoxanthine

IMP

inosine monophosphate

xvii
IMPCH

inosine monophosphate cyclohydrolase

IRS

insulin receptor substrate

kB

kilobase

KD

knockdown

kDa

kilodalton

LCA

Lilly compound AICART inhibitor

M

molar

m

meters

MEF

mouse embryonic fibroblast

MFT

mitochondrial folate transporter

mg

milligram

ml

milliliter

mLST8

mammalian lethal with Sec12 protein 8

mM

millimolar

mmol

millimole

MPM

malignant pleural mesothelioma

MTHFR

5,10-methylene-H4PteGlun reductase

mTOR

mammalian target of rapamycin

MTX

methotrexate, 2-amino-10-methyl-folic acid

nM

nanomolar

nm

nanometers

nmol

nanomole

NSCLC

non-small cell lung cancer

xviii
PABA

para-aminobenzoic acid

PBS

phosphate-buffered saline

PCFT

proton-coupled folate transporter

PI3K

phosphatidylinositol-3-OH kinase

PIP2

phosphatidylinositol-4,5-bisphosphate

PIP3

phosphatidylinositol-3,4,5-triphosphate

pmol

picomole

PPAT

phosphoribosylpyrophosphate amidotransferase

PRAS40

proline-rich AKT substrate 40 kDa

Protor

protein observed with Rictor

PRPP

5-phosphoribosyl-1-pyrophosphate

PTEN

phosphatase and tensin homolog

PTX

pemetrexed, LY231514, Alimta®

PVDF

polyvinylidene fluoride

Raptor

regulatory associated protein of mTOR

RFC

reduced folate carrier

rh

recombinant human

Rictor

rapamycin-insensitive companion of mTOR

RNA

ribonucleic acid

RTK

receptor tyrosine kinase

RTX

raltitrexed, Tomudex®, ZD1694

SAR

structure-activity relationship

SHMT

serine hydroxymethyltransferase

xix
SIN1

stress-activated protein kinase interacting protein

siRNA

small interfering RNA

TCA

trichloroacetic acid

TdR

thymidine

TMP

thymidylate, thymidine-5-monophosphate

TS

thymidylate synthase

TSC

tuberous sclerosis complex

TSC1

hamartin

TSC2

tuberin

TTP

thymidine-5-triphophosphate

µg

microgram

µl

microliter

U.S. FDA

United States Food and Drug Administration

γ

gamma

ZMP

5-aminoimidazole-4-carboxamide ribonucleotide

xx

Abstract
ANTIFOLATE MODULATORS OF AMP-ACTIVATED PROTEIN KINASE SIGNALING
AS CANCER THERAPEUTICS
By Scott Barri Rothbart, B.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2010
Mentor: Richard G. Moran, Ph.D.
Professor, Department of Pharmacology & Toxicology
Since its discovery, it was appreciated that the antifolate pemetrexed had multiple targets
within folate metabolism. This laboratory was instrumental in showing that pemetrexed elicited
its primary action as a thymidylate synthase inhibitor. Unusual for an antifolate, pemetrexed
showed significant clinical activity against malignant pleural mesothelioma and non-small cell
lung cancer. Accordingly, the FDA recently issued first-line approvals for pemetrexed in these
diseases, leading us to question whether the effects of pemetrexed on other folate-dependent
targets could explain this atypical clinical activity of the drug. Studies in this dissertation
showed that in addition to thymidylate synthase inhibition, pemetrexed was also an inhibitor of
aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART), the second folatedependent enzyme of de novo purine synthesis. Consequent of AICART inhibition, pemetrexed
caused robust activation of a key energy-sensing regulatory enzyme of the PI3K-AKT signal
transduction pathway, AMP-activated protein kinase (AMPK). AMPK activation resulted from

xxi
accumulation of the AMP-mimetic, ZMP, behind the AICART block. Constituents of the PI3KAKT cascade are frequently deregulated in human carcinomas, uncoupling nutrient supply from
proliferative capacity. Therefore, interventions that reinstate control over aberrant signaling
along this axis, such as AMPK activation, are of significant cancer therapeutic interest. The
cellular consequences of AMPK activation in response to pemetrexed were assessed.

In

particular, effects on the downstream target of PI3K-AKT signaling, the mammalian target of
rapamycin complex 1 (mTORC1), were studied. Unlike targeted mTORC1 inhibitors, such as
rapamycin and its analogs, pemetrexed-mediated activation of AMPK also signaled to mTORindependent controlling elements of protein and lipid synthesis, highlighting additional benefits
of AMPK activating agents that extend beyond effects on mTOR signaling. We therefore
propose that the unusual activity of pemetrexed in mesothelioma and non-small cell lung cancer
is due in part to effects on signaling processes downstream of AMPK activation. These findings
present a novel approach to AMPK activation secondary to an AICART block, define
pemetrexed as a molecularly targeted agent, and ultimately extend the utility of antifolates
beyond their traditional function.

CHAPTER 1
BACKGROUND AND SIGNIFICANCE

Structural, absorptive, and transport characteristics of naturally occurring folates
Antifolates have been a mainstay in cancer therapeutic regimens for over 50 years. Much
of our understanding of the cellular metabolism and utilization of dietary folates can be credited
to basic and clinical research on their synthetic antagonists. Folates were first discovered in the
early 1940’s as the factors in yeast and liver extracts responsible for reversing macrocytic anemia
in pregnant women (1). The generalized chemical structure of the folate molecule was deduced
from the isolation and crystallization of folic acid from spinach (2). Folic acid, the most
oxidized form of folate, consists of three distinct moieties. A 2-amino-4-hydroxy-pteridine ring
is conjugated by a methylene group to para-aminobenzoic acid (PABA), which forms a peptide
linkage to glutamic acid (Fig 1-1). While folic acid is the most stable form of the folate
molecule, modified forms are utilized for cellular metabolism. These folic acid metabolites
(herein referred to collectively as “folates”) are reduced to di or tetrahydro forms in the 5,6 and
7,8 positions of the pteridine ring, respectively. The N5 or N10 nitrogen atoms of 5,6,7,8tetrahydrofolate (H4PteGlu) are routinely conjugated to methyl (CH3), formyl (CHO), methenyl
(=CH+), or methylene (=CH2) groups. Additional glutamate residues are processively added to
the γ-carboxyl tail by the enzyme folylpoly-γ-glutamate synthetase (FPGS), forming H4PteGlun(29)

(Fig 1-1) (3, 4).
Although humans can synthesize all components of the folate molecule individually, they

do not produce the dihydropteroate synthase enzyme activity essential to conjugate the pteridine
and PABA ring (pteroic acid), or the dihydrofolate synthetase enzyme activity usually associated
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Figure 1-1. Chemical structures of folic acid and tetrahydrofolate.
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with bacterial FPGS. Thus, humans obtain folates solely from dietary and supplemental sources.
These hydrophilic B9 vitamins are abundant in raw green vegetables, peanuts, legumes, citrus
fruits, and liver. However, most folates are destroyed in the cooking process. Cereals, grains,
and flour have been fortified with folic acid (1.4 µg folate/gram of product) in the United States
since 1998 (5). Folate deficiency in pregnant women is causal of fetal neural tube defects.
Deficiency is also associated with cardiovascular disease and blood disorders such as
megaloblastic anemia, and can manifest as malnourishment or malabsorption from acute and
chronic alcoholism, or secondary to pathologies that affect nutrient absorption by the small
intestine (6).
The most abundant natural forms of folate found in the diet are polyglutamated
derivatives of 5-CH3-H4PteGlu (Figure 1-1). Polyglutamation limits the transport of folates
across membranes. Therefore, γ-glutamyl carboxypeptidases, located in the brush-border of the
proximal jejunum, hydrolyze 5-CH3-H4PteGlu polyglutamates to monoglutamates, optimal for
transport (7). Folate monoglutamates (including folic acid) are transported across the apical
surface of the proximal jejunum in a facilitated manner primarily by the proton-coupled folate
transporter (PCFT). The acidic microenvironment of the small intestine is favorable for PCFTmediated folate transport, which symports folates optimally at pH 5.5 against its concentration
gradient with protons along their concentration gradient into the enterocytes (8, 9). It is during
intestinal uptake that folic acid from fortified foods is reduced to 5-CH3-H4PteGlu. The efflux
mechanism of 5-CH3-H4PteGlu across the basolateral membrane into the vasculature is not
known, but most likely involves facilitated transport by multidrug resistance-associated protein 3
(10).
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Circulating 5-CH3-H4PteGlu is first delivered to the liver, where it can be passed through
to the systemic circulation, secreted into the bile for reabsorption, or can be polyglutamated for
storage. Systemic 5-CH3-H4PteGlu transport into cells is facilitated primarily by the reduced
folate carrier (RFC) in neutral pH microenvironments (11, 12). The driving force for folate
uptake by the RFC is likely the anion gradient generated by retained intracellular organic
phosphates (13). 5-CH3-H4PteGlu can also be transported into cells by folate receptor-mediated
endocytosis, a process less efficient than RFC-mediated transport.
Once inside peripheral cells, folates are rapidly polyglutamated by FPGS (14).
Polyglutamation is essential to trap folates within the cell, and it also increases the affinity of
folates for their target enzymes. Folate polyglutamates are distributed relatively equally between
the cytosol and mitochondria (15). This compartmentalization of cellular folate polyglutamates
is facilitated by cytosolic and mitochondrial FPGS, isoforms synthesized from the same gene
(16, 17). Folates are transported into the mitochondria by the mitochondrial folate transporter
(MFT), a family member of the inner mitochondrial membrane transport carriers that was cloned
and characterized by our lab (18-20). It is likely that folate monoglutamates are the substrates
for mitochondrial transport, suggesting substrate competition between cytosolic FPGS and the
MFT (16, 20).

Folates and one-carbon metabolism
Folate polyglutamates donate and accept single carbon units in transfer reactions for
essential cellular biosynthetic processes. Folate metabolism is compartmentalized between the
cytosol and mitochondria, each of which are supplied with their own pool of folate
polyglutamates as described above (21). In the cytosol, folates are essential for the vitamin B12-
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mediated conversion of homocysteine to methionine.

Methionine is synthesized from the

transfer of a CH3 group of polyglutamated 5-CH3-H4PteGlu to homocysteine by methionine
synthase in a vitamin B12-dependent reaction.

Methionine is conjugated to adenosine by

methionine adenosyltransferase to produce S-adenosyl-methionine (AdoMet), one of the most
frequently used cellular co-substrates.

AdoMet serves as the CH3 donor for DNA, RNA,

neurotransmitter, histone, and other protein methyltransferase reactions (22). AdoMet-dependent
methylation of DNA and histone intimately links folates to processes such as DNA replication,
transcription, and the DNA-damage response through the regulation of chromatin architecture
and organization. AdoMet deficiency, resulting from folate malnourishment or defects in folate
metabolism, has been linked to certain types of cancers, heart disease, Alzheimer’s, Downs
Syndrome, alcoholic liver disease, and developmental disorders such as neural tube defects (23,
24).
Cytosolic folate polyglutamates also serve as cofactors for thymidylate and purines
needed for the biosynthesis of DNA and RNA (Figure 1-2). The methionine synthase reaction
releases H4PteGlun, which is reversibly converted to 5,10-methylene-H4PteGlun by serine
hydroxymethyltransferase (SHMT), interconverting serine and glycine in the process. 5,10methylene-H4PteGlun is formylated to 10-CHO-H4PteGlun. This reaction is likely dependent on
the proliferative needs of the cell, as 2 moles of 10-CHO-H4PteGlun are utilized in de novo
purine synthesis by β-glycinamide ribonucleotide formyltransferase (GART) and 5-amino-4imidazolecarboxamide ribonucleotide formyltransferase (AICART) as carbon donors for
assembly of the purine skeleton. These enzymes are discussed in detail in chapter 2. 10-CHOH4PteGlun can also be hydrolyzed to 5,10-methenyl-H4PteGlun, which is then reduced to 5,10methylene-H4PteGlun. 5,10-methylene-H4PteGlun reductase (MTHFR) irreversibly converts
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Figure 1-2. Key therapeutic targets of folate metabolism. Drug discovery efforts targeting
folate metabolism over the last 20 years emphasized pharmacophores away from the traditional
target of folate metabolism, DHFR, and towards enzymes requisite for thymidylate and purine
biosynthesis. Adapted from Muhsin M et al., 2004. Nat. Rev. Drug Disc. 3(10):825-826 (25)
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5,10-methylene-H4PteGlun back to 5-CH3-H4PteGlun. Thymidylate synthase (TS) also uses 5,10methylene-H4PteGlun as a carbon donor for the reductive methylation of 2’-deoxy-uridylate
(dUMP) to thymidylate (TMP). Dihydrofolate reductase (DHFR) then rapidly converts the
reduced H2PteGlun back to H4PteGlun. The central role of H4PteGlun in the maintenance of
cytosolic one-carbon metabolism can be appreciated from this description (Figure 1-2).
In the mitochondria, folate polyglutamates are essential for glycine and formate
synthesis. Like in the cytosol, H4PteGlun is the essential cofactor for these reactions, and is
converted to 5,10-methylene-H4PteGlun by a second pool of SHMT, interconverting serine and
glycine in the process. Interestingly, cells deficient in mitochondrial folate pools (due to a loss
of MFT function) are dependent on glycine supplementation for survival. Why cytosolic SHMT
cannot supply the glycine necessary for survival is unknown.

Discovery and development of antifolates as cancer therapeutics
Following the discovery that dietary folates could rescue megaloblastic anemia, it was
postulated that acute leukemias might be a disease of folate deficiency due to the morphological
similarities between these megaloblasts and acute leukemic bone marrow blasts (26). However,
this hypothesis was disproven by studies in children showing that folate supplementation
intensified acute leukemias, and that a folate-deficient diet caused remission (27).

It was

therefore proposed by Sidney Farber that these leukemias were dependent on folates for
proliferation and their proliferation rate was limited by the supply of folates.

Farber and

colleagues at Children’s Hospital in Boston obtained folate antagonists synthesized by Lederle
Laboratories, and were for the first time able to induce remission of childhood acute lymphocytic
leukemia (ALL) with one of these folate analogs, aminopterin (4-amino-folic acid) (Figure 1-3)
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(28). Aminopterin was initially used clinically to treat childhood leukemias, but was ultimately
replaced by a close structural analog with a superior therapeutic index, methotrexate (2-amino10-methyl-folic acid) (29).

Almost 50 years later, methotrexate is still used in multidrug

treatment regimens for childhood ALL, and has also proven effective in combating autoimmune
diseases like psoriasis and rheumatoid arthritis (30, 31).
Shortly after the discovery of methotrexate and its analogs, the primary folate-dependent
therapeutic target of this drug was identified to be DHFR (32). Methotrexate is a tight-binding
inhibitor of DHFR (Ki ~ 0.004 nM) (33). DHFR inhibition by methotrexate prevents DNA and
RNA synthesis by preventing the reduction of H2PteGlun to H4PteGlun, the vital precursor for
thymidylate and purine biosynthesis cofactors (Figure 1-2). Additional H4PteGlun-dependent
reactions, such as serine-glycine interconversions and methionine synthesis, are also hindered.
It is now appreciated that, like natural folates, methotrexate is polyglutamated in cells.
(34). This is important, as polyglutamation of methotrexate enhances intracellular retention of
the drug and permits methotrexate to inhibit DHFR for longer periods of time in the face of an
expanding H2PteGlun pool (35). Polyglutamation also increases the spectrum of target inhibition.
While methotrexate polyglutamation does not enhance DHFR inhibition, it does increase the
potency of methotrexate for TS (Ki(glu1) ~ 13,000 nM, Ki(glu5) ~ 47 nM) and AICART (Ki(glu1) ~
143,000 nM, Ki(glu5) ~ 56 nM) (36, 37). However, this enhanced affinity for other folatedependent targets is likely irrelevant to the therapeutics of such a tight-binding DHFR inhibitor,
since the cofactors for these reactions (5,10-methylene-H4PteGlun and 10-CHO-H4PteGlun,
respectively) are already depleted in the absence of H4PteGlun. Significant to cancer therapy,
polyglutamation adds a layer of selectivity to methotrexate, as metabolites accumulate in tumor
cells to a much greater extent than in bone marrow and intestinal tissues (38).
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Figure 1-3. Classes of clinically evaluated antifolates and representative compounds from
each class
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Thousands of methotrexate analogs were synthesized and tested as cancer therapeutics,
with the goal of maintaining the potency for DHFR while enhancing the substrate specificity of
transport and polyglutamation, but limiting the uptake in normal tissues. Most attempts failed, as
methotrexate was indeed a superior drug in this sense.

However, recent studies emerged

showing the analog pralatrexate (10-propargyl-10-deazaaminopterin, Folotyn®) met these criteria
and showed remarkable responses in T-cell lymphomas. This study ultimately led to the U.S.
Food and Drug Administration (FDA) approval of pralatrexate for relapsed peripheral T-cell
lymphoma, a rare form of non-Hodgkins lymphoma, in 2009 (39).

Second-generation antifolates move away from DHFR inhibition
Antifolate drug discovery efforts over the past few decades shifted focus away from the
2,4-diamino-pteridine pharmacophore (targeting DHFR) and towards pharmacophores targeting
the folate-dependent enzymes of thymidylate and purine biosynthesis. The first potent antifolate
thymidylate synthase inhibitor (Ki ~ 3 nM) to come from this effort was CB3717 (40). CB3717
had antitumor activity in breast, ovarian, and liver cancers, but was ultimately withdrawn from
the clinic due to life-threatening renal toxicity from poor solubility at low pH (41, 42).
Keeping this same 5,8-dideazafolate pharmacophore, analogs of CB3717 were
synthesized in an attempt to increase solubility. Raltitrexed (Tomudex®, ZD1694) was identified
from this effort. Raltitrexed is a 2-desamino-2-methyl-N10-substituted-5,8-dideazafolate analog
with a thiophene substitution for the PABA ring (Figure 1-3) (43). Compared to CB3717, these
characteristics not only increased solubility, they made raltitrexed a superior substrate for both
RFC-mediated transport and polyglutamation by FPGS (43). In addition to intracellular trapping
of raltitrexed metabolites, polyglutamation increased the potency of raltitrexed as a TS inhibitor
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by more than 100-fold. Raltitrexed showed significant clinical response rates in colorectal and
breast cancer patients. It is currently in widespread use outside the United States for the
treatment of colorectal cancer, but never gained U.S. FDA approval, as it was not determined
superior to the current standard of care for colorectal cancer, 5-fluorouracil (5-FU, also a TS
inhibitor) with leucovorin (44, 45).
The discovery of the first antifolate inhibitor of de novo purine biosynthesis, 5,10dideaza-H4PteGlu (DDATHF, lometrexol) was somewhat serendipitous (Figure 1-3).

The

structure was originally proposed by G. Peter Beardsley as a potential TS inhibitor, but cell
culture end-product reversal experiments performed in our lab showed it was targeting purine
synthesis (46). Subsequently, enzyme kinetic studies demonstrated that DDATHF was a potent
inhibitor of GART, the first folate-dependent enzyme of de novo purine synthesis (47-49).
DDATHF is transported into cells via the RFC as well as the PCFT, and is a good substrate for
FPGS (46).

Polyglutamates showed potent antitumor activity against a broad spectrum of

carcinomas, but the development of DDATHF was halted in Phase I clinical testing due to
induction of severe thrombocytopenia (50). Importantly, the unfavorable toxicity of DDATHF
was ablated with oral folic acid supplementation (51, 52). These findings set a precedent for
future clinical regimens to include folic acid and vitamin B12, although the protective mechanism
is not fully understood.

Pemetrexed: a multi-targeted antifolate
DDATHF not only faced troubles in the clinic, it was also a medicinal chemist’s
nightmare. Synthesis involved 23 steps, producing a mixture of diastereomers about the 6position, and separation of these isomers resulted in extremely low yields (47). Pemetrexed
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(LY231514, Alimta®) (Figure 1-3) was discovered from synthetic approaches aimed at
eliminating this chirality of carbon 6 of DDATHF, in which a pyrrolopyrimidine ring replaced
the 5-deazapteridine (53).

Surprisingly, this modification also changed the target profile.

Pemetrexed polyglutamates were potent inhibitors of thymidylate synthase both in vitro (Ki ~ 1.3
nM) and in cell culture. However, it was apparent from end-product cell culture reversal
experiments that higher doses of pemetrexed had a significant secondary target, reversible with
the addition of preformed purine (53, 54). This suggested that, like its predecessor DDATHF,
pemetrexed was also targeting de novo purine synthesis. In vitro kinetic analysis of recombinant
human TS, DDATHF, AICART, and mouse GART indicated that most potent purine synthesis
target was GART (Table 1-1) (54). Data presented in Chapter 2 challenges the interpretation of
the results of this study, showing that the de novo purine synthesis cellular target of pemetrexed
is AICART, the second folate-dependent enzyme of this pathway. At the time, the effects of
pemetrexed on purine synthesis by Shih et al were duly noted, but the therapeutic effect of the
drug was attributed primarily to TS inhibition since the drug was 60-times less potent as a GART
inhibitor. Of significance, DHFR inhibition is irrelevant to the therapeutics of a potent TS
inhibitor like pemetrexed, due to depletion of H2PteGlu, the cofactor of the DHFR reaction (55).
Indeed, gene amplification of DHFR did not correlate with resistance to pemetrexed. However,
TS amplification and FPGS mutations are common resistance mechanisms to pemetrexed (56).
Pemetrexed has several favorable properties that contribute to its therapeutic efficacy.
Early studies identified pemetrexed as one of the most efficient substrates for FPGS ever tested,
permitting much greater cellular accumulation and extended target inhibition at lower doses than
other antifolates (53, 56, 57). Pemetrexed uses both the RFC and the PCFT for transport.
Importantly, pemetrexed is transported efficiently by the PCFT in both low and neutral
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Table 1-1. Inhibitory activity of pemetrexed and its polyglutamates against folatedependent enzymes.

Static Ki determinations for pemetrexed and its polyglutamate derivatives against human
thymidylate synthase (rhTS), human dihydrofolate reductase (rhDHFR), mouse GART
(rmGARFT), and human AICART (rhAICARFT). Adapted from Shih C et al, 1997. Cancer
Research. 57(6):1116-1123. (54)
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pH microenvironments, and in tumors with compromised RFC-mediated transport, an inherent
resistance mechanism to antifolates (58-61). It has been suggested that the PCFT is in fact the
primary transporter of pemetrexed in solid tumors, whose extracellular microenvironment is
acidified due to profuse lactic acid secretion, a byproduct of aerobic glycolysis, the so-called
“Warburg Effect” (62).

The unusual clinical utility of pemetrexed suggests alternative targets
Cell-based and clinical studies with pemetrexed have demonstrated a broad spectrum of
activity in carcinomas of the bladder, breast, cervix, colon, gastrointestinal tract, and pancreas
(63, 64). Additionally, pemetrexed is active in malignant pleural mesothelioma (MPM) and nonsmall cell lung cancer (NSCLC), which is atypical for an antifolate and particularly for a
thymidylate synthase inhibitor. MPM is a rare, highly aggressive malignancy of the pleural
cavities lining the lungs and chest wall whose genesis is highly associated with exposure to
asbestos fibers (65). While the U.S. Environmental Protection Agency banned the material use
of asbestos in the early 1970’s, symptoms of MPM typically present up to 50 years following
initial exposure (66).
The median survival following diagnosis of MPM is only 11 months, and the disease is
resistant to most chemotherapeutic regimens, including methotrexate or 5-FU with leucovorin
(67-69). The clinical utility of pemetrexed in MPM was recognized from two studies in regions
of Europe where asbestos exposure was abnormally high, and hence, was enriched for MPM
patients (70, 71). Pemetrexed was combined with cisplatin based on observed synergism in an
MPM cell line, and this combination was the first therapeutic regimen to show a survival benefit
in this disease (64, 72). The U.S. FDA ultimately approved pemetrexed plus cisplatin for first-
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line treatment of MPM patients who are not candidates for surgery based on an increased
survival (16 months overall following diagnosis) compared to cisplatin alone (67). Pemetrexed
(500 mg/m2) is given in a 10-minute infusion once every 21 days. This is likely an effective
treatment modality due to the retention of polyglutamated metabolites in target tissues following
plasma clearance (73). Like its predecessor DDATHF, folic acid and B12 supplementation is
indicated to limit overt toxicity (67).
The recent approvals of pemetrexed for the treatment of NSCLC come at the crossroads
of a global lung cancer epidemic. Over 1 million people are diagnosed with lung cancer each
year, 90% of which are of non-small cell origin (74). Diagnosis is matched by the annual
mortality rate, placing lung cancer as one of the top ten cause of death in the world (75).
Cigarette smoking is the primary risk factor. The World Health Organization classifies lung
cancers by histological subtypes, with 99% of lung carcinomas meeting the criteria of small cell
and non-small cell.

NSCLC is further subdivided among squamous and nonsquamous

adenocarcinoma and large cell histologies (76).
NSCLC is highly progressive, with a median survival of 6 months following diagnosis if
left untreated (77). The clinical success of pemetrexed against MPM suggested it might be
beneficial in treatment regimens for NSCLC. This hypothesis was tested in a large clinical trial
comparing pemetrexed to docetaxel (Taxotere®), which at the time was standard of care for
second-line treatment of NSCLC (78). While the median survival time of patients treated with
pemetrexed and docetaxel were comparable (8.3 vs. 7.9 months median survival, respectively),
pemetrexed was significantly less toxic. This led to 2004 FDA approval of pemetrexed for
second-line treatment of NSCLC.
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On the heels of this study was a head to head trial of pemetrexed in combination with
cisplatin compared to the first-line treatment option, gemcitabine (Gemzar®) with cisplatin (79).
Overall, the survival rates on each arm were identical (10.3 months), but when the statistics were
separated based on histologies, it was clear that pemetrexed/cisplatin was advantageous in the
nonsquamous population, with median survival rates approaching 16 months. Recent studies
have equated elevated TS expression to pemetrexed resistance among squamous histologies,
although our studies would suggest TS-independent genetic factors might be involved (80).
Accordingly, the FDA approved pemetrexed/cisplatin for first-line treatment of nonsquamous
NSCLC in 2008, representing the first antifolate approved as a first-line cancer agent in the U.S.
in over 50 years.
In 2009, pemetrexed became the first drug approved by the FDA for maintenance therapy
of NSCLC (81). This treatment strategy entails administering pemetrexed prior to disease
progression following a platinum-based treatment cycle. Although this limits the treatment-free
period following therapy, the low overt toxicity of pemetrexed combined with best supportive
care has shown significance in survival benefit.

Scope of the dissertation
In an era of cancer biology dominated by the development and trial of molecularly
targeted therapeutics, the clinical future of conventional cytotoxic agents like antifolates remains
uncertain.

However, with the recent first-line approvals of the multi-targeted antifolate

pemetrexed for the treatment of MPM and NSCLC, the 21st century ushered in a new wave of
interest in antifolate research. The response of MPM and NSCLC to pemetrexed was a bit
surprising, as other TS inhibitors (raltitrexed and 5-FU/leucovorin) showed minimal response
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rates in clinical studies (82, 83). This suggested that the TS-independent effects of pemetrexed
might be of therapeutic importance. Studies in this dissertation contributed to the elucidation of
a novel mechanism by which pemetrexed and its analogs elicit their antitumor effects. In
Chapter 2, a series of whole-cell biochemical experiments are presented that identified AICART
as the relevant secondary cellular target of pemetrexed. AICART inhibition caused a striking
accumulation

of

the

purine

synthesis

intermediate

5-aminoimidazole-4-carboxamide

ribonucleotide (ZMP), behind the metabolic block. ZMP signaled to AMPK, mimicking the
activating effects of AMP on this vital cellular energy sensor.

Additionally, effects of

accumulated ZMP on AICART activity were studied in vitro. AMPK activation by pemetrexed
and ensuing downstream consequences are studied in Chapter 3, with particular focus on
signaling through the mTOR pathway. For the first time, we showed that the consequences of
folate-dependent target inhibition extend beyond folate metabolism to gain control of cellular
signaling pathways commonly unrestrained in tumors. In Chapter 4, the therapeutic outcomes of
TS and AICART inhibition by pemetrexed are studied individually. We conclude that while
inhibition of folate-dependent processes remains an essential component of the therapeutics of
pemetrexed, our studies suggest that the full spectrum of antitumor activity elicited by the drug is
in part attributed to effects outside folate metabolism.
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CHAPTER 2
DISCOVERY OF AICART AS THE SECOND FOLATE-DEPENDENT
TARGET OF PEMETREXED

E.C. Taylor and colleagues at Princeton University first synthesized pemetrexed as part
of a series of analogs of the GART inhibitor DDATHF that eliminated the C-6 chiral center
(Figure 1-3) (53). Pemetrexed was selected for further evaluation because studies showed it
potently inhibited (IC50 ~ 30 nM) the growth of both mouse L1210 and human CCRF-CEM
lymphoblastic leukemic cells.

Cell culture end-product reversal experiments have proven

enormously useful in defining the folate-dependent targets of antifolates. For instance, addition
of thymidine (TdR) to cell culture media, converted intracellularly to thymidylate (TMP; the
end-product of the thymidylate synthase reaction) by thymidine kinase, negates the effect of
thymidylate synthase inhibition by providing an exogenous source of the reaction end-product.
Figure 2-1 illustrates this effect, showing that high doses of the pure antifolate thymidylate
synthase inhibitor, raltitrexed, do not inhibit clonogenic survival in the presence of TdR.
Surprisingly, when end-product reversals were applied to pemetrexed, it was clear that
pemetrexed was not behaving like its predecessor DDATHF, but more like the TS inhibitor
raltitrexed. However, TdR rescued the growth inhibitory effect of pemetrexed only at low drug
concentrations (53). Higher concentrations of drug required addition of TdR and a preformed
purine to rescue growth inhibition. This result suggested that pemetrexed (or its polyglutamates)
were primarily targeting thymidylate biosynthesis, but had inhibitory activity against de novo
purine biosynthesis at higher concentrations.
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Figure 2-1. The cytotoxicity of the thymidylate synthase inhibitor raltitrexed is reversed by
addition of thymidine to cell culture media. Clonogenic survival assays were done as
described in the Methods section on H460 cells exposed to the indicated concentrations of
raltitrexed for 48 hours. In rescue conditions, 5.6 µM thymidine was used, and remained present
in culture media throughout the duration of the experiment.
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Thymidylate biosynthesis
Thymidylate synthase (TS) catalyzes the reductive methylation of 2’-deoxyuridine-5monophosphate (dUMP, uridylate) to thymidine-5-monophosphate (TMP, thymidylate) using the
cofactor 5,10-methylene-H4PteGlun as both the one-carbon source and the reducing agent. TMP
serves as the only de novo source of thymidine-5-triphophosphate (TTP) for DNA synthesis,
making TS one of the most evolutionarily conserved enzymes in nature (84). Therefore, TS was
identified early as a target for anticancer therapeutics, and the enzyme kinetics as well as the
consequences of inhibition have been extensively characterized. Steady-state kinetic analysis
indicated that TS follows an ordered-sequential mechanism with the substrate dUMP binding
first, followed by 5,10-methylene-H4PteGlu. H2PteGlu then dissociates, followed by the product
TMP (85, 86). Folate polyglutamates, including antifolates, have been shown to bind TS in the
absence of substrate under phosphate-buffered conditions, suggesting a mixed reaction order
(87). However, this observation is likely influenced by phosphates competing with dUMP for
binding, combined with polyglutamation greatly enhancing the affinity of cofactors for TS (88).
X-ray crystal structures of TS from multiple species in various states of catalysis have
shown dramatic conformational changes associated with cofactor binding that bring the substrate
and cofactor together in a deep pocket protected from solvent where the reaction takes place (8991). A brief description of the reaction mechanism is important to understand how the enzyme is
inhibited pharmacologically. Details of this mechanism are described by C.W. Carreras and
D.V. Santi (92). Catalysis begins by nucleophilic attack of an essential active-site cysteine
(Cys195 of human TS) to C6 of dUMP (93). This converts C5 to a nucleophilic enolate
intermediate that accepts C11 of 5,10-methylene-H4PteGlu, activated by formation of an
iminium ion at N5. With substrate, cofactor, and Cys195 now covalently linked, the proton at
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C5 of the pyrimidine is abstracted, and H4PteGlu is released by β-elimination. The 6-hydrogen
of 5,10-methylene-H4PteGlu is transferred to the methylene intermediate as a hydride (H-1) ion,
and Cys195 is released by β-elimination to give the products TMP and H2PteGlu. The kinetic
constants derived from human TS are listed in Table 2-1 (94).
Inhibition of thymidylate synthase results in “thymineless death,” a term coined by S.S.
Cohen in the early 1950’s from observations made by culturing a thymidine auxotrophic strain of
E. coli in the absence of thymidine (95). In aerated cultures lacking thymidine, cell viability was
diminished but turbidity increased, suggesting unbalanced growth, that is, a condition in which
DNA synthesis was inhibited while RNA and protein synthesis continued. This led to the
conclusion that irreversible DNA lesions were causal of thymineless death (96, 97). It is now
know that the cytotoxic effect of TS inhibition results from both a diminution of TTP as well as
accumulation of 2’-deoxyuridine-5-triphosphate (dUTP) (98). The rise in dUTP is credited to
both accumulation of dUMP behind the TS block combined with saturation of dUTPases that
catabolize dUTP to dUMP. Since DNA polymerases do not show substrate preference for TTP
over dUTP, uracil is misincorporated into newly synthesized DNA at a high rate (99). Uracil
glycosylases recognize and excise uracil, but dUTP is likely misincorporated again during the
repair process. These ineffective cycles of excision and repair ultimately lead to DNA strand
breaks that trigger apoptosis. As one would expect, the cytotoxic effects of TS inhibition are
seen only in S-phase of the cell cycle. It would therefore seem likely that inhibition of S-phase
entry would limit the cytotoxicity of a TS inhibitor. This concept will be revisited in Chapter 4.
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Kinetic constants for TS were derived from Santi DV et al. J. Biol. Chem. 1989. 264(16):91459148. Kinetic constants for GART were derived from Sanghani SP et al. Biochemistry. 1997.
36(34):10506-10516 (49). Kinetic constants for AICART were derived from research presented
in the results section of this chapter.
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The first clinically used thymidylate synthase inhibitor was the pyrimidine analog 5fluorouracil (5-FU). Synthesized by C. Heidelberger and colleagues, it was rationalized that 5FU would produce a preferential toxicity to tumors, because they utilized uracil for nucleic acid
biosynthesis to a greater extent than normal tissues (100). 5-FU is a prodrug, metabolized
intracellularly to FdUMP as well as to FUTP and FdUTP. The latter allows for misincorporation
directly into RNA and DNA, although incorporation of 5-FU into DNA is a rare event. The
incorporation of 5-FU into RNA is a major effect of the drug and has been implicated in toxicity
to the GI tract and hematopoiesis (101). FdUMP competes with dUMP for binding to TS. When
catalysis is initiated by Cys195, an essentially irreversible covalent ternary complex forms
between FdUMP, 5,10-methylene-H4PteGlu, and the enzyme (Figure 2-2) (85). This results in
accumulation of dUMP and the ensuing events described above. The formation of this ternary
complex is likely dependent on binding of 5,10-methylene-H4PteGlu to the enzyme, causing a
conformational shift to bring the substrates into close proximity. Indeed, it has been shown that
5,10-methylene-H4PteGlu is essential to stabilize the ternary complex and prevent FdUMP
dissociation (85, 102). In agreement, the sensitivity of tumors to 5-FU was improved by cotreatment with 5-CHO-H4PteGlu (leucovorin) by enhancing TS inhibition through ternary
complex stabilization (42).

Based on these studies, 5-FU was combined with leucovorin

clinically, and has been a mainstay in the treatment of colorectal cancer in the U.S. for the past
20 years.
Folate-based inhibitors of TS were pursued partly due to the clinical successes of 5-FU
and methotrexate. It was rationalized that a more specific TS effect would be obtained from
folate antagonism than from pyrimidine antagonism, as the off-target and overt toxic effects of 5FU from non-selective DNA and RNA incorporation were well documented (103).
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Figure 2-2. Crystal structures of thymidylate synthase with fluoropyrimidine (left) and
antifolate (right) inhibitors bound illustrate differences in modes of inhibition. E. coli TS
(PDB Code: 1TSN) is depicted on the left in a ternary complex with FdUMP (blue) and 5,10CH2-H4PteGlu (orange). Cys195 is in red. Human TS (PBD Code 1HVY) is depicted on the
right in a closed conformation with raltitrexed (purple) and dUMP (yellow) bound to Cys195
(red). Images generated with PyMOL (www.pymol.org).
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Additionally, on the basis of the ordered-sequential mechanism of TS, accumulation of dUMP
behind a TS block was thought to limit FdUMP ternary complex formation through direct
competition (104). On the contrary, dUMP accumulation was expected to enhance ternary
complex formation with a folate-based inhibitor (103). Furthermore, competition with 5,10methylene-H4PteGlu would likely be irrelevant, as this cofactor is maintained at low intracellular
levels (14).
In an attempt to direct antifolates away from DHFR and towards TS, a series of 10substituted 5,8-dideazafolic acid analogs were synthesized. Carbon substitutions at N5 and N8
of a quinazoline ring and substitutions at the N10 position significantly enhanced TS binding
(40). From this series came raltitrexed, whose cytotoxic effect was abolished by addition of
thymidine to culture medium, indicating a primary effect on TS (105, 106). A crystal structure
of raltitrexed bound to human TS with dUMP suggests antifolate binding locks TS in a closed
conformation (Figure 2-2) (107). Raltitrexed is an efficient substrate for the RFC (Km ~ 2.5 µM)
and FPGS (Km ~ 1.3 µM as a pentaglutamate) (106). Polyglutamates of raltitrexed potently
inhibit TS (Ki ~ 1 nM) (105, 106). While most cell lines were significantly more sensitive to
raltitrexed than 5-FU/Leucovorin, clinical studies evaluated by the U.S. FDA determined
raltitrexed was not superior to 5-FU/Leucovorin in the treatment of colon cancer (44, 45, 105).

De novo purine biosynthesis
Humans rely on salvage and de novo pathways for the synthesis of purines for DNA and
RNA synthesis (Figure 2-3). The precursor of the adenosine and guanosine nucleotides is
inosine monophosphate (IMP). The salvage pathway regenerates IMP from degraded nucleic
acids. The free bases hypoxanthine and guanine are converted to IMP in a single step by
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hypoxanthine-guanine

phosphoribosyltransferase

(HGPRT)

using

5-phosphoribosyl-1-

pyrophosphate (PRPP) as a cofactor. The ribose form of hypoxanthine, inosine, is converted to
IMP by inosine kinase. Additionally, adenine can be converted directly to AMP by adenine
phosphoribosyltransferase (APRT) using PRPP.

Nucleotide salvage is indeed essential to

humans, as deficiency in HGPRT causes accumulation of uric acid, resulting in Lesch-Nyhan
syndrome (108).
Proliferating cells have a high demand for purine nucleotides due to active replication
and transcription. Therefore, they rely heavily on the synthesis of purines de novo, an energyconsuming process consisting of a series of 10 enzymatic reactions in which the inosine skeleton
is assembled stepwise on the backbone of PRPP (Figure 2-3). Salvage of preformed purines like
hypoxanthine or inosine negates the effect of de novo purine synthesis inhibition (Figure 2-3). In
addition to providing the end-products of the pathway, de novo purine synthesis is also subjected
to several mechanisms of feedback inhibition by salvage nucleotide synthesis. First, the de novo
and salvage pathways compete for PRPP, the substrate for the first and committed step of de
novo purine synthesis catalyzed by phosphoribosylpyrophosphate amidotransferase (PPAT).
Therefore, consumption of PRPP by the more energy-efficient process of salvage synthesis
diminishes de novo synthesis (109). Additionally, the activity of PPAT is inhibited by purine
nucleotides IMP, AMP, GMP, and ATP (110). For these reasons, we supplement cell culture
media with serum in which nucleic acids have been removed by dialysis. This limits the salvage
synthesis of purines, allowing us to study the biochemistry and pharmacology of de novo
synthesis that is unrestricted by feedback regulation.

Two reactions of de novo purine

biosynthesis are dependent on the folate cofactor 10-CHO-H4PteGlu (111). Glycinamide
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Figure 2-3. The folate-dependent steps of de novo purine biosynthesis and mechanisms of
salvage. De novo purine biosynthesis consists of ten sequential enzymatic reactions in which 5phosphoribosyl-1-pyrophosphate (PRPP) is converted to inosine monophosphate (IMP). IMP is
converted to AMP and GMP thorough additional enzymatic steps (not shown). The two folatedependent formyl transfer reactions of this pathway are catalyzed by GART and AICART, using
the substrates glycinamide ribonucleotide (GAR) and ZMP respectively to produce
formylglycinamide ribonucleotide (FGAR) and N-formylaminoimidazole-4-carboxamide
ribonucleotide. ZMP can be produced by salvage of its cell-permeable precursors, AICA and
AICAR. Adenine phosphoribosyltransferase (APRT) uses PRPP to convert the free base AICA
to ZMP, and the nucleobase AICAR is phosphorylated to ZMP by adenosine kinase.
Additionally, IMP can be produced by salvage of the preformed purine, hypoxanthine, by
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and the cofactor PRPP.
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ribonucleotide formyltransferase (GART) catalyzes the third step of the de novo pathway, the
conversion of glycinamide ribonucleotide (GAR) to N-formylglycinamide ribonucleotide
(FGAR) (111, 112). Aminoimidazolecarboxamide ribonucleotide formyltransferase (AICART)
catalyzes the penultimate step of de novo purine synthesis, the transfer of a CHO group from 10CHO-H4PteGlu to the exocyclic NH2 group of 5-aminoimidazole-4-carboxamide ribonucleotide
(ZMP) to form 5-formylaminoimidazole-4-carboxamide ribonucleotide (fZMP). Addition of a
de novo pathway intermediate between these steps allows for delineation between inhibition of
these two reactions. 5-aminoimidazole-4-carboxamide (AICA) is converted intracellularly to the
purine synthesis intermediate ZMP by adenine phosphoribosyltransferase (APRT). ZMP is
conveniently positioned downstream of GART, and upstream of AICART. Therefore, addition
of AICA to culture media rescues the effect of GART inhibition, but not AICART inhibition.
This strategy helped define GART as the folate-dependent target of the antifolate DDATHF and,
surprisingly, suggested AICART as the purine synthesis target of pemetrexed. The data from
these pivotal experiments are discussed in detail at the beginning of the results section of this
chapter.

Glycinamide ribonucleotide formyltransferase
Human GART occupies the C-terminal domain of a monomeric trifunctional enzyme that
also catalyzes steps 2 (glycinamide ribonucleotide synthetase, GARS) and 5 (aminoimidazole
ribonucleotide synthetase, AIRS) of de novo purine synthesis (Figure 2-3) (113). Dead-end
inhibitor studies with recombinant human enzyme suggested that GART followed an orderedsequential mechanism with 10-CHO-H4PteGlu binding first (114). However, previous studies in
our lab with recombinant mouse GART provided evidence for a random-sequential binding
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order, since the folate-antagonist DDATHF and the endogenous substrate GAR bound with equal
affinity in the presence or absence of one another (115). This binding mechanism was also
confirmed by stopped-flow kinetics with E. coli GART and is now commonly accepted as the
mode of binding of substrates to bacterial and mammalian GART (116). The kinetic constants
derived from mouse GART are listed in Table 2-1 (115).
Our lab with collaborators at Princeton and Yale Universities discovered that DDATHF
was the first potent antifolate inhibitor of GART (46, 47). DDATHF is an analog of H4PteGlu
with carbon substitutions at the N5 and N10 positions (Figure 1-3). The growth of tumors in
culture and in vivo is strongly inhibited by DDATHF, validating GART as a cancer therapeutic
target (46, 47). DDATHF monoglutamates are tight binding inhibitors of recombinant mouse
GART (Ki ~ 5.6 nM), and polyglutamation enhances the potency by more than more than 10fold (Ki ~ 0.11 nM) (115). Analysis of nucleotide pools in CCRF-CEM cells following a short
DDATHF exposure (4 hours) indicated depletion of both ATP and GTP pools, an effect
sustained for greater than 24 hours (117). Hypoxanthine and AICA both prevented purine
depletion, further indicating GART as the primary target. Thymidylate pools were not depleted
with DDATHF, and growth inhibition of cells in culture was not rescued by addition of
thymidine, collectively indicating that DDATHF was not inhibiting thymidylate synthase (117).
A series of DDATHF analogs were synthesized for structure-activity relationship (SAR)
studies to determine the features of the molecule essential for interaction with GART (47, 48,
115, 118).

From these studies, it was observed that the co-product of the reaction, (6S)-

H4PteGlu was a weak GART inhibitor, and inhibition was competitive with the commonly-used
in vitro substrate 10-CHO-5,8-dideazafolate. Additionally, the 2-amino group on the pteridine
ring was determined to be essential for inhibition, suggesting a role of hydrogen bonding for this
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functional group. The observation that the carbon-substituted N5 derivative of H4PteGlu (5deaza-H4PteGlu) was a potent GART inhibitor suggested this modification alone was enough to
direct the molecule to GART. A subsequent structural study with recombinant E. coli GART
bound to 5-deaza-H4PteGlu and GAR provided a basis for the observations made with SAR
(Figure 2-4) (119). Hydrogen bonding stabilized the modified pteridine ring at positions 1, 2, 4,
and 8. Additionally, the potency increase by carbon-substituting the N5 position was confirmed.
Since there was no ligand-enzyme interaction at this position, it was proposed that desolvating a
NH group would be more costly than for a methylene group.

The crystal structure also

suggested a higher degree of stabilization of the pteridine ring compared to the rest of the
molecule and showed the glutamate moiety protruding towards the surface of the enzyme, not
contributing to binding in the active site.

Aminoimidazolecarboxamide ribonucleotide formyltransferase
Human AICART occupies the C-terminal domain (residues 199-592) of a bifunctional
polypeptide encoded by the ATIC (purH) gene (120). The N-terminal domain (residues 1-198)
encodes inosine monophosphate cyclohydrolase (IMPCH), which catalyzes the final step of de
novo purine synthesis, the cyclization of the inosine ring. While the multi-subunit nature of de
novo purine synthesis enzymes is conserved in eukaryotes, ATIC is the only multi-protein
complex of de novo purine synthesis in bacteria. This evolutionary conservation suggested a
crosstalk between the two enzymes, possibly in the form of substrate channeling. However,
when expressed as individual domains, each reaction proceeded at a rate equivalent to the
catalysis as a fusion protein (120). Moreover, single-turnover kinetics were consistent with a
lack of substrate channeling between the enzymes (121). A more likely explanation for this
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Figure 2-4. Crystal structure of E. coli GART with 5-deaza-H4PteGlu and GAR supports
SAR studies with recombinant mouse GART. The carbons of 5-deaza-H4PteGlu are depicted
in green. Relevant hydrogen bonds with E. coli GART (PDB code 1CDE) are depicted as
dashed lines. GAR is depicted in red. Image generated with PyMOL (www.pymol.org).
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evolutionary conservation was suggested by kinetic analysis of the reaction, in which the formyl
transfer was reversible, highly favoring the reverse reaction producing 10-CHO-H4PteGlu and
ZMP (kcat ~ 6.7 s-1) over the forward reaction producing H4PteGlu and formyl-ZMP (kcat ~ 2.9 s1

) (121). Therefore, having IMPCH in close proximity to cyclize the newly synthesized formyl-

ZMP would drive the AICART reaction towards product formation. The crystal structure of the
avian bifunctional enzyme placed the AICART and IMPCH active sites within 50 Å, and
provided no evidence for substrate channeling (122).
Although GART and AICART both utilize the same folate cofactor and carry out similar
reactions, there are very little mechanistic and structural similarities between these two enzymes.
In contrast to the random-sequential order of the GART reaction, the AICART reaction obeys an
ordered-sequential mechanism, in which 10-CHO-H4PteGlu binds first, followed by ZMP (121,
123). The kinetic constants derived from recombinant human AICART expressed and purified
in this dissertation are listed in Table 2-1. An alignment study with several enzymes that use 10CHO-H4PteGlu revealed a supposedly conserved cofactor binding site (124).

However,

mutagenesis studies of multiple residues in the human GART and AICART domains
corresponding to this conserved site indicated a loss of activity for GART, but no effect on
AICART activity (120).

These findings clearly illustrated that there were fundamental

differences in the active site structures of these two enzymes, and support the argument that a
competitive inhibitor of one formyltransferase would not necessarily be an inhibitor of another.
Indeed, studies in this dissertation and by others have shown that the potent antifolate GART
inhibitor (6R)-DDATHF is not an AICART inhibitor (46, 125, 126). Structural studies of avian
and human AICART/IMPCH illustrated major differences in AICART organization and active
site structure compared to TS, DHFR, and GART. The bifunctional AICART/IMPCH protein
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crystallizes as a homodimer, and a small region rich in β-sheets bridges the AICART and
IMPCH domains (122).

While active sites of IMPCH reside exclusively in each of the

monomers, the active site of AICART was uniquely identified at an interface between
homodimers of the enzyme (Figure 2-5). Prior cross-linking and sedimentation equilibrium
dialysis experiments suggested that dimerization was indeed required for AICART activity, and
the structural data supports this conclusion (127, 128).
A recent report by M. Vincent and colleagues at Universitaires Saint-Luc (Brussels)
identified a young patient with biallelic mutations in the AICART domains of the ATIC gene,
producing inactive enzyme from both alleles (129). This important study set a precedent for our
observations consequent to AICART inhibition by pemetrexed, detailed in this chapter. The
patient was born healthy, but her condition rapidly deteriorated. By 6 months, the patient had
psychomotor delay, partial occipital seizures, congenital blindness, and noticeable dysmorphic
features of the face. A follow-up visit at age 4 identified massive accumulation of the cellpermeable catabolite of ZMP, 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), in the
patient’s urine. Low levels of urinary AICAR have been detected in patients with folate and
vitamin B12 deficiencies, ALL, and HGPRT deficiencies (Lesch-Nyan syndrome) (130, 131).
However, AICAR measured in this patient was 300-fold over levels in control urine, in which
AICAR was undetectable (129). Relevant to our studies, high concentrations of ZMP (as well as
ZDP and ZTP) were measured in erythrocytes from this patient compared to control patients. It
was subsequently determined that AICART activity was lost in cultured fibroblasts from this
patient. Genetic analysis determined that one ATIC allele showed a frameshift in exon 2,
producing an unstable mRNA. This frameshift was also present on one allele from the healthy
mother. The patient’s other ATIC allele had a K426R mutation in exon 13 of the AICART

33

Figure 2-5. Crystal structure of human AICART/IMPCH bound to ZMP and a sulfonylcontaining antifolate illustrates that the AICART active site is formed by
homodimerization. The sulfonyl-containing antifolate BW1540U88UD (white ball and stick)
and ZMP (orange ball and stick) are depicted in the active site of human AICART (PDB Code
1P4R). The crystal structure for AICART is a homodimer, and the active site is at the interface
of monomer 1 (brown) and monomer 2 (green).
Image generated with PyMOL
(www.pymol.org).
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domain, also present in the healthy father. Recombinant AICART with the K426R mutation was
inactive and structural studies with avian AICART suggested this residue was essential for
stability of the tertiary structure (122, 129). Interestingly, the activity of IMPCH in this pediatric
case was 40% of control, consistent with a frameshift in one allele of the ATIC gene, and that
these two fused reactions were indeed independent of one another, as indicated by IMPCH
enzyme activity in the allele with the K426R mutation within the AICART domain (129).

Defining the folate-dependent targets of pemetrexed
Pemetrexed was discovered to be a TS inhibitor serendipitously, as it was synthesized
from a drug discovery program targeting GART (53). An in vitro enzymology study conducted
by scientists at Eli Lilly and Company (Indianapolis, IN) identified the secondary target of
pemetrexed as glycinamide ribonucleotide formyltransferase (GART), the first folate-dependent
enzyme of de novo purine synthesis (54). A summary of their kinetic measurements is presented
in Table 1-1. The reported Ki of GART for pentaglutamates was 65 nM, which was quite weak
compared to DDATHF (Ki ~ 0.3 nM) (49). Interestingly, AICART was concluded from this
study to be a minor target of pemetrexed, with a reported Ki of 260 nM for the pentaglutamate.
The results of this study were taken as definitive, and for the next decade, GART inhibition was
credited as the second mechanism of pemetrexed action. Studies presented in this section begin
by describing a pivotal CCCRF-CEM end-product reversal experiment performed by Dr. Moran
that suggested the second target of pemetrexed was not GART, but AICART. The results that
follow indeed define the elusive secondary target of pemetrexed as the second folate-dependent
enzyme of de novo purine synthesis, AICART.
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MATERIALS AND METHODS
Chemicals and reagents
Pemetrexed (LY231514), (6R)-DDATHF, and LCA (Lilly compound AICART inhibitor)
were obtained from Eli Lilly and Company (Indianapolis, IN). In some experiments, pemetrexed
was purchased from LC Laboratories (#P-7177 Woburn, MA).

3

H-Pemetrexed was obtained

from Eli Lilly and Company at a specific activity of 10.6 Ci/mmol and was purified by HPLC
prior to use as described below.

14

C-glycine was from Moravek Biochemicals (#MC-408 Brea,

CA) and was supplied at a specific activity of 53 mCi/mmol.

(6S)-5-Formyl-5,6,7,8-

tetrahydrofolic acid, calcium salt (#16.221) and (6R,S)-5,10-methenyl-5,6,7,8-tetrahydrofolic
acid chloride (#16.230) were from Schircks Laboratories (Jona, Switzerland). AG1X-8 100-200
mesh anion exchange resin, chloride form ((#140-1443) was from Bio-Rad Laboratories
(Hercules, CA). Safety Solve scintillation cocktail (#111177) was from Research Products
International (Mount Pleasant, IL).

The pET-28A bacterial expression vector (#698643)

originally from Novagen/EMD (Darmstadt, Germany), was a generous gift from Dr. David
Williams (VCU Department of Pathology). The BL21(DE3) Escherichia coli strain (#C600003), TRIzol Reagent (#15596026), SuperScript III First-strand Synthesis System (#18080), highfidelity PCR supermix (#12532016), 1 kB plus molecular mass ladder (#10787018), and T4DNA ligase (#15224-041), TOP-10 chemically competent E. coli (#C4040), and primers were
from Invitrogen (Carlsbad, CA).

Restriction enzymes were from New England Biolabs

(Ipswich, MA). The DNA Gel Extraction Kit (#28704) was from Qiagen (Valencia, VA). The
PureYield Plasmid Midiprep System (#A2492) was from Promega (Madison, WI). 2YT Broth
(#22712020) was from Invitrogen. B-PER Bacterial Protein Extraction Reagent (#78248) was
from Thermo Scientific (Rockford, IL).

Bradford Reagent (#5000006) was from Bio-Rad
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Laboratories. All other reagents were from Fisher Scientific (Waltham, MA) or Sigma Aldrich
(St. Louis, MO) and were of the highest available purity.
Some routinely used stock solutions for rescue experiments were made as follows. A
hypoxanthine stock solution (5 mM) was made by dissolving 0.034 g of hypoxanthine in 47 ml
of 75 mM HCl. The concentration was determined by measuring absorbance at 250 nm from a
1:100 dilution of the stock solution in 1x PBS using an extinction coefficient of 10.6 mM-1 cm-1.
The volume was adjusted accordingly with 75 mM HCl for a final concentration of 5 mM. This
solution was filter-sterilized and was stable at 4°C for at least 1 year. Hypoxanthine typically
was used at a final concentration of 32 µM in rescue experiments unless otherwise noted. Stock
solutions of thymidine (560 µM) were routinely made by dissolving 0.00678 g of thymidine
powder in 48 ml of 1x PBS. The concentration was determined by measuring absorbance at 267
nm from a 1:10 dilution of the stock solution in 1x PBS using an extinction coefficient of 9.7
mM-1 cm-1. The volume was adjusted accordingly with 1x PBS for a final concentration of 560
µM.

This solution was filter-sterilized and was stored in single-use aliquots at -20°C.

Thymidine was typically used at a final concentration of 5.6 µM in rescue experiments unless
otherwise noted. HEPES/MOPS buffer (20 mM HEPES, 10 mM MOPS, pH 7.4) was added to
all cell culture media containing hypoxanthine to buffer the HCl. A 40x stock solution of
HEPES/MOPS was made and stored at 4°C for at least 1 year. 19.06 g HEPES and 8.37 g
MOPS were dissolved in 70 ml 1 N NaOH. The pH was adjusted to 7.4 with approximately 3 ml
of 6 N HCl. The volume was adjusted to 100 ml before being filter-sterilized and stored at 4°C.
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Cell culture
All cell lines were from the American Type Culture Collection (ATCC) (Manassas, VA)
unless otherwise noted.

The CCRF-CEM human lymphoblastic leukemia cell line was

maintained at a density between 105 and 106 cells/ml in RPMI-1640 medium (#11875
Gibco/Invitrogen Carlsbad, CA) supplemented with 10% dialyzed fetal bovine serum (dFBS)
(#100108 Gemini Bio-Products West Sacramento, CA). CEM cells were grown at 37°C with
5% CO2 and given fresh media every 2-3 days. AICART (-/-) human skin fibroblasts were a
generous gift from Marie-Francois Vincent (Universite Catholique de Louvain, Brussels,
Belgium) and were maintained in DMEM (#11995 Gibco/Invitrogen Carlsbad, CA)
supplemented with 15% FBS (#100106 Gemini Bio-Products West Sacramento, CA);
experiments were performed in dFBS. Carcinoma cell lines were also maintained in RPMI-1640
medium supplemented with 10% dFBS and were grown at 37°C with 5% CO2. Carcinoma cell
lines were passaged by seeding in T-75 flasks at a density of 106 cells/dish every 2-3 days.
Passaging of adherent cell lines included washing with 1x phosphate buffered saline (#10010
Gibco/Invitrogen) and trypsinizing for 5 minutes at 37°C with 1x trypsin-EDTA (#15400
Gibco/Invitrogen).

Cellular end product reversal experiments
Adherent cells were seeded at a density of 104 cells/well of a 12-well plate and allowed to
adhere overnight. Conditions were usually plated in triplicate. Fresh media containing drugs
and rescue agents was added the next day. Rescue experiments typically lasted 72 hours, and
fresh media containing drugs and rescue agents was added if cells were incubated for longer
periods of time. Following the incubation period, cells were washed 1x with PBS, trypsinized in
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2ml 1x trypsin-EDTA, and 1 ml of a single-cell suspension was counted electronically using a
Z1 Coulter Particle Counter (Beckman Coulter Brea, CA). Data is presented as percent cell
growth of experimental samples relative to rescue agent controls in the absence of drug.

N-Formyl glycinamide ribonucleotide synthesis from 14C-glycine
The isolation of

14

C-N-Formyl glycinamide ribonucleotide (FGAR) by ion-exchange

chromatography was adapted from a procedure previously published by our laboratory (46).
AG1X-8 100-200 mesh anion exchange resin, chloride form (5 g) was suspended in 25 ml of 4
M formic acid. The slurry was stirred at room temperature for 10 minutes and filtered through
Whatman #1 using a Buchner funnel. The filtered resin then was washed with 60 ml of 4 M
formic acid and 2 L ddH2O to neutralize the resin. The equilibrated resin was then resuspended
in 25 ml of 50 mM formic acid and stored in a glass bottle at room temperature.
Following drug treatments, 7 x 106 CCRF-CEM cells were pelleted by centrifugation at
1,000 rpm for 5 minutes in a 50 ml conical tube, washed 1x with PBS, and resuspended in 2 ml
37°C RPMI 1640 without glutamine or serum. A final concentration of 10 µM azaserine or PBS
was added and the cell suspension was incubated for 30 min at 37°C mixing occasionally.
Glutamine at 2 mM and 0.25 µCi/mL of 14C-glycine were added, and the incubation continued at
37°C for 1 hour. Cells were centrifuged at 3,000 rpm for 10 minutes, washed 1x with cold 1x
PBS, spun at 1,000 rpm for 10 minutes, and resuspended in 2 ml cold 5% (w/v) trichloroacetic
acid. Samples were vortexed vigorously and held on ice for 5 minutes before being centrifuged
at 7,000 rpm for 10 minutes at 4°C to remove debris (macromolecules). The supernatant, which
contained free nucleotides, was transferred to a new tube. The supernatant was extracted twice
with cold diethyl ether by adding an equal volume of ether to each tube, spinning at 1,000 rpm
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for 5 minutes, and discarding the top ether layer as radioactive liquid waste. An aliquot (1.5 ml)
of the aqueous layer was loaded onto plastic Pasteur pipettes columns whose tops were removed,
plugged with glass wool, and packed with a 6-7 cm bed volume of equilibrated AG1X-8 anion
exchange resin. The column was eluted first with 10 ml 0.5 M formic acid, then with 10 ml 4 M
formic acid. Scintillation cocktail (5 ml) was added and 14C was counted for 2 minutes per vial
on a Multi-Purpose Scintillation Counter (#LS 6500 Beckman Coulter). A typical chromatogram
of azaserine-blocked CCRF-CEM cells is depicted Figure 2-6, with the area under fractions 1214 representing labeled FGAR.

High performance liquid chromatography analysis of ZMP
ZMP was quantified from whole-cell acid-soluble extracts using a procedure modified
from Corton et al (132). Typically, 106 cells were plated on 100 mm dishes and allowed to
adhere overnight prior to drug treatment. For suspension cultures, 106 cells were resuspended
directly in media containing drugs. Following drug exposure, cultures were washed 1x with
PBS, scraped, and densities were determined electronically using a Z1 Coulter Particle Counter
(Beckman Coulter). Cells were pelleted by centrifugation at 1,500 rpm for 5 minutes and
resuspended in 5% (w/v) trichloroacetic acid (TCA) at a density of 5,000 cells/µl TCA.
Suspensions were vortexed vigorously and held on ice for 5 minutes before being spun at 7,500
rpm for 10 minutes to remove debris. Supernatants were transferred to new tubes and extracted
twice with an equal volume of cold diethyl ether under a fume hood to remove the acid. The
extraction procedure consisted of centrifugation at 1,500 rpm for 5 minutes and removal of the
upper ether-containing layer. Extracts were passed through a 0.45 µm syringe filter before being
stored at -80°C until ready for HPLC analysis.
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Figure 2-6. FGAR accumulates in CEM cells treated with azaserine. 14C-FGAR was
isolated by anion-exchange chromatography in 1 ml fractions as described in the Methods
section.
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ZMP was analyzed by high-performance liquid chromatography (HPLC) using a SpectraPhysics P4000 pump, UV2000 absorbance reader set to monitor a wavelength of 280 nm, and a
Datajet integrator. A strong anion exchange (SAX) 250 x 2 mm HPLC column (#00G4149B0
Phenomenex Torrance, CA) fitted with a guard column (# KJ04282, #AJ04310 Phenomenex
Torrance, CA) was equilibrated with Buffer A (5 mM NH4H2PO4, pH 2.8) at a flow rate of 0.2
ml/min. Typically, 5 µl acid-soluble extract was injected onto the column in a volume of 300 µl
Buffer A. After passing Buffer A over the column for an additional 2 minutes, ZMP was eluted
from the column using a linear gradient of 100% Buffer A to 100% Buffer B (750 mM
NH4H2PO4, pH 3.9) over 25 minutes at a flow rate of 0.2 ml/min. ZMP had a retention time of
approximately 16 minutes under these conditions (Figure 2-7A). Buffer B was flowed over the
column for an additional 8 minutes following each run to clean the column, and the mobile phase
was returned to Buffer A over the next 10 minutes. Total time from injection to injection was
approximately 45 minutes. To determine ZMP concentration from extracts, results were fitted to
a standard curve generated from synthetic ZMP (Figure 2-7B). The detection limit using this
protocol was approximately 25 pmol ZMP.

Expression and Purification of recombinant human ATIC
The general strategy for expression and purification of recombinant human ATIC was
similar to that of Beardsley et al (120, 123), and entailed cloning the human ATIC cDNA into
the pET-28A bacterial expression vector with BamH1 and Nhe1 restriction sites. The resulting
construct, pET28A_ATIC, now in frame with a N-terminal 6-His affinity purification tag, was
transformed into BL21(DE3) cells for expression. His-tagged ATIC was purified over a nickel
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Figure 2-7. Identification and quantification of ZMP by HPLC. ZMP was analyzed by
HPLC from whole-cell acid soluble extracts as described in the Methods section. (A) A
representative HPLC chromatogram measuring ZMP from CEM cells treated with 500 µM
AICAR. (B) A standard curve was generated with synthetic ZMP.
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affinity column and was polished on a gel filtration column before being stored at -20°C.
Detailed procedures are outlined below.
Total RNA Isolation: Total RNA was extracted from HCT116 cells grown to 75%
confluency on a 100 mm tissue-culture dish with TRIzol Reagent according to the manufacturers
protocol. All materials and reagents used were sterile and RNAse-free. Diethylpyrocarbonate
(DEPC) H2O (0.01% v/v) was prepared by incubating at room temperature overnight and
autoclaving before use. Pipettes were cleaned with RNAse ZAP (Invitrogen), and crosslinked
with a UV Stratalinker 2400 (#400075 Stratgene La Jolla, CA). Cells were placed on ice,
washed 1x with cold PBS, and lysed directly in 2 ml cold TRIzol Reagent. Cells were scraped,
the slurry was transferred to a 14 ml round bottom Falcon tube, and the sample was incubated at
room temperature for 5 minutes. An aliquot (400 µl) of chloroform was added to the sample in
the fume hood. The sample was shaken vigorously for 15 seconds and incubated at room
temperature for 3 minutes. The sample was spun at 7,000 rpm for 15 minutes at 4°C. The
mixture separated into 3 phases. RNA remained exclusively in the aqueous upper phase. This
aqueous phase was transferred to a fresh 14 ml tube and 1 ml isopropanol was added to
precipitate the RNA. This sample was incubated at room temperature for 10 minutes before
being centrifuged at 7,000 rpm for 10 minutes at 4°C. The supernatant was removed, and the
RNA pellet was washed 1x with 75% ethanol in DEPC H2O. The sample was mixed and spun at
7,000 rpm for 5 minutes at 4°C. The ethanol was removed and spun again to remove excess
ethanol. The pellet was resuspended in 200 µl DEPC H2O. For storage purposes, 75 µl
dissolved RNA was suspended in 225 µl 100% ethanol and stored at -80°C. This sample could
then be re-precipitated and solubilized if necessary.

RNA concentration and purity was

determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies
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Wilmington, DE). Pure RNA has an OD260/280 of 2.0. The OD260/230 ratio was also used as a
secondary indicator of RNA purity, and values below the range of 1.8-2.2 indicated the presence
of copurified contaminants. RNA integrity was also determined by resolving RNA on a 1% TAE
agarose gel stained with ethidium bromide at 100 volts for 30 minutes. A distinct banding
pattern and intensity difference between 28s and 18s rRNA indicated that the RNA was intact.
cDNA Synthesis: cDNA was reverse-transcribed from 5 µg of total RNA using the
SuperScript III First-strand Synthesis System from Invitrogen.

SuperScript III Reverse

Transcriptase is similar to the Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV
RT), but has been engineered to diminish RNase H activity and enhance thermal stability. RNA
was mixed with a final concentration of 5 µM oligo(dT)20 primer and 1 mM dNTP mix in a
volume of 10 µl adjusted with DEPC-H2O. The mixture was incubated at 65°C for 5 minutes,
then placed on ice for at least 1 minute. The cDNA synthesis mix was prepared in a separate
tube by combining 2 µl of 10x RT buffer (200 mM Tris-HCl pH 8.4, 500 mM KCl), 4 µl 25 of
mM MgCl2, 2 µl of 0.1 M DTT, 1 µl of RNaseOUT (40 U), and 1 µl of SuperScript III Reverse
Transcriptase (200 U) per reaction.

10 µl of the cDNA synthesis mix was added to the

RNA/primer mixture, gently mixed, and cDNA was reverse-transcribed by incubating at 50°C
for 50 minutes. The reaction was terminated by incubating at 85°C for 5 minutes before being
held on ice. 1 µl of RNase H (2 U) was added to each tube and the tube was incubated for 20
minutes at 37°C. cDNA was stored at -20°C until use.
Primer design: Primers to amplify the 1.77 kilobase human ATIC cDNA were designed
based on the published cDNA sequence (GenBank accession #U37436.1). The sense primer (1)
was designed to incorporate a Nhe1 restriction site (GCTAGC) directly upstream of the first in-
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frame ATG (start codon). The antisense primer (2) was designed to incorporate a BamH1
restriction site (GGATCC) directly downstream of the first in-frame TAG (stop codon).
(1)

5’

GAGTTAAGCTAGCATGGCTCCCGGCCAGC

3’

(2)

5’

CCCATGGATCCTCAGTGGAAGAGCCGAAG

3’

Primers were analyzed using the OligoAnalyzer from Integrated DNA Technologies
(http://www.idtdna.com/analyzer/Applications/OligoAnalyzer). Primers were designed with a
50-60% GC content, melting temperature between 55-75°C, and were 18-30 nucleotides in
length. Six random nucleotides were added upstream of the restriction site on the 5’ to allow for
recognition and digestion by restriction enzymes. Strings of 3 or more G’s, C’s, or T’s were
avoided in the 3’ end, but 1 G or C was placed at the 3’ end to help tack down the primer during
annealing. Lyophilized primers were dissolved in HPLC-grade H2O to stock concentrations of
100 µM and were further diluted in HPLC-grade H20 to a working stock concentration of 7.5 µM
before being added to Polymerase Chain Reactions (PCR). Primers were routinely stored as 100
µM stocks at -20°C as well as 7.5 µM working stocks in single-use aliquots.
Cloning the human ATIC cDNA: The human ATIC open reading frame was amplified by
PCR from HCT116 cDNA using Platinum PCR SuperMix High Fidelity from Invitrogen. This
SuperMix contains anti-Taq DNA polymerase antibody bound to recombinant Taq DNA
polymerase, Mg+2, dNTPs, and Pyrococcus species GB-D thermostable polymerase.

The

polymerase activity of antibody-bound Taq is inhibited, allowing reactions to be set up at room
temperature. Taq polymerase activity is restored by heating the reaction to 94°C (“hot start”)
(133, 134). Pyrococcus species GB-D thermostable polymerase has proofreading ability due to
its 3’ to 5’ exonuclease activity. A typical 25 µl PCR reaction contained 300 nM sense and
antisense primers, 22 µl high-fidelity PCR SuperMix and 1 µl template cDNA. Negative control
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reactions were always ran in the absence of cDNA. Amplifications were carried out on a DNA
Engine Peltier Thermal Cycler (Bio-Rad Laboratories) using the following program: 1) 1 cycle
of 94°C for 4 minutes, 2) 35 cycles of 94°C for 30 seconds, followed by a 57.1-62.8°C annealing
gradient for 30 seconds, and then 72°C for 2 minutes (1 min/kB), 3) 1 cycle of 72°C for 15
minutes, and 4) a 4°C hold. Reactions were ran next to a 1 kB plus molecular mass ladder on a
1% TAE agarose gel stained with ethidium bromide at 100 volts for 30 minutes, and the 1.77 kB
fragment was excised from the gel and purified using a Qiagen Gel Extraction Kit as described
below. This kit contains silica-membrane columns that fit into microcentrifuge tubes, allowing
purification by centrifugation at 17,900 x g in a tabletop centrifuge at room temperature. The
excised agarose slice was dissolved in a high-salt buffer (1 mg/3 µl) at 50°C for 10 minutes,
gently mixing several times. The solubilized DNA was bound to the silica column, washed
twice with an ethanol-containing buffer, and eluted in 30 µl of 10 mM Tris-HCl pH 8.5. DNA
concentration and purity was determined using the NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies). DNA was used only if the OD260/280 was greater than 1.8.
The amplified human ATIC cDNA and pET28A bacterial expression vector were both
sequentially digested with Nhe1 and BamH1 according to the manufacturers double-digest
recommendation (http://www.neb.com/nebecomm/doubledigestcalculator.asp). These restriction
sites were chosen because they are both present in the vector only once (both in the multiple
cloning site), and they are not present in the endogenous human ATIC cDNA sequence. The
doubly digested vector and insert were then gel purified with a Qiagen gel extraction kit as
described above and ligated with T4-DNA Ligase. Ligation reactions were carried out at room
temperature for 2 hours and contained 4 µl of 5x Ligase Reaction Buffer (250 mM Tris-HCl pH
7.6, 50 mM MgCl2, 5 mM ATP, 5 mM DTT, and 25% (w/v) polyethylene-glycol-8000), 30 fmol
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vector, 90 fmol insert, and T4 DNA Ligase (1 U) in a total volume of 20 µl (q.s. with sterile
ddH20).
The ligated construct was transformed into Invitrogen TOP-10 chemically competent E.
coli as described. One vial of TOP-10 chemically competent E. coli was thawed on ice for 10
minutes. An aliquot (2 µl) of the ligated construct was added to the thawed E. coli, the tube was
mixed gently, and placed on ice for 5 minutes before being heat-shocked for 30 seconds at 42°C
without shaking. The tube was returned to ice, and 250 µl of room temperature S.O.C. media
was added. The transformation tube was shaken horizontally (200 rpm) at 37°C for 1 hour. An
aliquot of the transformation (20-100 µl) was plated on kanamycin-resistance plates (50 µg/ml
kanamyin in LB agar) and incubated at 37°C overnight. Colonies were picked, inoculated in 25
ml LB cultures (with 50 µg/ml kanamycin), and shaken at 225 rpm overnight at 37°C. Plasmids
were isolated as described below from the transformed bacteria using the Promega PureYield
Plasmid Midiprep System. This kit uses a silica-membrane column attached to a vacuum
manifold, and is designed to purify 100-200 µg of plasmid DNA from 25-100 ml overnight
bacterial cultures. Overnight cultures were pelleted at 5,000 x g for 10 minutes and resuspended
in a buffer containing 50 mM Tris-HCl pH 7.5, 10 mM EDTA pH 8.0, and 100 µg/ml RNase A.
Cells were lysed in a solution containing 0.2 M NaOH and 1% SDS, mixed 5 times by inversion,
and incubated at room temperature for 3 minutes. A neutralization solution containing 4.09 M
guanidine HCl pH 4.8, 759 mM potassium acetate, and 2.12 M glacial acetic acid was added, and
the sample was mixed by inversion 5 times. The lysate was centrugifed at 15,000 x g for 15
minutes to remove cellular debris. The cleared lysate was decanted onto a silica-membrane
column, and vacuum was applied to bind DNA to the column. The column was washed with 20
ml of a buffer containing 60% ethanol, 60 mM potassium acetate, 8.3 mM Tris-HCl pH 7.5, and
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0.04 mM EDTA pH 8.0. DNA was eluted in 500 µl nuclease-free water, and quantity and
integrity of DNA was measured using the NanoDrop as described above. Clones were screened
for the presence of the insert by digestion with Nhe1 and BamH1, and verified plasmids were
sent for sequencing at the VCU Nucleic Acids Research Core Facility using gene-specific
primers designed to cover every 200 base pairs of the human ATIC cDNA to ensure high-quality
sequencing runs.
rhATIC Expression:

pET28A_ATIC clone 2 was chosen for transformation into

Invitrogen BL21(DE3) E. coli. The transformation procedure was performed as described above
for TOP-10 E. coli. Transformants were plated on kanamycin-resistance LB-agar plates and
grown overnight at 37°C. A streak of colonies was inoculated into a 5 ml 2YT Broth (with 50
µg/ml kanamycin) and grown overnight at 37°C with shaking at 225 rpm. A 1 ml fraction of this
inoculate was mixed with a final concentration of 20% sterile (autoclaved) glycerol, and stored at
-80°C (expression starter cultures could readily be inoculated from ice chips taken off this
plasmid glycerol stock). A 1:50 dilution of an overnight culture was diluted in fresh 2YT Broth
(with 50 µg/ml kanamycin) and grown at 37°C with shaking at 225 rpm until the OD600
measured 0.6 (approximately 1.5 hours). The incubation temperature was dropped to 30°C and
cultures were induced with 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 hours.
Cultures were pelleted by centrifugation at 4,000 rpm for 10 minutes, washed 1x with cold
0.85% NaCl, and frozen at -80°C until purification.
rhATIC Purification:

Thawed cell pellets were lysed in B-PER Bacterial Protein

Extraction Reagent (4 ml/gram of cell pellet) supplemented with 150 mM NaCl. BPER is a
proprietary mild nonionic detergent in 20 mM Tris HCl pH. 7.5. The lysate was incubated at
room temperature for 10 minutes and was spun at 10,000 rpm for 10 minutes to separate soluble
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and insoluble protein. The majority of ATIC protein expressed was present in the insoluble
fraction (Figure 2-8A). Inducing expression at 16°C overnight or expressing in a strain of
bacteria sensitive to IPTG concentration (TunerDE3) did not increase the soluble protein yield.
Scaling my expression cultures up to 1 L did produce a sufficient amount of soluble protein for
my needs, so I luckily did not have to attempt purification from inclusion bodies. Soluble human
ATIC was purified with the help of Dr. David Williams using an AKTA Purifier fast protein
liquid chromatography (FPLC) system (GE Lifesciences Piscataway, NJ) fitted with a P-900
pump, a UV-900 absorbance detector, and a Frac-920 fraction collector. Soluble protein was
loaded onto a nickel-charged purification column. This column was 16 mm in diameter and
contained a 5 ml bed volume of chelating sepharose (#17057501 GE Lifesciences ) charged with
NiCl2.

The loading capacity of the resin was 20 mg/ml bed volume.

The column was

equilibrated with 5 bed volumes of Buffer A (20 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.2 mM
2-mercaptoethanol) at a flow rate of 4 ml/min. Protein absorbance was monitored at 280 nm as
well as 330 nm to detect aggregates. Nonspecific proteins were washed off first with 5 column
volumes of 4% Buffer B (total imidazole = 20 mM) (20 mM Tris-HCl pH 8.0, 150 mM NaCl,
0.2 mM 2-mercaptoethanol, 500 mM imidazole), then with 5 column volumes of 12% Buffer B
(total imidazole = 60 mM), and ATIC was eluted over 5 column volumes with a stepwise
gradient from 20-50% Buffer B (total imidazole = 100-250 mM). Fractions of equivalent
volume from each step of the nickel purification procedure were ran on a 7.5% SDS-PAGE gel
and visualized with a coomassie staining solution (#1610786 Bio-Rad) (Figure 2-8A). Eluted
fractions containing protein (as detected by absorbance at 280 nm) were pooled and loaded onto
a HiLoad 26 mm/60 inch Superdex 75 gel filtration column (#17107001 GE Lifesciences)
equilibrated with Buffer C (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 mM KCl, 5 mM EDTA,
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5 mM DTT) at a flow rate of 1.8 ml/min. The loading capacity of this column was 12 ml.
Absorbance was monitored at 280 nm, and the chromatogram showed one prominent peak
eluting at the correct size (62 kDa) based on a calibration of the column proteins of known size.
The fractions containing a protein of ≈ 62 kDa were pooled and concentrated with an Amicon
Ultra Centrifugal Filter Device with a 3 kDa molecular weight cutoff (#UFC900324 Millipore
Billerica, MA) by centrifuging at 4,000 rpm for 30 minutes. The protein concentration was
determined using the Bradford Reagent according to the manufacturers protocol with BSA as a
standard. An equal volume of glycerol was added to the concentrated protein, which was stored
at -20°C in Buffer C. The yield from a 1 L culture was approximately 5.5 mg of protein. Purity
was greater than 99% as determined by SDS-PAGE and coomassie staining, in which no trace
proteins were detected when 50 µg of purified protein was electrophoresed (Figure 2-8B).

Production of 10-CHO-H4PteGlu from 5-CHO-H4PteGlu
The formyl donor 10-CHO-H4PteGlu was synthesized by acid-catalyzed dehydration of
(6S)-5-CHO-H4PteGlu to form (6R)-5,10-CH+-H4PteGlu. (6R)-5,10-CH+-H4PteGlu was then
hydrolyzed to (6R)-10-CHO-H4PteGlu by a basic pH shift. Because of the instability of 10CHO-H4PteGlu, it was produced on demand from 5-CHO-H4PteGlu for use in enzyme assays.
The synthesis procedure that follows is based on the method of Stover and Schirch (6).
Typically, 500 nmol (6S)-5-CHO-H4PteGlu was dissolved in 0.1 N HCl (pH 1.5) to a
final concentration of 500 µM. The solution was protected from light and rotated at room
temperature.

The formation of (6R)-5,10-CH+-H4PteGlu was detected by monitoring an

increased absorbance spectrophotometrically at 352 nm (ε = 25 mM-1 cm-1 at pH 1.5) after a
1:50 dilution in 0.1 N HCl. Complete conversion was attained after a 2.5-hour incubation. The
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Figure 2-8. Recombinant human AICART expression and purification. Recombinant
human AICART was expressed and purified as described in the Methods section. (A) I:
insoluble, S: soluble, FT: Ni-NTA column flow through, W1: 20 mM imidazole wash, W2: 60
mM imidazole wash, E1: 100 mM imidazole elution, E2: 175 mM imidazole, E3: 250 mM
imidazole. (B) S: soluble, FT: Ni-NTA column flow through, Ni-NTA: pooled nickel column
elutions (100 and 175 mM imidazole), GF: pooled gel filtration elutions.
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solution also had a characteristic yellow tinge. (6R)-5,10-CH+-H4PteGlu is stable in solution for
several months as long as the pH is maintained below 2.0 and the temperature does not exceed
40°C (6).

(6R)-5,10-CH+-H4PteGlu was stoichiometrically converted to (6R)-10-CHO-

H4PteGlu by adding a final concentration of 50 mM 2-mercaptoethanol to the solution and
adjusting the pH to 8.5 with 5N KOH. The pH was adjusted carefully, as the solution was not
buffered. The reaction was again shielded from light and rotated at room temperature. The
reaction was monitored by a decrease in absorption at 352 nm, and was complete by 1 hour. The
solution also no longer had a yellow tinge. (6R)-10-CHO-H4PteGlu was placed on ice, shielded
from light, and was used in assays the same day. In some instances, (6R,6S)-5-CHO-H4PteGlu
or (6R,6S)-5,10-CH+-H4PteGlu powder was used as starting material.

AICART activity assay
The AICART activity assay was based on previously reported methods in which the
formation of H4PteGlu was monitored spectrophotometrically at 298 nm (135, 136). Assays
were performed on a Hewlett Packard UV-VIS 8453 Spectrophotometer with ChemStation data
acquisition software (Agilent Technologies Santa Clara, CA). Reactions were 1 ml in volume
and were done in 1-cm pathlength quartz cuvettes (#14385916A Fisher) at room temperature.
Unless otherwise noted, reactions contained 1x assay buffer (33 mM Tris-HCl pH 7.4, 25 mM
KCl, 5 mM 2-mercaptoethanol), 100 µM (6R)-10-CHO-H4PteGlu, 50 µM ZMP, and 3 µg
enzyme. Blank measurements were taken, and the reactions were started by the addition of
enzyme followed by a quick plunge with a cuvette mixer (# Z370835). Linear absorbance
readings at 298 nm were taken every 2 seconds for 20 seconds, and an initial velocity was
measured as absorbance units (AU)/second. The concentration of H4PteGlu formed in a given
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reaction was calculated using ε = 19.7 mM-1 cm-1 at pH 7.4, the difference in extinction
coefficients for 10-CHO-H4PteGlu plus ZMP and H4PteGlu plus CHO-ZMP (136).

Stock

solutions of pemetrexed were dissolved in 10x assay buffer. Data was analyzed using the
Kinetics module of Sigma Plot v10.0.
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RESULTS
End-product reversal studies define the folate-dependent cellular targets of antifolates
Cell growth reversal experiments performed in our lab using L1210 mouse leukemic cells
(46, 47) and more recently by R.G. Moran in CEM human leukemic cells (Figure 2-9A) defined
(6R)-DDATHF as a GART inhibitor (125). Complete reversal of the growth inhibitory effect of
(6R)-DDATHF in CEM cells indicated that the antifolate was targeting de novo purine
biosynthesis. To determine whether the first (GART) or second (AICART) folate-dependent
enzyme of de novo purine synthesis was inhibited by (6R)-DDATHF, the purine synthesis
intermediate AICA was included in culture medium. The nucleobase AICA is metabolized to
ZMP by APRT and PRPP, introducing a metabolic intermediate between GART and AICART
(Figure 2-3).

Therefore, if the secondary target of pemetrexed were GART, inclusion of

thymidine and AICA in the medium would completely reverse growth inhibition (46, 47),
whereas, if AICART were inhibited, either no effect or a mild exacerbation of growth inhibition
would be expected. The growth inhibitory effect of (6R)-DDATHF was indeed rescued by
AICA, demonstrating that (6R)-DDATHF is primarily a GART inhibitor (Figure 2-9A).
Using this same strategy, R.G. Moran performed cell growth reversal experiments to
define the folate-dependent targets of pemetrexed (Figure 2-9B) (125). The growth of CEM
human leukemic cells was inhibited by pemetrexed at low nM concentrations. Inclusion of
thymidine in the culture medium partially rescued growth inhibition by pemetrexed, shifting the
IC50 approximately 10-fold. Growth inhibition by pemetrexed was not rescued by inclusion of
hypoxanthine, but inclusion of both thymidine and hypoxanthine reversed the growth inhibitory
effects of pemetrexed even at high concentrations. This reversal pattern is in agreement with
previous literature (53, 54) and has been interpreted to mean that pemetrexed is primarily a
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thymidylate synthase inhibitor and also has a second site of action along de novo purine
biosynthesis, only affected at higher drug concentrations. Others have shown that AICA by itself
at 300 µM did not change the potency of pemetrexed against CEM cells (54). This data was
uninformative, as hypoxanthine by itself had no rescue effect on pemetrexed, confirming the
effect on purine synthesis as secondary to thymidylate synthase inhibition. R.G. Moran repeated
this experiment, adding AICA (320 µM) in the presence of thymidine (to alleviate effects of
pemetrexed on thymidylate synthase), which mildly enhanced the growth inhibition by
pemetrexed (Figure 2-9B) (125). The data presented in Figure 2-9B was our first indication that
the purine synthesis target of pemetrexed was most likely AICART, not GART.
CEM cells were chosen for this initial reversal experiment, because it is fairly simple and
reproducible to electronically count cells in suspension. Indeed, most of the initial studies
defining pemetrexed as an AICART inhibitor were done in the CEM background (125).
However, since pemetrexed is clinically indicated for MPM and NSCLC, it was essential to
extend our studies in leukemic cells to carcinomas. The H460 human NSCLC cell line was
subjected to end-product reversal experiments in the presence of pemetrexed (Figure 2-10A).
The low nM growth inhibitory effect of pemetrexed was similar in H460 to that in CEM.
Likewise, inclusion of thymidine shifted the IC50 approximately 10-fold, and inclusion of
thymidine and hypoxanthine completely rescued the growth inhibitory effects of pemetrexed
even at high concentrations (Figure 2-10A). Thus, it was concluded that the growth inhibitory
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Figure 2-9. Reversal of CEM cell growth inhibition by AICA suggests that the second
target of pemetrexed is AICART, not GART. Exponentially growing CEM human leukemic
cells were treated with the indicated concentrations of (A) (6R)-DDATHF or (B) pemetrexed
alone (no add), or in the presence of thymidine (TdR, 5.6 µM), hypoxanthine (Hx, 32 uM),
AICA (320 µM), or a combination of TdR with either Hx or AICA. Drug and modifying agents
were added simultaneously and drug-containing media was changed at 48 hours. Cell growth
was determined after 96 hours by Coulter counting and cell number is expressed relative to
controls without drug. These experiments were performed by RG Moran.
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Figure 2-10. Thymidine and hypoxanthine reversal profiles of growth inhibition induced
by pemetrexed in H460 and HCT116 cells. Exponentially growing (A) H460 human colon
carcinoma cells and (B) HCT116 human non-small cell lung carcinoma cells were treated with
the indicated concentrations of pemetrexed alone (closed circles), or in the presence of 5.6 µM
thymidine (open circles), 32 µM hypoxanthine (closed triangles), or a combination of TdR with
Hx (open triangles). Drug and modifying agents were added simultaneously and cell growth was
determined after 72 hours electronically by Coulter counting. Cell number is expressed relative
to controls without drug. Cultures were set up in triplicate, and error bars are representative of
standard deviation from three biological and two technical replicates.
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effects of pemetrexed in H460 cells, like CEM, were due to a primary inhibition of thymidylate
synthase and secondary inhibition of a purine synthesis intermediate, likely AICART. While
AICA was not included in these reversal experiments, a more extensive analysis of AICART
inhibition by pemetrexed in H460 cells is presented in Chapter 3.
Cell culture reversal studies were not always a completely clear indicator of the growth
inhibitory effects of pemetrexed. A case in point is seen in an experiment on the HCT116 human
colon tumor cell line (Figure 2-10B). The growth of HCT116 cells was potently inhibited by
pemetrexed at low nM concentrations, with an IC50 shifted a half log left of both CEM and
H460. Exposure to drug in the presence of thymidine only shifted the growth inhibitory effect of
pemetrexed approximately 3-fold, suggesting that inhibition of thymidylate synthase contributed
less to the growth inhibitory effect than in CEM and H460. Although the most sensitive folatedependent step in intact HCT116 cells was thymidylate synthase, the secondary target in purine
synthesis was affected even at minimal inhibitory concentrations of pemetrexed. Unlike CEM
and H460 cells, inclusion of thymidine and hypoxanthine did not completely rescue growth
inhibition at higher doses of pemetrexed (Figure 2-10B). This surprising result suggested that
pemetrexed might have targets outside the folate pathway in HCT116 cells. After confirming
this puzzling result with several biological repeats, I questioned whether the lack of complete
reversal was due to insufficient concentration of rescue agents. The concentrations of rescue
agents commonly used in our reversal studies, 5.6 µM thymidine and 32 µM hypoxanthine, were
chosen from optimization studies done in L1210 cells by R.G. Moran (137). The effect of
increasing concentrations of thymidine in HCT116 cultures was tested in the presence of 1 µM
pemetrexed with and without hypoxanthine (Figure 2-11A). Increasing the concentration of
thymidine in the presence of pemetrexed but absence of hypoxanthine had no added rescue effect
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Figure 2-11. HCT116 growth inhibition in the presence of pemetrexed and thymidine is
not rescued any further by increasing the thymidine (A) or hypoxanthine (B)
concentration. Exponentially growing HCT116 human colon carcinoma cells were treated with
the indicated concentrations of pemetrexed (PTX), thymidine (TdR), and/or hypoxanthine (Hx).
Drug and modifying agents were added simultaneously, and cell growth was determined after 72
hours electronically by Coulter counting. Cell number is expressed relative to controls without
drug. Cultures were set up in triplicate, and error bars are representative of standard deviation
from three biological and two technical replicates.
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in HCT116. In the presence of hypoxanthine and pemetrexed, thymidine concentrations above
5.6 µM were growth inhibitory. Therefore, insufficient thymidine could not explain the lack of
complete HCT116 growth rescue in the presence of pemetrexed and hypoxanthine. A similar
experiment was performed with increasing hypoxanthine concentrations, but no additional rescue
effect was observed (Figure 2-11B). Several hypotheses regarding this conundrum in HCT116
cells that integrate data from Chapters 2 and 3 are presented in the Chapter 3 discussion section
of this dissertation.

Effects of pemetrexed on GART in intact cells
In the lab’s original determination of the site of action of (6R)-DDATHF along the de
novo purine biosynthesis pathway, 14C-FGAR accumulation was measured in azaserine-blocked
mouse leukemic cells following drug exposure (46, 138, 139). This method takes advantage of
several key metabolic aspects of the pathway: 1) The enzyme immediately downstream of
GART, FGAR amidotransferase, is sensitive to the glutamine analog azaserine. 2) Glycine is
incorporated into the purine skeleton by the enzyme immediately upstream of GART, GAR
synthetase (Figure 2-3). When cells were incubated with azaserine and subsequently pulselabeled with

14

C-glycine, labeled FGAR accumulated, and could be isolated by ion-exchange

chromatography as described in the Methods section. If GART was inhibited, the incorporation
of radiolabel into FGAR would be prevented. This was demonstrated in intact CEM cells treated
with growth-inhibitory concentrations of (6R)-DDATHF, indicating GART as a primary target
(Figure 2-12). On the contrary, growth inhibitory concentrations of pemetrexed only gradually
inhibited

14

C-FGAR accumulation to an extent that did not reach 50% even at high

concentrations (Figure 2-12). Thus, any effect of pemetrexed on GART appears to be limited
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Figure 2-12. 14C-FGAR accumulation in CEM cells suggests that pemetrexed is a weak
inhibitor of GART. Cells were exposed to the indicated concentrations of either (6R)DDATHF or pemetrexed with 5.6 µM thymidine for 24 hours. Nucleotides were then extracted
from azaserine-blocked cells pulsed with 14C-glycine, and radiolabeled FGAR was separated by
anion-exchange chromatography as described in the Methods section. Results are representative
of pooled averages from two biological replicates.
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and does not correlate with growth inhibition observed in the presence of thymidine (Figure 29B).

ZMP accumulates to high levels in intact cells following AICART inhibition
Inhibition of AICART results in accumulation of the reaction substrate, ZMP, behind the
metabolic block. This was illustrated by measuring ZMP content in human skin fibroblasts from
a patient identified to have AICART inactivating mutations in both alleles of the ATIC gene, the
product of which produces the bifunctional enzyme, AICART and IMP-CH (Table 2-2). These
cells were generously provided to us by Dr. Marie Vincent at Universitaires Saint-Luc
(Brussels). To determine whether ZMP accumulated in these cells, HPLC was used to separate
and quantify ZMP from whole-cell acid-soluble extracts (Figure 2-7). ZMP concentrations were
calculated from a standard curve established with synthetic ZMP. To convert moles of ZMP to
molarity, it was estimated that 106 cells contained 1 µl cell water. ZMP levels in AICART -/human skin fibroblasts were measured to 1.16 mM, greater than 1000-fold above those seen in
the normal human lung fibroblast, WI-38 (Table 2-2). Interestingly, ZMP was only detected in
these cells when grown in media containing dialyzed FBS. ZMP was undetectable when grown
in normal FBS, which often contains free nucleotides as a result of breakage of red blood cells
during the serum isolation process. Therefore, de novo purine synthesis was likely feedback
inhibited by salvage of purine nucleotides in the presence of undialyzed FBS.
Figure 2-13 depicts a seminal experiment of this dissertation, showing that the ZMP pool
in CEM cells expanded at growth inhibitory concentrations of pemetrexed. This indicated that
the de novo purine synthesis target of pemetrexed or its metabolites was AICART, not GART. If
GART inhibition played a role in the secondary effect of pemetrexed, ZMP accumulation would
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Table 2-2. ZMP accumulates in human skin fibroblasts devoid of AICART activity.

Human skin fibroblasts (HSF) from a patient with inactivating mutations in both alleles of the
AICART gene or WI38 human lung fibroblasts were cultured in medium containing dialyzed
fetal bovine serum and harvested for ZMP measurements in mid-log growth as described in the
Methods section. Results are presented as averages ± standard deviations from two biological
and two technical replicates.
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Figure 2-13. ZMP accumulation in CEM cells indicates that pemetrexed is an inhibitor of
AICART. Cells were exposed to the indicated concentrations of either (6R)-DDATHF or
pemetrexed with 5.6 µM thymidine for 48 hours. Nucleotides were then extracted, and ZMP
was separated by HPLC as described in the Methods section. The area units under HPLC peaks
corresponding to ZMP were converted to moles using the equation derived from a standard curve
generated with synthetic ZMP. The cytosolic volume of 106 cells was roughly equivalent to 1 µl
cell water. Error bars are representative of standard deviation from two biological and two
technical replicates.
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not have been measurable, as observed with growth inhibitory concentrations of the GART
inhibitor (6R)-DDATHF (Figure 2-13). Based on in vitro kinetic studies, it had also been
suggested that pemetrexed was a DHFR inhibitor (54). However, if pemetrexed substantially
inhibited DHFR, 10-CHO-H4PteGlu would be diminished, the GART reaction would not
proceed, and thus ZMP would not accumulate because it would not be synthesized. To test this
hypothesis, we measured the effect of the DHFR inhibitor methotrexate on ZMP accumulation in
HCT116 cells (Figure 2-14).

Although it had been previously reported that methotrexate

inhibited AICART as well (36, 37), ZMP was undetectable in methotrexate-treated HCT116
cells (Figure 2-14). While methotrexate likely inhibited AICART in these cells, this experiment
proved that an AICART block would be irrelevant when DHFR was also inhibited and would not
result in ZMP accumulation.
When CEM cells were treated with AICA in the presence of pemetrexed, the
accumulation of ZMP was exacerbated (Figure 2-15). This implied that blockage of de novo
purine synthesis at the AICART step was restricting the flow of intermediates through this
pathway. It is important to note that the concentrations of AICA used in this challenge did not
cause measurable ZMP accumulation in the absence of pemetrexed (Figure 2-15).

This

suggested that AICART was either not rate-limiting to the flow of de novo purine synthesis, as
suggested previously by Wilson et al (140), or that the rate of conversion of AICA to ZMP by
APRT at this concentration was slower than the rate or conversion of ZMP to FAICAR by
AICART (see Figure 2-3).
The massive level of ZMP measured in pemetrexed-treated CEM cells was quite
surprising and impressive, reaching 1-2 mM following 48-hour exposure to pemetrexed and
thymidine. This was over a 1000-fold increase in the steady-state concentration of ZMP in
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Figure 2-14. ZMP does not accumulate in response to methotrexate treatment in HCT116
cells. HCT116 cells were exposed to 1 µM pemetrexed (PTX) or 1 µM methotrexate (MTX) for
24 hours in the presence of 5.6 µM thymidine (TdR). Nucleotides were then extracted, and ZMP
was separated by HPLC as described in the Methods section. Synthetic ZMP (50 pmol) was
added to the samples labeled + ZMP as an internal standard.
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Figure 2-15. Expansion of the ZMP pool by AICA in pemetrexed-treated CEM cells
indicates an AICART block. Exposure to AICA for 48 hours increased the intracellular ZMP
levels in a dose-dependent manner in pemetrexed-treated, but not untreated CEM cells.
Nucleotides were then extracted, and ZMP was separated by HPLC as described in the Methods
section. Error bars are representative of standard deviation from two biological and two
technical replicates.
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untreated CEM cells, which was undetectable by our HPLC method, with an estimated
sensitivity of 20 pmol ZMP. This result was extended to carcinoma cell lines, in which ZMP
measurements were made at a single dose of pemetrexed (1 µM) and a single exposure time (24
hours) (Table 2-3). ZMP accumulated greater than 1000-fold in all cell lines tested, illustrating
the conserved biochemical nature of this effect. The variability in ZMP measurements across
cell lines was unexpected, especially in the TE85 osteosarcoma cell line, which accumulated
12.4 mM ZMP (Table 2-3).

Of note, researchers at Eli Lilly Research Laboratories also

observed a human cell line that accumulated greater than 15 mM ZMP following pemetrexed
treatment (personal communication).

ZMP inhibits cell growth
The question arose as to whether the levels of ZMP measured in pemetrexed-treated
tumor cells was sufficient to contribute to the growth inhibitory effects of the drug. This seemed
likely, as concentrations of pemetrexed that caused dose-dependent accumulation of ZMP
correlated with the thymidine-insensitive growth inhibitory concentrations of pemetrexed in
HCT116 cells (Figure 2-16). To approach this question, we compared the levels of ZMP that
accumulated in pemetrexed-treated cells with the levels of ZMP in cells treated with growthinhibitory concentrations of AICAR, whose growth-suppressive effects are thought to be
exclusively dependent on conversion to ZMP (141, 142). In CEM cells, exposure to growthinhibitory concentrations of AICAR resulted in the accumulation of ZMP that was measured to
be 0.4-2 mM (Figure 2-17A). A re-plot of this data showed a strong correlation (r2 = 0.9563)
between intracellular ZMP concentration and growth inhibition (Figure 2-17B). We therefore
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Table 2-3. ZMP accumulates in human carcinoma cell lines following exposure to
pemetrexed and thymidine.

Exponentially growing cells were treated with 1 µM pemetrexed and 5.6 µM thymidine for 24
hours. ZMP was measured by HPLC from trichloroacetic acid extracts as described in the
Methods section. 1 mM ZMP is equivalent to 1 nmol ZMP in 1 µl cell water. ZMP in all cell
lines tested in the presence of thymidine alone was less than 1 µM. Results are presented as
averages ± standard deviations from three biological replicates.
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Figure 2-16. The secondary growth-inhibitory mechanism of pemetrexed correlates with
ZMP accumulation. HCT116 cells were treated with pemetrexed for 72 hours in the absence
(circles) or presence (open triangles) of thymidine. ZMP (closed triangles) was measured by
HPLC as described in the Methods section following 15 hour exposure to pemetrexed and
thymidine. Measured values of ZMP in nmol/106 cells were converted to mM concentrations in
cell water. Cultures were set up in triplicate, and error bars for cell growth are representative of
standard deviation from three biological and two technical replicates. ZMP measurements are
representative of standard deviation from two biological and two technical replicates.
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Figure 2-17. ZMP inhibits growth in CEM cells. (A) CEM cells were exposed to the
indicated concentrations of AICAR for 24 hours and ZMP (open circles) was analyzed by HPLC.
Cell number (closed circles) was measured by Coulter counting. (B) A strong correlation exists
between cell growth after 24 hours and the intracellular ZMP pool from panel A. Cultures were
set up in triplicate, and error bars for cell growth are representative of standard deviation from
three biological and two technical replicates. ZMP measurements are representative of standard
deviation from two biological and two technical replicates.
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concluded that ZMP levels measured in pemetrexed-treated cells were sufficient to be causal of
the growth inhibition observed in the presence of thymidine.
If ZMP was the growth-inhibitory trigger for pemetrexed in the absence of thymidylate
synthase inhibition, how was it that a preformed purine such as hypoxanthine could then
completely rescue growth inhibition? Rescue of depleted purine nucleotides could not explain
this question, as pemetrexed does not deplete GTP or ATP pools (Figure 3-7) (143). We
performed a dose response of hypoxanthine rescue in CEM cells treated with pemetrexed and
thymidine and made ZMP measurements at each of these doses. Surprisingly, we determined
that hypoxanthine dose-dependently inhibited the accumulation of ZMP in CEM cells, which
correlated with the growth rescue effect (Figure 2-18). We hypothesized that this was due to the
negative feedback effect of intracellular nucleotides made from hypoxanthine on PPAT, the first
and committed step of de novo purine synthesis, switching the cells from de novo synthesis to
purine salvage.

The dynamics of ZMP accumulation
ZMP levels were measured as a function of time in HCT116 cells exposed to 1 µM
pemetrexed (Figure 2-19). A time course of ZMP accumulation following pemetrexed exposure
showed that, after an initial delay of a few hours, ZMP accumulated linearly a rate of 0.2
mM/hour up to 15 hours, and remained elevated at high levels out to 48 hours (Figure 2-19).
Longer time points were not measured, but if the trend of this graph continued, ZMP levels
would remain elevated above 1 mM for greater than 96 hours with continuous exposure to drug.
We hypothesized that the plateau of ZMP accumulation between 15 and 24 hours was a
reflection of an equilibrium being reached whereby the rate of accumulation (corresponding with

73

Figure 2-18. Hypoxanthine dose-dependently prevents the accumulation of ZMP and
growth inhibition by pemetrexed in CEM cells. CEM cells were exposed to 1 µM pemetrexed
and 5.6 µM thymidine for 48 hours with the indicated concentrations of hypoxanthine in the
medium. Cell growth (closed circles) was determined by Coulter counting and ZMP (open
circles) was measured by HPLC. Cultures were set up in triplicate, and error bars for cell growth
are representative of standard deviation from three biological and two technical replicates. ZMP
measurements are representative of standard deviation from two biological and two technical
replicates.
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Figure 2-19. ZMP accumulates as a function of time in HCT116 cells exposed to
pemetrexed. Cells were exposed to 1 µM pemetrexed and 5.6 µM thymidine for 0, 4, 7, 15, 24,
and 48 hours. Acid-soluble extracts were analyzed by HPLC as described in the Methods
section. The area units under HPLC peaks corresponding to ZMP were converted to moles using
the equation derived from a standard curve generated with synthetic ZMP. The cytosolic volume
of 106 cells was roughly equivalent to 1 µl cell water. Error bars are representative of standard
deviation from two biological and two technical replicates.
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the flow of purine synthesis) was being matched or slightly exceeded by the rate of ZMP
metabolism to either higher order phosphates or to AICAR and AICA, which could efflux from
the cell.
Interesting to us was the observation that after 15 hours of drug exposure, ZMP levels
slowly diminished over time even in the continued presence of drug. The concentrations of
pemetrexed that cause accumulation of ZMP in vitro in HCT116 cells (0.01-1 µM) (Figure 2-16)
are maintained in serum of patients treated with this drug for more than 48 hours (144).
However, serum levels of pemetrexed are probably not an accurate reflection of intracellular
concentration of pemetrexed metabolites, as polyglutamation shifts the kinetics of the
bidirectional transport equilibrium.

Therefore, it is likely that intracellular pemetrexed

concentrations are maintained at several orders of magnitude greater than concentrations
measured in serum. We therefore wanted to determine the dynamics of ZMP accumulation after
drug removal, which would likely be a more accurate reflection of the behavior of this effect in
patients treated with pemetrexed. The schematic for this experiment is depicted in Figure 2-20.
HCT116 cells were treated with 1 µM pemetrexed and thymidine for 15 hours to allow for
maximal accumulation of ZMP. Cells were then either maintained in pemetrexed and thymidine
supplemented media or bathed in media that did not contain drug. Acid-soluble extracts were
taken at several time points following the pemetrexed pre-incubation, and ZMP measurements
were made. We expected that ZMP levels would remain elevated in the absence of pemetrexed,
because polyglutamation of pemetrexed would allow for intracellular retention of potent
metabolites of the drug. We were surprised to determine that ZMP levels steadily decreased in
the absence of pemetrexed (Figure 2-20).
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Figure 2-20. Dynamics of ZMP accumulation in HCT116 cells in response to pemetrexed
withdrawal. HCT116 cells were exposed to 1 µM pemetrexed and 5.6 µM thymidine for 15
hours (time 0) and drug either remained in the media (open circles) or was removed (closed
circles) at this time. Whole-cell acid-soluble extracts were made from cells at the indicated time
points following the initial 17 hour drug exposure, and were analyzed by HPLC for ZMP content
as described in the Methods section. Error bars are representative of standard deviation from two
biological replicates.
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The pemetrexed analog, LCA, is an AICART inhibitor
When pemetrexed was discovered to be a potent anti-cancer agent, medicinal chemists at
Eli Lilly synthesized many analogs of pemetrexed in an attempt to enhance the drug-like
properties of the compound. Our lab received several hundred analogs on the pemetrexed
pharmacophore. When we discovered that pemetrexed had AICART as a second target, we
sought to discover pemetrexed analogs from this library that had AICART as a primary target.
Previous studies suggested that compounds with an extra methylene group between C9 and C10
(homofolates) were inhibitory to the folate-dependent enzymes of de novo purine synthesis and
had minimal effects on TS (145-147). Several members of this pemetrexed analog library were
indeed homofolates, one of which was LCA (Figure 1-3). We therefore sought to determine
whether LCA was an AICART inhibitor.
R.G. Moran performed an end-product reversal experiment in CEM cells that first
suggested LCA was an AICART inhibitor (Figure 2-21). LCA inhibited the growth of CEM
cells at low nM concentrations. Unlike pemetrexed, thymidine only slightly rescued the growth
inhibitory effects of LCA. Hypoxanthine, however, shifted the growth inhibition curve roughly
5-fold, but did not fully rescue the antiproliferative effect of the drug. Conversely, AICA did not
have any rescue effect on LCA-treated cells either when added by itself or when added with
thymidine, suggesting an AICART block.

Inclusion of both thymidine and hypoxanthine

completely rescued the growth inhibitory effects of LCA (Figure 2-21). This result suggested
that LCA had the opposite selectivity of pemetrexed.

Thus, it likely inhibited AICART

primarily, and had a secondary effect on thymidylate synthase. This was
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Figure 2-21. The reversal pattern of CEM cell growth inhibition by LCA suggests that the
primary target is AICART, with a secondary inhibition of thymidylate synthase.
Exponentially growing CEM human leukemic cells were treated with the indicated
concentrations of LCA alone (no add), or in the presence of thymidine (TdR, 5.6 µM),
hypoxanthine (Hx, 32 µM), AICA (320 µM), or a combination of TdR with either Hx or AICA.
Drug and modifying agents were added simultaneously and drug-containing media was changed
at 48 hours. Cell growth was determined after 96 hours by Coulter counting and cell number is
expressed relative to controls without drug. These experiments were performed by RG
Moran.
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quite exciting to us that the selectivity of the compound could be altered just by a one-carbon
addition to the pemetrexed skeleton.
To definitively identify AICART as the primary site of action for LCA along de novo
purine synthesis, ZMP accumulation in response to LCA was determined.

Indeed, ZMP

accumulated dose-dependently in response to LCA treatment in CEM cells across growthinhibitory concentrations of this compound (Figure 2-22). This data in combination with Figure
2-21 indicated that the primary target of LCA was AICART. For the first time, we had an
antifolate in hand that was primarily an AICART inhibitor. In fact, LCA was likely a more
potent inhibitor of AICART in vivo than pemetrexed, as measured by the extent of ZMP
accumulation at equivalent doses.

In a screen of three different cancer cell lines (CEM,

HCT116, and H460), ZMP accumulated to a greater extent following LCA treatment than
pemetrexed treatment (Figure 2-23). The therapeutic effects of LCA will be more extensively
discussed in Chapter 4 of this dissertation.

Recombinant human AICART is sensitive to substrate inhibition in vitro
Based on in vitro Ki measurements for pemetrexed with recombinant mouse GART and
human AICART, it was determined that GART was the primary de novo purine synthesis target
of pemetrexed (54) (Table 1-1). However, our whole-cell biochemical data suggested otherwise.
It was not completely clear what was causing the discrepancy between the in vitro and in situ
kinetics. We therefore expressed and purified recombinant human AICART (Figure 2-8) in an
attempt to address this contradiction.
We chose a continuous spectrophotometric assay to measure AICART activity by
monitoring the formation of the co-product of the AICART reaction, H4PteGlu at 298 nm. Our

80

Figure 2-22. ZMP accumulates dose-dependently in CEM cells exposed to LCA. Cells were
exposed to the indicated concentrations of LCA for 24 hours. Acid-soluble extracts were
analyzed by HPLC as described in the Methods section. The area units under HPLC peaks
corresponding to ZMP were converted to moles using the equation derived from a standard curve
generated with synthetic ZMP. The cytosolic volume of 106 cells was roughly equivalent to 1 µl
cell water. Error bars are representative of standard deviation from two biological and two
technical replicates.

81

Figure 2-23. Comparing ZMP accumulation across cell lines in response to pemetrexed
and LCA. The indicated cell lines were exposed to 1 µM pemetrexed and 5.6 µM thymidine or
1 µM LCA for 48 hours. Acid-soluble extracts were subjected to HPLC analysis of ZMP as
described in the Methods section.
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measured kinetic parameters for AICART are listed in Table 2-1, and are mostly consistent with
parameters measured by others (121). The Km for 10-CHO-H4PteGlu was determined for both
the 6R and 6R,6S isomers (Figure 2-24 and Table 2-1), both routinely synthesized from 6R or
(6R,6S)-5-CHO-THF (see Methods section). In most experiments, 100 µM 10-CHO-THF was
used, because higher concentrations were inhibitory to AICART (Figure 2-25).

While

interesting, this observation is likely not physiologically relevant, as the concentration of 10CHO-THF in the cell rarely rises above 10 µM (14).
The Km for ZMP was also determined by a continuous spectrophotometric kinetic
analysis of product formation (Figure 2-26).

Indeed, the previous Ki determinations for

pemetrexed were performed with 50 µM ZMP and 100 µM 10-CHO-THF (54) (Table 1-1).
However, the levels of ZMP we measured from whole-cell acid-soluble extracts were greater
than 1 mM in all cell lines tested (see Table 2-3). This is greater than 100 times the measured
Km for ZMP and greater than 20 times the substrate concentration used to determine the Ki of
pemetrexed. We therefore sought to determine whether AICART activity was affected by
elevated substrate concentrations. We extended the concentration used for Km measurements out
to 1.5 mM ZMP, and were surprised to see a drastic diminution in enzyme activity beyond 500
µM ZMP (Figure 2-27). In fact, at 1.5 mM ZMP, AICART activity was diminished by greater
than 90% from its maximal velocity. This finding is of importance, because it suggests AICART
inhibition is enhanced by accumulation of substrate as a result of continued flow of the de novo
purine synthesis pathway. Therefore, even weak inhibition of AICART may dramatically affect
enzyme activity as substrate accumulates. Additionally, this result suggests that a dead-end
complex may be forming between AICART and ZMP. It is therefore likely that substrate
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inhibition of AICART by ZMP is contributing to the inhibitory effect of pemetrexed in cells, a
finding that was likely not accounted for in the initial in vitro kinetic workup.
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Figure 2-24. Km determination for 10-CHO-THF on recombinant human AICART. Initial
velocity measurements were taken in the presence of the indicated concentrations of (A) 6R-10CHO-THF or (B) 6R,6S-10-CHO-THF as described in the Methods section. All reactions
contained 3 µg AICART and 50 µM ZMP. Error bars are representative of standard deviation of
triplicate measurements.
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Figure 2-25. 10-CHO-THF inhibits AICART activity at high concentrations. Initial
velocity measurements were taken in the presence of the indicated concentrations of 6R-10CHO-THF as described in the Methods section. All reactions contained 3 µg AICART and 50
µM ZMP. Error bars are representative of standard deviation of triplicate measurements.
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Figure 2-26. Km determination for ZMP on recombinant human AICART. Initial velocity
measurements were taken in the presence of the indicated concentrations of ZMP as described in
the Methods section. All reactions contained 3 µg AICART and 100 µM 6R-10-CHO-THF.
Error bars are representative of standard deviation of triplicate measurements.
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Figure 2-27. Recombinant human AICART is sensitive to substrate inhibition by ZMP.
Initial velocity measurements were taken in the presence of the indicated concentrations of ZMP
as described in the Methods section. All reactions contained 3 µg AICART and 100 µM 6R-10CHO-H4PteGlu. Error bars are representative of standard deviation of triplicate measurements.
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DISCUSSION
Chemical synthesis aimed at eliminating the chiral center of carbon 6 of DDATHF
resulted in the discovery of pemetrexed, a potent inhibitor of thymidylate synthase (53).
However, it was quickly appreciated that pemetrexed had other folate-dependent targets
contributing to its therapeutics (53, 54). The successful clinical utility of pemetrexed in the
treatment of MPM and NSCLC, diseases typically unresponsive to thymidylate synthase
inhibitors (82, 83), led us to consider the biological relevance of thymidylate synthaseindependent targets of pemetrexed.

Although in vitro enzymology studies suggested the

secondary target of pemetrexed was GART (54), data presented in this chapter defined the
secondary target of pemetrexed as the second folate-dependent enzyme of de novo purine
synthesis, AICART (Figure 2-3). Central to the elucidation of AICART as the second target of
pemetrexed were two key observations. First, the discovery that AICA did not have any growthrescue effect on CEM cells treated with pemetrexed in the presence of thymidine, and slightly
potentiated the growth-inhibitory effect of the drug (Figure 2-9), suggested that passage through
de novo purine synthesis was blocked at AICART (Figure 2-3). Second, the dose-dependent
accumulation of the AICART reaction substrate, ZMP, following pemetrexed treatment, an
effect not seen in response to the GART inhibitor (6R)-DDATHF, illustrated that the flow of de
novo purine synthesis was inhibited at the AICART step by pemetrexed (Figure 2-13).

Why has AICART inhibition by pemetrexed or its metabolites not been previously recognized?
In vitro kinetic analysis of folate-dependent targets of pemetrexed and its polyglutamated
metabolites discounted AICART inhibition as a biologically relevant effect of the drug (54)
(Table 1-1). Inhibition assays with a fixed concentration of ZMP (50 µM) defined the Ki of
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monoglutamated and pentaglutamated pemetrexed as 3.58 µM and 0.265 µM, respectively. The
Ki measured against GART as a pentaglutamate was 0.065 µM, which was more favorable, but
still weak. Regardless, from this study, the de novo purine synthesis target of pemetrexed was
labeled as GART, and remained as such for the next decade. Our studies, however, defined
pemetrexed or its metabolites as a potent AICART inhibitor in situ, with minimal inhibitory
activity against GART. The massive accumulation of ZMP subsequent to an AICART block by
pemetrexed suggested the drug potently inhibited the enzyme (Table 2-3). Additionally, siRNA
knockdown of AICART by greater than 95% resulted in significantly less ZMP accumulation
than pemetrexed treatment as shown in Chapter 3 of this dissertation.
These observations, coupled with the previous enzymology of in vitro AICART
inhibition, suggested the behavior of the pemetrexed-AICART interaction in situ differed from
the behavior in the controlled in vitro environment. We propose that an in situ metabolic
trapping mechanism explains this discrepancy (Figure 2-28A). The AICART reaction obeys an
ordered-sequential binding mechanism, in which 10-CHO-H4PteGlun binds first, followed by
ZMP (121, 123). As ZMP accumulates behind an AICART block by pemetrexed, the binary
AICART-pemetrexed complex will reform a ternary inhibited complex whenever ZMP
dissociates. This would prevent the dissociation of pemetrexed from the binary complex, thus
metabolically trapping the enzyme in inhibited complexes. This trapping mechanism is similar
to that described for FdUMP to thymidylate synthase in the presence of an expanded pool of
5,10-methylene-H4PteGlun induced by co-treatment of 5-FU with leucovorin (42, 85).
We therefore propose that the Ki of pemetrexed and its polyglutamates for AICART
would decrease as the ZMP concentration increases. This effect would not have been measured
with the fixed concentration of ZMP (50 µM) used in the prior in vitro studies (54). We
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Figure 2-28. Proposed kinetic mechanisms for inhibition of AICART by ZMP. (A) ZMP
metabolically traps AICART in a ternary complex with pemetrexed. (B) ZMP traps AICART in
a dead-end complex.
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expressed and purified recombinant human AICART (Figure 2-8) and attempted to prove our
hypothesis by repeating the in vitro Ki studies in the presence of pemetrexed and increasing
concentrations of ZMP. However, we ran into a dilemma. We discovered that AICART was
extraordinarily sensitive to substrate inhibition by ZMP at concentrations greater 500 µM (Figure
2-27). This finding was interesting in and of itself, as it suggests that ZMP forms a dead-end
complex with AICART at these physiologically relevant concentrations of ZMP measured in
pemetrexed-treated cells (Figure 2-28B). However, this effect also limits our ability to use
activity measurements to test the metabolic trapping hypothesis. Confounded by effects of
substrate inhibition, we were only able to use this kinetic approach to test the metabolic trapping
hypothesis at concentrations of ZMP that did not exceed 500 µM. Comparing the concentrationdependent inhibitory effect of pemetrexed on AICART activity at 50 µM and 500 µM ZMP, we
did not measure enhanced enzyme inhibition at the higher ZMP concentration (Figure 2-29). We
therefore propose to determine the extent of trapping by direct binding measurements. One
could theoretically determine the extent of metabolic trapping by incubating recombinant human
AICART with 3H-pemetrexed and increasing concentrations of ZMP, and passing the ternary
complex through a Sephadex G-50 column. These experiments are underway, and the assay
workup will be similar to that of the microassay for FPGS activity, previously developed by our
lab (148).

Is there biological relevance to the variability of ZMP accumulation across cell lines?
Our initial observation that ZMP accumulated following pemetrexed treatment in CEM
human leukemic cells (Figure 2-13) prompted us to question the generality of this effect in cells
of varying histologies (Table 2-3). While all cell lines in our screen measured ZMP
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Figure 2-29. ZMP (500 µM) does not increase the potency of pemetrexed as an AICART
inhibitor. Initial velocity measurements were taken in the presence 50 µM ZMP (closed circles)
or 500 µM ZMP (open circles) with the indicated concentrations of pemetrexed as described in
the Methods section. All reactions contained 3 µg AICART and 100 uM 6R-10-CHO-THF. The
ordinate is expressed as such to normalize the data for substrate inhibition by ZMP at 500 µM.
Error bars are representative of standard deviation of triplicate measurements.
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accumulation greater than 1000-fold above control, there was significant variability in static
measurements across and even among histologies. What could explain this variability, and more
importantly, was there additional therapeutic gain when the ZMP pool was expanded beyond a
certain point? This latter question will be addressed first.
Comparing ZMP accumulation with growth inhibition in response to pemetrexed (Figure
3-12) illustrated no correlation between these measurements. For instance, while the TE85
osteosarcoma cell line measured ZMP accumulation above 12 mM, by far the highest
measurement in our screen, TE85 was the fifth most sensitive cell line to pemetrexed. Indeed,
the H460 NSCLC cell line was as sensitive to pemetrexed as TE85, but accumulated roughly 6fold less ZMP (Table 2-3). This suggests that other factors, either biochemical or genetic,
contribute to the variability among these cell lines to growth inhibition, independent of excessive
ZMP accumulation. I hypothesize that there is a threshold of ZMP accumulation that must be
exceeded to trigger AMPK activation and subsequent signaling events downstream of AMPK
(detailed in Chapter 3), and the Vmax of AMPK likely occurs at ZMP concentrations well below
levels we are measuring in response to pemetrexed. In support of this hypothesis, studies by
Corton et al showed that the half maximal effect of ZMP on activation of purified rat liver
AMPK was 164 µM ± 44 (132). Additionally, an unpublished experiment by A.C. Racanelli in
our lab showed that AMPKα was maximally hyperphosphorylated at T172 (see Chapter 3 for
details) in CEM cells following a 0.1 µM pemetrexed treatment for 48 hours (A.C. Racanelli,
Ph.D. dissertation, 2009). Figure 2-13 shows that ZMP levels at this concentration and time
point are just below 1 µM.
Several hypotheses were considered to identify the cause of variability in ZMP
concentrations measured across cell lines. First, it was suggested that variability could arise
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from differences in the flow of intermediates through the de novo purine synthesis pathway.
However, the doubling time for each cell line tested was roughly 20-24 hours, suggesting that the
rate of DNA synthesis and subsequent necessity for purines across cell lines would be roughly
equivalent. Therefore, drastic differences in the flow of de novo purine synthesis would be an
unlikely explanation of the variability. To test this, however, one could measure the rate of de
novo purine synthesis in these cell lines by measuring the extent of

14

C-glycine or

14

C-formate

incorporation into ATP as a function of time.
Alternatively, but not necessarily mutually exclusive from the above hypothesis, the rate
of metabolism of ZMP may be different across these cell lines.

For instance, ZMP that

accumulates behind the AICART block may be catabolized to the cell-permeable precursors
AICAR and/or AICA. Additionally, ZMP is converted to the –di and-triphosphate nucleotide
forms, and measurable amounts of ZTP are detected by HPLC in acid-soluble extracts within 15
minutes of AICAR treatment in rat hepatocytes (132). Our HPLC protocol could be adapted to
optimally measure ZDP and ZTP to determine whether this was occurring. Furthermore, an
HPLC protocol was previously described to measure AICAR and/or AICA with a C18 reverse
phase column (129, 149), but interpretation of these measurements may be complicated, as these
metabolites can efflux from the cell.
Most likely, the variability in ZMP accumulation across cell lines is due to differences in
transport and metabolism of pemetrexed. For instance, variability in FPGS activity would
influence the intracellular concentration of polyglutamated metabolites of pemetrexed, known to
be more potent inhibitors of AICART than the parent compound (54).

Differences in

pemetrexed uptake across cell lines may also contribute to variability, and this hypothesis could
be tested experimentally with 3H-labeled pemetrexed uptake studies. It would be interesting to
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compare expression of the RFC and PCFT across these cell lines to determine whether
transporter expression correlates with the ZMP measurements. Regardless of differences in
ZMP concentrations, I suspect that the levels of ZMP measured in all cell lines tested is well
above the threshold to trigger activation of AMPK and provide the signal necessary to promote
signaling events described in Chapter 3.

Defining the pharmacophore of an AICART inhibitor
The discovery that pemetrexed targets AICART is of interest both from a therapeutic
standpoint (see Chapters 3 and 4) as well as from a drug development standpoint. It is not
understood why the substitution of a pyrrolopyrimidine ring for the 5-deazapteridine of
DDATHF (Figure 1-3) directs pemetrexed away from GART and towards TS and AICART.
The observation that addition of an extra methylene group between the C9 and C10 position of
the folate backbone (homofolate) directed compounds towards the folate dependent enzymes of
de novo purine synthesis (145-147) led us to the discovery that LCA had AICART as its primary
target (Figures 2-21 and 2-22).

Therefore, our studies are beginning to define the

pharmacophore of an AICART inhibitor, and the discovery of potent and selective inhibitors of
AICART is warranted based on the consequences of AICART inhibition descried in this
dissertation.
To date, very few potent inhibitors of AICART have been discovered. Structure-based
drug design efforts by the Burroughs Wellcome group resulted in the synthesis of two sulfamidobridged 5,8-dideazafolate analogs (BW1540 and BW2315) that potently inhibited (Ki ~ 7 nM)
AICART (150). Although these compounds were potent AICART inhibitors in vitro, they were
weakly cytotoxic in human colon cancer cell lines, with IC50 values of approximately 4 µM
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(150). This suggests that these compounds are poor substrates for transport and polyglutamation.
Nevertheless, crystal structures of BW1540 and BW2315 bound in the active site of human
AICART (PBD codes 1P4R and 1PLO and Figure 2-5) revealed key structural features of the
AICART folate-binding site that may be exploited in future drug discovery efforts to direct
inhibitors away from GART and TS and towards AICART. One such unique feature was the
presence of an oxyanion hole in the AICART active site (residues 450-468), previously shown to
stabilize the transition-state intermediates of several enzymes of the α/β hydrolase family (151,
152). Hydrogen bonding interactions between the sulfonyl oxygens of these inhibitors and
nitrogen atoms of several residues in this oxyanion hole were suggested to be a primary
determinant of the positioning of these inhibitors in the AICART active site, and likely stabilize
the transition state during the formyl-transfer reaction (153). Neither GART nor TS possess this
structural feature (153).
The Moran lab has acquired a library of pemetrexed and DDATHF analogs synthesized
primarily by chemists at Eli Lilly. We propose a cell-based screening assay to determine the
extent of AICART inhibition by these compounds. Based on our findings with LCA, which
came from this same library set, we believe the likelihood of a hit is good. Using ZMP
accumulation as an indicator of AICART inhibition, we will build a layer of kinetics into this
assay by performing the screen in situ, an important factor that was disregarded in the structurebased drug design scheme described above. In addition to kinetics, an additional advantage of an
in situ screen as opposed to an in vitro screen (which we are now equipped to do) is the ability to
rule out potential interference by other folate-dependent targets. This is important, as there is
clear hierarchy that exists in folate-dependent target inhibition. For instance, a compound that is
an AICART inhibitor, but also potently inhibits GART, would make AICART inhibition
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irrelevant, as no ZMP would be synthesized subsequent to GART inhibition. Likewise, an
AICART inhibitor that is also a potent DHFR inhibitor (like methotrexate; see Figure 2-14)
would not accumulate ZMP, since 10-CHO-H4PteGlu would be depleted, and therefore de novo
purine synthesis intermediates would not be synthesized.
Several studies have led to the discovery of non-folate-based AICART inhibitors.
Crystallographic comparisons of both the apo and substrate-bound forms of AICART indicated
that the active site was fairly rigid, and no major conformational changes took place upon ligand
binding (122, 150). Therefore, virtual ligand docking has been used to screen for novel AICART
inhibitors (153). In a virtual screen of 2,000 compounds selected from the NCI diversity set, 44
compounds were identified as potential AICART inhibitors. In vitro kinetic analysis identified 8
of these compounds as µM inhibitors, and one compound, NSC30171, had a Ki of 154 nM (153).
The discovery that the AICART active site is constructed by homodimerization (Figure 2-5)
suggests compounds that hinder dimerization would be selective as AICART inhibitors over
other folate-dependent enzymes that function as monomers. This concept was explored by
screening a 40,000-member peptidomimetic library for dissociative AICART inhibitors (154).
One inhibitor from this screen, Cappsin 1, was identified to be a low µM noncompetitive,
dissociative inhibitor of AICART. Additionally, Cappsin 1 did not inhibit GART or DHFR. It
would be of importance to determine whether these novel AICART inhibitors described in this
section display similar biological effects observed with pemetrexed (see Chapter 3 and 4).

Diminution of ZMP following drug washout
To determine whether ZMP levels remained elevated following pemetrexed removal, we
performed an experiment in HCT116 (and H460) cells in which a 17 hour treatment with
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pemetrexed was followed by drug washout. Time points were taken intermittently following
washout and ZMP measurements were made (Figure 2-20). We were surprised and a bit puzzled
by the result. Our data clearly showed that in the absence of pemetrexed, ZMP levels were
diminishing with time at a rate of 0.08 nmol/106 cells hr-1. Our expected outcome for this
experiment was that ZMP would continue to accumulate following washout, as polyglutamation
would trap pemetrexed metabolites intracellularly, and target inhibition would continue in the
absence of an exogenous source of drug.
Several hypotheses were generated that might explain this data. One possibility is that
pemetrexed monoglutamates are the inhibitory forms of the drug towards AICART. Since
pemetrexed is such an efficient substrate for polyglutamation by FPGS (53, 56, 57), drug
washout would remove the “active” form of the drug.

Any remaining intracellular

monoglutamates would be polyglutamated and would no longer target AICART.

Since

pemetrexed is such a good FPGS substrate, in order for the cell to maintain a sufficient pool of
pemetrexed monoglutamates, FPGS would need to be saturated with substrate. If the metabolic
trapping mechanism described above is occurring, the potency of pemetrexed monoglutamates as
AICART inhibitors may be sufficient to promote ZMP accumulation. Interestingly, in vitro,
pemetrexed monoglutamates are more potent inhibitors of AICART than GART (Table 1-1).
Studies addressing the transport and polyglutamation profile of 3H-pemetrexed are warranted to
address this hypothesis.
Another possibility is that efflux of pemetrexed is rapid, and the presence of an
exogenous source of drug maintains an equilibrium necessary for target inhibition. Again,
transport studies with 3H-pemetrexed would allow us to address this hypothesis. Upon removal
of drug from the media, it is presumed from this data that pemetrexed is no longer inhibiting

99

AICART. Therefore, the rate of diminution in the ZMP pool measured would be a reflection of
ZMP metabolism to either higher order phosphates or to AICAR and AICA. To determine
whether an AICART block is still present in the absence of exogenous drug, cells could be
treated with 320 µM AICA. If AICART were still inhibited, ZMP would accumulate (Figure 215).
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CHAPTER 3
PEMETREXED TRIGGERS AN ENERGY-SENSITIVE METABOLIC CHECKPOINT
SECONDARY TO AICART INHIBITION

The metabolic block induced consequential to AICART inhibition by pemetrexed
resulted in massive intracellular accumulation of ZMP, presumably due to continued flow of
intermediates through de novo purine synthesis in the presence of a downstream blockade. The
unusual therapeutic profile of pemetrexed coupled to the observation that ZMP was not
accumulating in response to DDATHF or methotrexate led us to question how this effect that
distinguished pemetrexed from other antifolates was contributing to the cellular response to the
drug. Our studies were guided in the direction of signaling through AMP-activated protein
kinase (AMPK), because of parallel literature using the riboside of ZMP, 5-aminoimidazole-4carboxamide ribonucleoside (AICAR), as a chemical tool to activate AMPK. AICAR was
shown in vitro, in situ, and in vivo to activate AMPK following its metabolism to ZMP (132,
155, 156).

We therefore suspected that pemetrexed was indirectly modulating signaling

processes through AMPK secondary to ZMP accumulation behind the AICART block. This
hypothesis was examined in the experiments described in this chapter.

AMP-activated protein kinase – a cellular energy sensor
Signaling mediated by AMP-activated protein kinase (AMPK) is the primary cellular
regulatory mechanism for maintaining energy homeostasis.

Its activation in response to

diminished cellular ATP levels promotes catabolic processes to generate energy while inhibiting
anabolic processes that consume it (157). Cancer cells routinely possess genetic abnormalities in
PI3K-AKT and MAPK signaling that hyperactivate the mammalian target of rapamycin complex

101

1 (mTORC1) in the absence of extracellular stimuli, leading to autonomous growth and
proliferation (Figure 3-1) (158, 159). AMPK constitutes an endogenous controlling mechanism
that limits mTORC1 activity. Therefore, modulation of AMPK signaling presents as a probable
point of therapeutic intervention for molecularly targeted cancer agents (160).
The Energy Charge Hypothesis:

AMPK was originally identified as a kinase

allosterically modulated by adenosine-5’-monophosphate (AMP) (161). We now know that
AMPK responds to changes in the AMP:ATP ratio, the most sensitive indicator of cellular
energy status (162, 163). The first observation that nucleotides themselves controlled cellular
signaling processes was by D.E. Atkinson, who showed that AMP and ATP reciprocally
regulated enzymes of the glycolytic pathway (164). At the time, it was thought that nucleotides
acted directly on these enzymes, which led Atkinson to postulate this sensitivity to AMP and
ATP as the energy charge hypothesis. It is now recognized that AMPK is the nucleotide sensor
in this cascade, not the target enzymes themselves.
That AMPK is sensitive to the AMP:ATP and not the ADP:ATP ratio is attributed to the
reaction equilibrium maintained by adenylate kinase (Reaction 1).

Healthy cells keep the

ATP:ADP ratio at approximately 10:1 by ATP synthase (Reaction 2) to ensure adequate ATP for
cellular processes. The driving force for the ATP synthase reaction comes from the downhill
flow of protons across the inner mitochondrial membrane, a gradient maintained by oxidative
phosphorylation pumping protons against this gradient (165).
(1) 2ADP ⇔ ATP + AMP
(2) ADP + Pi ⇒ ATP
ATP synthase disrupts the equilibrium imposed by adenylate kinase. Therefore, to maintain
equilibrium, the adenylate kinase reaction is driven from right to left. The leftward adenylate
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Figure 3-1. Cellular signaling upstream and downstream of mTORC1 and mTORC2. The
mTOR signaling pathway senses and responds to changes in cellular nutrient, energy, and redox
status. The best characterized of the two mTOR complexes, mTORC1, controls proliferative
capacity in part by regulating processes such as CAP-dependent translation, ribosome
biogenesis, and autophagy. mTORC2 contributes to the negative-feedback regulation of
mTORC1 signaling, and has also been implicated in regulating ion transport, cell growth, and
cytoskeletal organization.
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kinase reaction coupled with the ATP synthase reaction maintains the ATP:AMP ratio at
approximately 100:1 under conditions of ATP homeostasis. Under conditions of cellular stress,
the rate of ATP consumption increases, driving the adenylate kinase reaction from left to right to
maintain equilibrium, generating AMP in the process. Dividing both sides of the equilibrium
reaction of adenylate kinase ( [ATP][AMP] = [ADP]2 K ) by [ATP]2, it can be determined that
the AMP:ATP ratio varies by the square of the ADP:ATP ratio. For example, if the ADP:ATP
ratio rises by 10-fold, the AMP:ATP ratio would rise by 100-fold. Therefore, it can be seen how
the AMP:ATP ratio is a much more sensitive indicator of compromised energy status than the
ADP:ATP ratio (163).
Subunit Structure: AMPK is a heterotrimeric protein consisting of a catalytic α subunit
and regulatory β and γ subunits. Humans have seven genes that encode isoforms of the three
subunits, creating the potential for great diversity in complex formation. Isoform expression
seems to be tissue-specific, but much is still to be learned about the regulation and characteristics
of the different isoforms both as monomers and as part of the trimeric complex. Two genes
encode α subunits. α1 is ubiquitously expressed while α2 is most abundant in skeletal and
cardiac muscle as well as in the liver (166). Both α subunits share 90% sequence identity in
their N-terminal catalytic domains, which contain a conserved threonine residue (T172) in an
activation loop, a feature shared by other serine/threonine protein kinases. Phosphorylation of
this residue was thought to be essential for kinase activity of the trimer (167, 168). However,
data presented in this chapter as well as from others suggests this essentiality of T172
phosphorylation may be substrate-specific (169). The α subunit also contains an autoinhibitory
domain, postulated from structural studies to bind the catalytic domain and constrain its mobility
(170). The C-terminal domains of the α subunit isoforms share 60% sequence identity and
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contain the binding site for the β subunit (171, 172). Two genes encode isoforms of the β
subunit. β1 is ubiquitously expressed and β2 is most abundant in skeletal muscle (173). The Cterminal domain of the β subunit acts as a scaffold, binding both the α and γ subunits (171, 174).
The β subunit also contains a glycogen-binding domain, which is thought to allow AMPK to
sense stored cellular energy in addition to free energy (175, 176). Three genes encode isoforms
of the γ subunit, which contain binding sites for AMP and ATP (177). The N-termini of the
three isoforms have a conserved region that binds to the β subunit (178). Structural studies show
the γ subunit contains four tandem cystathione-β-synthase (CBS) motifs that generate two
Bateman domains, common in proteins that bind adenosine-containing ligands (171, 177). AMP
binds cooperatively to two of the CBS motifs, and their binding is competitive with ATP. A
third AMP was tightly bound in the crystal structure, and it was hypothesized that this AMP did
not exchange with ATP. The fourth site did not contain either AMP or ATP (171). Binding
assays showed enhanced association of AMP to the γ subunit as concentrations rose through the
µM range, even in the presence of physiologic ATP concentrations (171).
Mechanism of Activation: The binding of AMP to the γ subunit allosterically activates
the kinase by several known mechanisms. Structural studies suggest that AMP binding to the γ
subunit causes a conformational shift in the α subunit, relieving the constrained conformation
imposed by the autoinhibitory domain (170). Additionally, AMP allosterically modulates the
conformation of residues surrounding T172 in the α subunit, protecting this key residue from
phosphatases. Therefore, it is suggested that AMP protects T172 from dephosphorylation rather
than promoting its phosphorylation (179, 180). It is not clear whether the above-mentioned
consequences of AMP binding are mutually exclusive, but both seem to be necessary for full
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activation of the kinase. Importantly, ZMP mimics both effects of AMP, the allosteric activation
of AMPK as well as inhibition of T172 dephosphorylation (132).
Upstream Kinases: AMPKα T172 is the substrate for several known upstream kinases.
The predominant T172 kinase in most cells is thought to be LKB1 (181-183). LKB1 was
originally identified as a tumor suppressor gene product mutated in Peutz-Jeghers syndrome, a
premalignant familial disorder characterized by benign hamartomas of the gastrointestinal tract
(184). Of significance, LKB1 is also frequently mutated in lung adenocarcinomas (Figure 3-2),
and it has been suggested that the tumor suppressor function of LKB1 is mediated through
effects downstream of AMPK activation (185-187). LKB1 expression is ubiquitous and it
functions as part of a complex with the accessory proteins STRAD and MO25 (182). LKB1 is
thought to constitutively phosphorylate AMPKα T172, a mark easily removed by phosphatases
in the absence of protection by allosteric binding of AMP (see above) (181). In the presence of
calcium or a calcium ionophore, AMPKα T172 is also phosphorylated by calmodulin-dependent
protein kinase kinases (CAMKKs), especially CAMKKβ (188-190).

Phosphorylation of

AMPKα T172 by CAMKKβ has been shown in the absence of elevated AMP, suggesting
CAMKKβ itself or downstream effectors elicit control of T172 phosphatases. While calcium
alone stimulates activity of AMPK, AMP does synergize with calcium to further stimulate
AMPK activity, supporting the conclusion that full activity requires both T172 phosphorylation
and allosteric modulation (191). Most recently, a third upstream kinase of AMPKα T172 has
been identified, transforming growth factor-β-activated protein kinase-1 (TAK1), which may
play a role in the autophagy response induced by AMPK (see Chapter 4) (192-194).
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Figure 3-2. The most commonly mutated genes upstream of mTORC1 in human non-small
cell lung cancer cell lines. Mutation data from the Wellcome Trust Catalog of Somatic
Mutations in Cancer (COSMIC) database was compiled from 67 human non-small cell lung
cancer cell lines.
Compiled from: http://www.sanger.ac.uk/perl/genetics/CGP/core_line_viewer?action=cell_lines
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Downstream targets of AMPK
The signals transmitted by AMPK to downstream targets temporarily stimulate energyproducing processes and limit nonessential energy-consuming processes to restore cellular ATP
homeostasis. To accomplish this, AMPK inhibits both protein synthesis and lipid metabolism,
and promotes the mobilization and breakdown of glucose. A list of several well-characterized
direct targets of AMPK is presented in Table 3-1 (195-209). The downstream targets of AMPK
predominantly studied in this dissertation converge on mTORC1, which is discussed in detail as
follows.
PI3K-AKT signaling: The PI3K-AKT signal transduction pathway responds to both
extracellular and intracellular signals to coordinate cell growth and proliferation by promoting
the anabolic processes of protein and lipid biosynthesis, while limiting catabolic processes such
as autophagy (210). Effectors of the pathway are activated by environmental stimuli such as
growth factors, oxygen, amino acids, and glucose (Figure 3-1). Deregulation of components of
this signaling network are hallmarks of most human cancers and a number of benign hamartoma
syndromes, conditions in which cell growth and survival are uncoupled from environmental
triggers. Therefore, therapeutic interventions that restrict uncontrolled signaling through the
PI3K-AKT pathway are being heavily pursued for the management of these diseases (158, 211).
Signals converging on mTOR: Class I phosphatidylinositol-3-OH kinases (PI3K) are
heterodimeric proteins consisting of a regulatory p85 subunit and a catalytic p110 subunit (212).
The binding of growth factors to receptor tyrosine kinases (RTK) promotes the
autophosphorylation of tyrosine residues on the cytoplasmic tails of the receptor. This recruits
PI3K and adaptor proteins such as insulin receptor substrates (IRS1 and IRS2) to the RTK,
where PI3K is activated by phosphorylation. The GTPase RAS can also recruit, bind, and
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activate PI3K through its association with the p110 subunit at the plasma membrane (213). The
catalytic p110 subunit of PI3K converts the membrane lipid phosphatidylinositol-4,5bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3).

This catalysis is

antagonized by the tumor suppressor gene product phosphatase and tensin homolog (PTEN),
second only to p53 in mutation frequency among human tumor suppressor genes (158, 212).
The p110 subunit of PI3K is also commonly hyperactivated by mutation in breast, colon, brain,
and gastrointestinal tumors (214, 215).
PIP3 functions as a second-messenger in the PI3K signaling cascade, recruiting lipidbinding pleckstrin-homology (PH) domain-containing proteins, such as protein kinase B (AKT),
to the plasma membrane. Activation of the oncogene product AKT requires PIP3-mediated
recruitment to the plasma membrane through its N-terminal PH domain, where it is
phosphorylated in its activation loop at T308 by another PH domain-containing protein, PDK1
(216, 217). While the T308-phosphorylated form of AKT is weakly active, maximal activity is
attained by an additional phosphorylation in a hydrophobic region of the C-terminal regulatory
domain at S473, catalyzed by the mammalian target of rapamycin complex 2 (mTORC2) (216219). Structural studies initially showed AKT phosphorylated solely at T308 crystallized in an
inactive conformation, and subsequent allosteric phosphorylation at S473 induced a
conformational shift in the catalytic domain to a more active conformation (220). More recently,
it was shown that membrane recruitment of AKT through its PH domain interacting with PIP3
was able to induce a conformational change allowing PDK1 acesss to T308, a structural change
likely missed in the preceding in vitro crystallography (221). Membrane localization is essential
for S473 phosphorylation by mTORC2, supporting the role of PI3K in this modification.
Importantly, S473 phosphorylation was not inhibited in PDK1-deficient cells or following
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treatment with PDK1 inhibitors, but conversely, T308 phosphorylation was undetectable in
several nonphosphorylatable S473 AKT mutants. This suggests that S473 phosphorylation by
mTORC2 may proceed and facilitate phosphorylation of T308 by PDK1, rendering the kinase
fully active (222, 223).
Structural components of mTOR complexes:

The downstream targets of AKT are

plentiful, and generally promote cell survival through inhibition of apoptosis, as well as growth
and proliferation through direct and indirect stimulation of mTORC1 (224). This uniquely
places AKT downstream of mTORC2 and upstream of mTORC1. Each of the mTOR complexes
is an assembly of distinct components, commonly nucleated by the mTOR catalytic
serine/threonine kinase subunit. mTOR was aptly named following its identification as the target
of the potent macrolide ester rapamycin, which forms a complex with its intracellular receptor
FKBP12 and binds in the N-terminus of the catalytic subunit (225-227). FKBP12-rapamycin
binds to mTORC1 complexes but not mTORC2 complexes (228, 229). However, FKBP12rapamycin is able to bind free mTOR (227, 230, 231). While acute exposure to rapamycin (less
than 1 hr) potently inhibits mTORC1 signaling, prolonged exposure to rapamycin (24 hr) inhibits
mTORC1 and mTORC2 by binding to newly-synthesized mTOR catalytic subunits, perturbing
new complex formation (232). The mechanism by which rapamycin acutely inhibits complexed
mTORC1 is not fully understood, but structural studies suggest rapamycin disrupts the binding
of the Raptor (regulatory associated protein of mTOR) subunit unique to the mTORC1 complex
(233, 234).
In addition to Raptor, the mTORC1 complex consists of mLST8 (mammalian lethal with
Sec12 protein 8), PRAS40 (proline-rich AKT substrate 40 kDa), and Deptor (DEP-domaincontaining mTOR-interacting protein). Raptor is proposed to regulate the assembly of the
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mTORC1 complex and to define the substrate specificity of mTORC1 by recruiting downstream
targets that contain TOR signaling motifs to the catalytic mTOR subunit of the complex (235237). mLST8 binds to the mTOR kinase domain, and is also a component of the mTORC2
complex assembly.

Its function is poorly understood, and knockout studies in mice show

mLST8 is dispensable for mTORC1 signaling, but is essential to the stability and activity of
mTORC2 (238). PRAS40 and Deptor were recently identified as endogenous inhibitors of
mTORC1, and activation of the kinase promotes the direct phosphorylation and subsequent
dissociation of these negative regulators (239, 240). The observation that PRAS40 has a TOR
signaling motif suggests the inhibitor may function by competing with mTORC1 for substrate
binding (241). The mechanism by which Deptor inhibits mTORC1 is unknown, but it is also an
endogenous inhibitor of mTORC2 (239).
The mTORC2 complex consists of Rictor (rapamycin-insensitive companion of mTOR),
SIN1 (stress-activated protein kinase interacting protein), Protor (protein observed with Rictor),
mLST8, and Deptor. Rictor has been implicated in stabilizing the mTORC2 complex through its
interaction with SIN1 and Protor. Compared to mTORC1, little is known about the biological
functions of mTORC2. This is partly because our understanding of mTORC1 biology was
facilitated by studies utilizing its potent inhibitor, rapamycin. However, important functions of
mTORC2 are emerging, such as the discovery that mTORC2 is the kinase upstream of AKT
S473 (242). Knockdown of Rictor limits cell motility as well as actin polymerization, but the
molecular mechanisms of these effects are poorly understood (228, 229).

Additionally,

mTORC2 phosphorylates SGK1 (serum-and-glucocorticoid-induced protein kinase 1) which,
similarly to AKT, phosphorylates and prevents the nuclear translocation of the FoxO1 (forkhead
box protein O1) and FoxO3a apoptosis-inducing transcription factors (243, 244).
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Opposing influences of AKT and AMPK on mTORC1: AKT activates mTORC1 through
direct and indirect mechanisms.

Directly, AKT phosphorylates the endogenous mTORC1

inhibitor PRAS40 at T246, which promotes its dissociation and sequestration to the cytosolic
anchor protein 14-3-3 (240, 245). Indirectly, AKT stimulates mTORC1 kinase activity through
inhibitory phosphorylation of S939 and T1462 on the Tuberin (TSC2) subunit of the Tuberous
Sclerosis Complex (TSC) (246, 247). The TSC complex is a heterodimer consisting of Hamartin
(TSC1) and TSC2. TSC2 is a GTPase activating protein, that, when bound to TSC1, triggers the
GTPase activity of the G-protein Rheb, promoting its conversion to a GDP-bound inactive form
(248). When bound to GTP, Rheb stimulates the activity of mTORC1 through a mechanism that
is not completely understood. Therefore, the TSC complex inhibits mTORC1 signaling through
its GTPase activating effect on Rheb. Interestingly, Rheb has been shown to associate with the
mTOR catalytic subunit as well as mLST8, and both are components of mTORC1 and mTORC2
complexes (249). However, studies thus far have not found evidence to support GTP-Rheb as a
modulator of mTORC2 activity (250).
The discovery of AMPK as a negative regulator of signaling through the PI3K-AKTmTOR axis arose partly from the identification of LKB1 as a major upstream kinase of AMPK
(181-183). As described above, mutations in LKB1 are causal of Peutz-Jeghers syndrome,
characterized by benign hamartomas of the gastrointestinal tract (184). Several clinical features
of Peutz-Jeghers syndrome are shared by other hamartoma syndromes such as Cowden’s disease,
caused by inactivating mutations in the PTEN, as well as TSC syndrome, resulting from
mutations in the TSC1 and TSC2 genes (211, 251). Common to these signaling molecules is
their convergence on mTORC1. Indeed, it has been shown that AMPK opposes both the direct
and indirect influences of AKT on mTORC1 activity. Specifically, AMPK phosphorylates
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Raptor at S792, promoting its dissociation from the mTORC1 complex and subsequent
sequestration to 14-3-3, preventing the recruitment of mTORC1 substrates (195). Additionally,
AMPK phosphorylates TSC2 at S1387 and T1271, marks that activate the TSC complex,
promoting mTORC1 inhibition through inactivation of Rheb-GTPase activity (196). Therefore,
AMPK activation promotes inhibition of signaling processes mediated by mTORC1 by opposing
the activation of two studied nodes of signal transduction by AKT, namely TSC1/2 and
mTORC1.
In addition to counteracting AKT signaling, AMPK also opposes the influence of
aberrant MAPK signaling converging on the TSC complex. The primary effector of the MAPK
signaling pathway is the GTPase RAS, which frequently harbors mutations that constitutively
activate the kinase in colon, thyroid, pancreatic, melanoma, and lung tumors (252). As described
above, RAS can directly stimulate PI3K signaling, which would in itself stimulate AKT and
subsequently, mTORC1. However, mTORC1 hyperactivity is retained when AKT is inhibited in
the presence of hyperactive K-RAS, and vise versa (253).

This illustrates that signaling

mediated by PI3K and RAS can independently converge on mTORC1. Indeed, RAS signaling
through the classical MAPK cascade to extracellular signal-regulated kinase (ERK) indirectly
promotes mTORC1 signaling. TSC2 S664 is a direct substrate for ERK, which perturbs the TSC
complex formation, and thus drives mTORC1 signaling through deregulation of Rheb-GTP
(254, 255). Additionally, it has been reported that phosphorylation of TSC2 at S1798 by RSK, a
downstream substrate of ERK, inhibits Rheb-GTPase activity (256).
Signaling downstream of mTORC1: The best characterized function of mTORC1 is the
regulation of the initiation step of 7-methyl guanosine CAP-dependent translation, in which a
multiprotein complex of translational initiation factors, collectively known as the eIF4F
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complex, binds the 5’ CAP of mature mRNAs and recruits the 40S ribosomal subunit (Figure 33). Subsequently, the ribosome-bound initiation complex scans the mRNA from 5’ to 3’ until it
encounters an optimal AUG translational start codon.

The 60S ribosomal subunit is then

recruited along with elongation factors, and translation elongation begins (257). The eIF4F
initiation complex consists of the initiation factors eIF4E, eIF4G, and eIF4A. eIF4E directly
binds the CAP structure, and recruits eIF4G and the helicase eIF4A, which functions to linearize
hairpins in the 5’ UTR of mRNA as the complex scans for the start codon (Figure 3-3). The
processivity of eIF4A is greatly enhanced by the binding of eIF4B (258). mTORC1 signals
directly to key controlling elements of the eIF4F initiation complex, 4E-binding protein 1
(4EBP1) and 40S ribosomal protein S6 kinase (S6K1) (259).

4EBP1 is a translation inhibitor

that functions by competing with eIF4G for binding to eIF4E (Figure 3-3). Therefore, when
4EBP1 is bound to eIF4E, the translation initiation complex cannot assemble, and CAPdependent translation is inhibited. mTORC1 phosphorylates 4EBP1 at four known residues
(T37, T45, S65, and T70), diminishing its affinity for eIF4E, thus promoting CAP-dependent
translational initiation.
S6K1 is also an important translational regulatory target of mTORC1.

S6K1 was

originally identified as the kinase upstream of the 40S ribosomal protein S6, whose
phosphorylation is essential for protein synthesis (259).

S6K1 activation requires

phosphorylation at two sites, T389 by mTORC1 and T229 by PDK1 (235).

S6K1

phosphorylates eIF4B at S422, a modification necessary to promote recruitment of eIF4B to the
initiation complex, where it stimulates the helicase activity of eIF4A (260) (Figure 3-3). In
addition to its direct regulatory roles on protein synthesis, S6K1 also indirectly influences
translation by promoting ribosome biogenesis (261).
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Figure 3-3. Regulation of CAP-dependent translation initiation. (A) The binding of 4E-BP1
to the CAP-binding protein eIF4E inhibits translation by preventing the recruitment of initiation
factors and the 40S ribosome to capped mRNAs. Phosphorylation of 4E-BP1 by mTORC1
inhibits it from binding eIF4E, which promotes CAP-dependent translation initiation. (B) S6K
and RSK promote cap-dependent translation by phosphorylating eIF4B, which then enhances the
helicase activity of eIF4A. Helicase activity of the CAP-dependent initiation complex is
necessary to unwind hairpinned structures in the 5’ untranslated regions of capped mRNAs.
Figure from Ma XM and Blenis J., 2009. Nat. Rev. Mol. Cell Biol. 10(5):307-318. (257)
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S6K1 is also an important feedback inhibitor of AKT signaling, controlling a negative
feedback loop essential to regulate mTORC1 activity. Evidence of a feedback loop surfaced
from studies with TSC-null mouse embryonic fibroblasts (MEFs) that have hyperactive
mTORC1 signaling, but are insensitive to insulin and have diminished AKT activity (262, 263).
Subsequent studies demonstrated that S6K1 phosphorylates the insulin receptor (an RTK)
scaffold protein IRS1 at S302 (264).

Phosphorylation disrupts the binding of IRS1 to its

receptor, which diminishes signaling mediated by PI3K. Moreover, free IRS1 is sequestered by
14-3-3 and degraded by the 26S proteasome (265). More recently, S6K1 was also shown to
diminish mTORC2-mediated phosphorylation of AKT S473 by phosphorylating Rictor at T1135,
promoting its sequestration to 14-3-3 (266). This feedback mechanism is likely the reason why
hamartomas in TSC patients are less aggressive, as PTEN inhibition in TSC2-null tumors
circumvents the feedback loop and drives tumor progression (255, 267). There are important
therapeutic implications associated with this feedback loop as well. For instance, in TSC-null
cells, chronic rapamycin treatment partially restores insulin sensitivity through inhibition of
feedback control (264, 268). However, in tumors presenting with hyperactivating mutations
along the PI3K-AKT-mTOR signaling axis, chronic rapamycin treatment potentiates the
oncogenic effects of AKT, an unfavorable consequence of mTORC1 inhibition (269). In the
research described in this chapter, we discovered that mTORC1 signaling is sensitive to this
feedback regulation by AKT hyperactivity in response to pemetrexed. Furthermore, we show
that inhibition of mTORC1 can be prolonged for therapeutic gain by dual targeting of AMPK
and AKT, suggesting a rational combination therapeutic approach.
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Pharmacological and environmental modulation of AMPK signaling
A number of pharmacological agents, endogenous ligands, and environmental cues have
been identified as having AMPK-activating effects in cells. The mechanisms by which these
stimuli activate AMPK are as diverse as the chemical space they occupy, partly because AMPK
is sensitive to stresses that alter ATP homeostasis. For simplicity, activators will be grouped into
classes based on known mechanisms of activation of the kinase. Classes of AMPK-activating
agents discussed below include AMP-mimetics, inhibitors of oxidative phosphorylation,
mitochondrial ATP synthase inhibitors, inhibitors of glycolysis, modulators of cytosolic calcium,
and direct activators.
AICAR and now pemetrexed fall into the AMP-mimetic group. AICAR was the first
agent identified as an AMPK activator, and much of our understanding of downstream signaling
mediated by AMPK is credited to studies with this compound. AICAR is transported into cells
by the adenosine transporter and is converted to ZMP by adenosine kinase (AK) ((270). The
cellular effects of AICAR are ablated in cells lacking AK or cells co-treated with an AK
inhibitor, confirming ZMP as the active metabolite (141, 142). The development of AICAR as a
cancer therapeutic agent has been limited, partly because of its limited bioavailability in vivo and
its ability to compete for transport at the adenosine receptor (270, 271).

Of note, the

concentrations of pemetrexed required to activate AMPK are several orders of magnitude less
than AICAR. Nevertheless, AICAR has served as an excellent positive control for effects of
pemetrexed mediated by accumulated ZMP.
Agents that deplete cellular ATP levels through various mechanisms often have a
resultant AMPK-activating effect. The antidiabetic biguanides (metformin, phenformin) and
thiazolidinediones (troglitazone, rosiglitazone, and pioglitazone) are representative of AMPK-
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activating agents that inhibit oxidative phosphorylation, thus altering the AMP:ATP ratio by
diminishing mitochondrial ATP production. Metformin has been a standard of care in the
treatment of type-2 diabetes for over 50 years, and it is now appreciated that the effects of
metformin on glucose uptake and metabolism are partially mediated by AMPK activation
secondary to inhibition of complex I of the electron transport chain (272, 273). Although studies
have suggested that metformin activates AMPK through various other mechanisms, metformin
was unable to activate AMPK in HEK293 cells that were transfected with an AMPKγ mutant
that rendered the kinase insensitive to elevated AMP levels (274). This illustrated that the effects
of metformin on AMPK are mediated exclusively by alterations in the AMP:ATP ratio.
Interestingly, chronic metformin administration in animal models of spontaneous breast cancer
and diet-induced prostate cancer decreased tumorigenesis (275, 276). Indeed, epidemiological
studies have noted a negative correlation of cancer incidence among diabetic patients taking
metformin (277, 278). Resveratrol and quercetin are plant-derived polyphenols that elicit their
AMPK-activating effects through inhibition of mitochondrial ATP synthase (279). The effects
of resveratrol on insulin sensitivity, glucose tolerance, and mitochondrial biogenesis were
ablated in AMPKα1 or α2 knockout mice, illustrating the centrality of AMPK in these beneficial
effects of resveratrol (280). While resveratrol likely mediates its effects on AMPK exclusively
through this mechanism, quercetin may affect AMPK in additional ways, since the abovedescribed HEK293 mutant cell line is not completely insensitive to quercetin, as it is with
resveratrol (274).
Drug discovery efforts by Abbott Laboratories (Abbott Park, IL) identified A-769662 as
the first direct AMPK activator (281). A-769662 has a thienopyridone core structure and was
initially shown to activate AMPK in vitro and significantly decrease plasma glucose in a diabetic
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mouse model.

A-769662 mimicked both effects of AMP, allosteric activation as well as

protection of AMPKα T172, but it did not compete with AMP for binding (157). Consistent
with this result, γ mutant HEK293 cells insensitive to AMP were sensitive to A-769662 (274).
Conversely, AMPKβ mutants completely lacking the glycogen binding domain were insensitive
to A-769662 while sensitivity to AMP remained (179). Interestingly, S108 in the glycogenbinding domain was identified as a critical residue for A-769662 action, but the significance of
this residue is unknown. While the binding site of A-769662 is elusive, these data suggest that
A-769662 either directly interacts with the β subunit or that allosteric binding causes a
conformational shift in the β subunit essential for activation of the kinase. Like pemetrexed,
activation of AMPK by A-769662 did not require the upstream kinase LKB1.
While AMPK classically responds to variation in the AMP:ATP ratio, AMPK was
discovered to be sensitive to changes in intracellular calcium homeostasis (188-190).

A

plausible explanation of why the kinase has adapted to respond in this way is that calcium
triggers many energy-consuming cellular processes, such as membrane trafficking,
neurotransmitter secretion, and the operation of ion channels and pumps (191). The predominant
effector of AMPK in response to calcium is CAMKKβ, as isoform-specific siRNA and the
CAMKK inhibitor STO-609 ablates residual AMPK activity in LKB1-null Hela cells following
treatment with the calcium ionophore A23187 (188). As described above, CAMKKβ is a known
alternative upstream kinase of AMPKα T172. This residue is hyperphosphorylated in response
to A23187, an effect blocked by STO-609 (188-190).

Activation of AMPK in response to

calcium occurs in the absence of allosteric binding of AMP, as γ mutant HEK293 cells
insensitive to AMP were as sensitive to A23187 as wild type cells, and the effect was blocked by
STO-609 (274).
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In addition to pharmacological activators, AMPK is sensitive to a number of pathological
stressors and physiological stimuli such as the endogenous hormones leptin, adiponectin, ghrelin,
and endocannabinoids (282). AMPK is activated in response to hypoxia and ischemia, and this
activation is thought to be causal of the increased glycolytic flux observed in cardiac tissue under
these conditions (283). Activation is likely the result of inhibition of oxidative phosphorylation
and subsequent changes to the AMP:ATP ratio. In neuronal tissue, it is unclear whether AMPK
activation under ischemic conditions is protective or detrimental (284). Interestingly, glial cell
AMPKα2 seems to be more sensitive to hypoxia than α1, and regulation of the kinase might
occur at both the mRNA and protein level (285). In skeletal muscle, AMPKα2 is activated in
response to exercise (286). This effect is likely a direct result of muscle contraction rather than
hormonal release, as the kinase is stimulated experimentally by electrical-induced contraction of
rat epitrochlearis muscles, albeit to a lesser extent than by perfusion with AICAR (287). In a
recent study, it was shown that treatment of sedentary C57B/6J mice with AICAR (500
mg/kg/day) for 4 weeks actually mimicked effects seen with exercise. Notably, mice had a
decreased ratio of epididymal fat mass to body weight ratio with no subsequent weight loss,
increased oxygen consumption, and mice ran longer (23%) and farther (44%) in a treadmill
endurance test than vehicle-treated mice (288).
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MATERIALS AND METHODS
Chemicals and reagents
SAMS peptide (#1344) was from Tocris Bioscience (Ellisville, MO).

Protein G

sepharose (#17061801) and m7GTP-Sepharose (27502501) were from GE Lifesciences
(Piscataway, NJ). AMPKα1 antibody (#07350) for immunoprecipitation was from Upstate
(Billerica, MA). [γ-32P]-ATP (#NEG002) was from Perkin Elmer (Waltham, MA) and was
supplied at a specific activity of 10 Ci/mmol. GSK690693 was from SYN Thesis Med Chem
(Melbourne, Australia).

OSU-03012 was a gift from Dr. Paul Dent (VCU Department of

Neurosurgery). DharmaFECT transfection reagent #2 (#T200201), Dharmacon siGENOME
SMARTpool

siRNAs

targeting

human

ATIC

(#M008292010005),

AMPKa1

(#M005027020005), and non-targeting siRNA pool #1 (#D0012061305) were purchased from
Thermo Scientific (Rockford, IL).

AICAR (#A611700) was from Toronto Research

Biochemicals (Toronto, Canada). Trans35S-Label (#51006) was from MP Biochemicals (Santa
Ana, CA) and was provided at a specific activity of 1175 Ci/mmol. Complete EDTA-free
Protease Inhibitor Cocktail tablets (#11873580001) were from Roche Applied Science
(Indianapolis, IN). Thirty % Acrylamide/BIS solution 37.5:1 (#1610158), Laemmli Sample
Buffer (#1610737), and Dual Color Precision Plus Protein Standard (#1610374) were from BioRad Laboratories. Immobilon polyvinylidene fluoride (PVDF) membrane (#IPVH00010) was
from Millipore (Billerica, MA). StartingBlock Blocking Buffer (#37542), Goat anti-rabbit IgG
(#31462), and Goat anti-mouse IgG (#31348) secondary antibodies were from Thermo
Scientific.

Blotting Grade Blocker Non-fat Dry Milk (#1706404) was from Bio-Rad

Laboratories. A list of antibodies and their sources can be found in Table 3-2. All other reagents
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were from Fisher Scientific (Waltham, MA) or Sigma Aldrich (St. Louis, MO) and were of the
highest available purity.

Immunoblotting
Total Protein Isolation: Protein was typically harvested from 2-5 x 106 cells grown on
100 mm dishes.

Prior to total protein harvest, one protease inhibitor cocktail tablet was

dissolved in 50 ml 1x PBS and placed on ice. Tissue culture plates were kept cold throughout
the harvesting procedure. Cells were washed once with cold 10 ml PBS (containing protease
inhibitor), scraped, and pelleted at 1,000 rpm for 5 minutes at 4°C. Cells were lysed in cold
buffer containing 62.5 mM Tris-HCl pH 6.5, 2% SDS, 5% glycerol, 5% 2-mercaptoethanol, 50
mM NaF, and a 1x concentration of Complete EDTA-free Protease Inhibitor Cocktail. Lysates
were sheared through 21-gauge needles 30 times before being spun at 14,000 rpm for 2 minutes.
This shearing procedure was repeated, and lysates were spun at 14,000 rpm for 5 minutes. The
protein concentration was determined using the Bradford Reagent according to the
manufacturers protocol with BSA as a standard. Typical protein concentration was 2-5 µg/µl.
Protein was placed in single-use aliquots and stored at -80°C.
SDS-PAGE and Protein Transfer: Gel electrophoresis and wet membrane transfers were
performed using the Mini PROTEAN-3 Cell system (#1653301) from Bio-Rad Laboratories.
Total protein was mixed with an equal volume of Laemmli Sample Buffer, boiled for 5 minutes,
and 20 µg was loaded onto 1.5 mm SDS-polyacrylamide gels, poured according to the recipe
provided with 30% Acrylamide/Bis 37:5:1 (#1610158) from Bio-Rad Laboratories. An aliquot
(5-10 µl) of Dual Color Precision Plus Protein Standard was also loaded onto every gel for mass
determination. Typically, protein was resolved on 7.5% or 12% gels in running buffer (25 mM
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Tris base, 250 mM glycine, 0.1% SDS) at 50 volts for 30 minutes (or until protein migrated out
of the stacking gel) followed by 120 volts for 1-1.5 hours to optimally separate the protein of
interest.
Polyvinylidene fluoride (PVDF) membrane that had been pre-soaked in methanol was
rinsed in water along with the gels, and, PVDF, gels, and sponges for the transfer were
equilibrated for at least 20 minutes in cold transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine,
10% methanol). Six pieces of Whatman paper per gel were cut to the approximate size of an
electrophoresis plate, and the transfer sandwich was assembled as follows. Layering on the
black face of a transfer cassette, 3 pieces of Whatman paper (dipped in transfer buffer) were
placed on top of 1 sponge. Air bubbles were removed by rolling with a 5 ml plastic pipette. The
gel was centered on the Whatman paper, and a PVDF membrane was placed on top of the gel.
Again, it was important to remove all air bubbles from the transfer sandwich by rolling. It also
helped to keep the sandwich as wet as possible with transfer buffer during assembly. 3 pieces of
Whatman paper (dipped in transfer buffer) were placed on top of the membrane, followed by
another sponge. The transfer cassette was closed, placed in its holder in the gel box along with a
plastic ice block, and the gel box was then filled with cold transfer buffer. Transfers were either
ran on ice or in the cold room (4°C) at 100 volts for 45 minutes (one gel) or 50 minutes (2 gels).
Following the transfer, membranes were dipped in methanol and dried on the lab bench for 15
minutes before being immunoblotted.
Antibody Detection: A general antibody detection procedure is described in this section.
For detailed conditions for each antibody, refer to Table 3-2. Dried membranes were soaked
briefly in methanol and non-specific proteins were blocked for 1 hour in either StartingBlock
Buffer or 5% Blotting Grade Blocker Non-fat Dry Milk 0.1% TBS-T (0.5 M Tris-HCl pH 7.5,
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0.14 M NaCl, 2.7 mM KCl, 0.1% Tween 20). Membranes were washed three times for 5
minutes in 0.1% TBS-T. Primary antibodies diluted in either StartingBlock Buffer or 5% BSA
(#A4503) from Sigma were incubated on the membranes overnight at 4°C with rotation in sealed
plastic bags to minimize antibody consumption. Membranes were washed 3 times with 0.1%
TBS-T for 5 minutes and incubated for 1 hour in horseradish peroxidase-conjugated secondary
antibody. Membranes were then washed 3 times with 0.1% TBS-T for 10 minutes. It was found
that washing more stringently during this step greatly diminished non-specific background
during exposure.

Membranes were incubated with West Pico or West Dura SuperSignal

chemiluminescence substrate (Pierce) for 5 minutes. Blots were exposed to autoradiography
film and processed on an automated film developer. If the chemiluminescent conditions were
not known, West Pico was applied first. If no signal was apparent, the blot was rinsed with 0.1%
TBS-T, and West Dura (diluted by 40% with PBS) was applied. Signal was usually observed
with one of these conditions, and rarely was a more stringent detection reagent applied. Blots
presented in this dissertation are representative of findings from at least two biological replicates.

AMPK activity assays
Immunoprecipitated AMPKα1 activity was measured as the amount of radiolabelled
phosphate transferred to the SAMS peptide based on the method described by Hardie et al (289).
HCT116 cells were plated at a density of 106 cells/100 mm dish and were drug-treated the
following day. Cells were washed once with PBS and scraped before being broken in cold lysis
buffer (50 mM Tris-HCl pH 7.4, 50 mM NaF, 5 mM Na pyrophosphate, 1 mM EDTA, 1 mM
EGTA, 250 mM mannitol, 1% (v/v) Triton X-100, 1 mM DTT, 1 mM benzamidine, 0.1 mM
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PMSF, and 5 µg/ml soybean trypsin inhibitor). Protein content was determined by Bradford
assay using BSA as a standard.
For each sample, a 10 ul bed volume of protein G sepharose was equilibrated with IP
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 50 mM NaF, 5 mM Na pyrophosphate, 1 mM
EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 1 mM DTT, 0.1 mM benzamidine, 0.1 mM PMSF,
and 5 µg/ml soybean trypsin inhibitor) by washing three times. Ten µg of AMPKα1 antibody
(Upstate) was bound to the equilibrated protein G beads by incubating for 45 minutes at 4°C
with rotation. Antibody-bound beads were washed 5 times with cold IP buffer and incubated
overnight with 100 µg of protein lysate at 4°C with rotation. The AMPKα1 IP was washed 4
times with cold IP buffer containing 1 M NaCl followed by 2 washes with cold buffer containing
62.5 mM HEPES pH 7.0, 62.5 mM NaCl, 62.5 mM NaF, 6.25 mM Na pyrophosphate, 1.25 mM
EDTA, 1.25 mM EGTA, 1 mM DTT, 1 mM benzamidine, 1 mM PMSF, and 5 µg/ml soybean
trypsin inhibitor. The IP was resuspended in 60 µl of assay buffer (50 mM HEPES pH 7.4, 1
mM DTT, and 0.02% (v/v) Brij-35).
Typical reactions were performed in 25 µl of assay buffer containing 0.2 mM SAMS
peptide, 0.2 mM AMP, 0.2 mM [γ-32P]-ATP (final specific activity ~500 cpm/pmol), 5 mM
MgCl2, and 5 µl (approximately 8 µg) of immunoprecipitated AMPKα1.

Reactions were

incubated in a water-bath shaker at 37° and were quenched by spotting onto Whatman P81 paper.
Papers were washed carefully by slow mixing twice for 5 minutes in 500 ml of 1% (v/v)
phosphoric acid, once in 500 ml H2O, and once in 100 ml acetone before being counted in
scintillation fluid.
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High performance liquid chromatography analysis of ATP
Whole-cell acid-soluble extracts were made as previously described in Chapter 2. ATP
was analyzed by HPLC using a Spectra-Physics P4000 pump, UV2000 absorbance reader set to
monitor a wavelength of 254 nm, and a Datajet integrator. A strong anion exchange (SAX) 250
x 2 mm HPLC column (#00G4149B0 Phenomenex Torrance, CA) fitted with a guard column (#
KJ04282, #AJ04310 Phenomenex Torrance, CA) was equilibrated with Buffer A (7.5 mM
NH4H2PO4, pH 4.5, 2% CH3CN) at a flow rate of 0.2 ml/min. Typically, 5 µl acid-soluble
extract was injected onto the column in a volume of 300 µl Buffer A. After passing Buffer A
over the column for an additional 2 minutes, ATP was eluted from the column using a linear
gradient of 100% Buffer A to 60% Buffer B (750 mM NH4H2PO4 pH 4.9, 2% CH3CN) over 25
minutes at a flow rate of 0.2 ml/min. ATP had a retention time of approximately 32 minutes
under these conditions (Figure 3-4A). 60% Buffer B was flowed over the column for an
additional 8 minutes following each run to clean the column, and the mobile phase was returned
to Buffer A over the next 10 minutes. Total time from injection to injection was approximately
45 minutes. To determine ATP concentration from extracts, results were fitted to a standard
curve generated from synthetic ATP (Figure 3-4B).

RNA interference
Cells were plated at 2 x 105 cells/well of a 6-well plate late in the day. siGENOME
SMARTpool siRNAs (Dharmacon) (50 nM) were transfected with 0.1% DharmaFECT reagent
according to the manufacturer’s instructions. The transfection media remained on the cells for
24 hours, at which time cells were washed with PBS and fresh media was replaced. Longer
incubations resulted in visually apparent toxicity under a microscope. All experiments were
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Figure 3-4. Identification and quantification of ATP by HPLC. ATP was analyzed by
HPLC from whole-cell acid soluble extracts as described in the Methods section. (A) A
representative HPLC chromatogram measuring ATP from CEM cells treated with 1 µM
pemetrexed and 5.6 µM thymidine for 24 hours. (B) A standard curve was generated with
synthetic ATP.
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controlled with the DharmaFECT transfection reagent in the absence of siRNA (mock), as well
as a non-targeting siRNA SMARTpool (scrambled). Drug treatments were started 48 hours after
transfection, and protein was harvested after 72 hours, unless otherwise noted. AICART siRNA
transfected using this method produced greater than 90% and less than 95% knockdown in
HCT116 cells that was apparent by 48 hours and persisted 72 hours post-transfection (Figure 35). A similar result was seen with AMPKα1 knockdown (Figure 3-11A).

Clonogenic survival assays
Cells were plated in triplicate from a single cell suspension at 100/60 mm dish and
allowed to attach overnight. Cells were then treated continuously with media supplemented with
drugs (and rescue agents) for the indicated times. Plates were washed with PBS, and fresh media
was added every 2-3 days until control colonies were easily counted (typically 7-10 days). When
rescue agents were included, they remained in the media throughout the duration of the
experiment. Plates were then washed twice with PBS, fixed with methanol for 20 minutes, and
stained with 5% Wright-Giemsa reagent for 20 minutes. Stain was washed off with H2O, and
plates were dried overnight at room temperature. All visible colonies were counted manually.

Assaying for global protein synthesis
To determine global translational effects of pemetrexed in HCT116 cells, protein
synthesis rates were determined by 35S-methionine incorporation following drug exposure. Cells
were plated at a density of 2 x 106 cells/150 mm dish late in the day and treated with drugs the
following morning. Drug-containing culture media was aspirated and the cells were washed
once with PBS before being trypsinized and counted. Cells (4 x 105) were transferred to a 1.5 ml
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Figure 3-5. AICART knockdown in HCT116 cells. HCT116 cells were transfected with
Dharmacon siGENOME SMARTpool siRNAs targeting human AICART as described in the
Methods section. Immunoblot analysis confirmed siRNA knockdown (KD) of AICART 48 and
72 hours after transfection (upper panel). Total protein (20 µg) was loaded into each lane in the
upper panel. Quantification of AICART KD (lower panel) after 72 hours indicated greater than
95% knockdown in these cells. Mock indicates treatment with transfection reagent alone.
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microcentrifuge tube and spun at 1,000 rpm for 5 minutes. Pelleted cells were resuspended in
500 µl RPMI 1640 with 10% dFBS and 0.5 µCi Trans35S-Label. A typical batch of Trans35SLabel contained greater than 70% 35S-methionine. Triplicate reactions were incubated in a 37°C
water bath with shaking for 0, 10, 20, 40, and 60 minutes, and were quenched by adding 500 µl
20% TCA (10% TCA

[final]),

vortexing vigorously, and holding on ice. When all incubations

were completed, samples were spun at 7,500 rpm for 5 minutes. The supernatant was aspirated,
and the pellet was washed twice with 2 ml 5% TCA. Pellets were resuspended in 200 µl 23 M
formic acid, and 90% was of the total volume counted in scintillation fluid. One µl of label was
counted with each experiment to correct for decomposition. Counts were expressed as nmol 35Smethionine incorporated/min/106 cells.

m7GTP-CAP pulldown
To determine whether pemetrexed treatment enhanced residence of 4E-BP1 at the m7guanosine CAP, cell lysates were incubated with m7GTP-sepharose beads, which have been
previously shown to bind both eIF4E and 4E-BP1 (290).

Following the indicated drug

treatments, cells were lysed on ice for 30 min in IP buffer (25 mM HEPES pH 7.5, 1% NP40,
100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 1 mM PMSF, 0.1% 2mercaptoethanol, and 1x Roche Complete Protease Inhibitor Tablet). Cleared lysate (500 µg)
was incubated with 40 µl of a 50% slurry of m7GTP-Sepharose (GE Lifesciences) for 2 hr at 4°C
with rotation. Cap complexes were washed with IP buffer four times, resuspended in Laemmli
Sample Buffer, and boiled for 5 min before being resolved on a 12.5% SDS-PAGE gel and
immunoblotted as described above.
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RESULTS
AMPK is activated by accumulated ZMP following AICART inhibition by pemetrexed
As described above, AMPK is sensitive to changes in the cellular AMP:ATP ratio. As
such, AMPK signals to key controlling elements of protein, lipid, and carbohydrate metabolism
to balance nutrient metabolism with energy supply (Table 3-1) (157). ZMP is a mimetic of
AMP, the primary allosteric activator of AMPK (132). The binding of AMP or ZMP to the
AMPKγ subunit causes both relief of autoinhibition of the catalytic AMPKα subunit as well as a
conformational shift in the AMPKα subunit, likely protecting T172 from phosphatases (179,
180). AMPKα T172 phosphorylation has been proposed to be essential for kinase activity, and
is therefore a conventional marker for AMPK activation (167, 168). In HCT116 cells treated
with pemetrexed, AMPKα T172 became robustly hyperphosphorylated (Figure 3-6A). A 3-fold
increase in kinase activity of AMPKα1 was also measured in HCT116 cells treated with
pemetrexed (Figure 3-6B). Kinase activity was assayed in vitro using the AMPK-specific SAMS
peptide as substrate and immunoprecipitated AMPKα1 from HCT116 cells pretreated with
pemetrexed.

The data in Figure 3-6 suggests that the hyperphosphorylation induced by

pemetrexed is sufficient to activate the kinase, while the increased phosphorylation measured
with thymidine alone was not sufficient to activate the kinase.

This increase in T172

phosphorylation in response to thymidine treatment is not completely understood and was not
always observed. AMPK activity was not measurable in immunoprecipitates from AMPKα2 in
either HCT116 or H460 cells, confirming that α1 is the primary catalytic subunit in these cells.
In addition to increases in AMP (or ZMP), AMPK is also activated in response to
decreases in cellular ATP levels. Since pemetrexed inhibits AICART, an intermediate of de
novo purine synthesis, it was necessary to determine the effect of pemetrexed on ATP pools.
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Figure 3-6. Pemetrexed induces AMPKα phosphorylation and activity in HCT116 cells.
HCT116 cells were treated with 1 µM pemetrexed in the presence of 5.6 µM thymidine to offset
the effects of TS inhibition. (A) The phosphorylation of T172 on AMPKα was detected by
western blot from 20 µg total protein, and (B) the kinase activity of 8 µg immunoprecipitated
AMPKα1 was measured using the SAMS peptide as a substrate as described in the Methods
section. In (B), error bars are representative of standard deviation from three technical
replicates.
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Previous studies have shown that pemetrexed does not diminish cellular ATP (291), and indeed,
we showed a similar result in CEM cells (Figure 3-7). In fact, ATP levels were slightly elevated
in response to pemetrexed, consistent with previous observations (291). Therefore, we suspected
that the AMPK response to AICART inhibition was a result of ZMP accumulation, not ATP
depletion (291).
To definitively link AICART inhibition to AMPK activation, we determined whether the
effects of pemetrexed treatment on AMPK activity could be recapitulated by depletion of
AICART. HCT116 cells were transfected with a pool of siRNA’s directed against AICART
mRNA (Figure 3-5). Indeed, AMPKα T172 phosphorylation was increased following AICART
knockdown, confirming the intermediacy of AICART inhibition in this effect (Figure 3-8A).
Surprisingly, the effect of approximately 95% knockdown of AICART (Figure 3-5) on ZMP
accumulation (Figure 3-8B) was less pronounced than that seen following treatment with
pemetrexed (Figure 2-16).

This suggested that pemetrexed treatment in these cells had a

stronger inhibitory effect on AICART than we initially suspected. Accumulation of ZMP in
AICART knockdown cells exposed to a low concentration of AICAR (100 µM) indicated that
the flow of de novo purine synthesis was becoming restricted by knockdown of AICART (Figure
3-8B). However, ZMP accumulation even under conditions of AICART knockdown with an
AICAR challenge in HCT116 cells did not match that seen following pemetrexed treatment in
these cells, in which the accumulation of up to 4 mM ZMP was commonly seen (Figure 2-16).
Therefore, it appears that AICART activity is not limiting the flux of de novo purine synthesis, as
previously postulated (140).

Importantly, this result indicates that extensive inhibition of

AICART is needed to cause the substantial accumulation of ZMP following pemetrexed
treatment.
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Figure 3-7. ATP is not depleted in CEM cells treated with pemetrexed. CEM cells were
treated with the indicated concentrations of pemetrexed and 5.6 µM thymidine for 48 hours.
ATP levels from whole-cell acid-soluble extracts were quantified by anion-exchange HPLC as
described in the Methods section. The area units under HPLC peaks corresponding to ATP were
converted to moles using the equation derived from a standard curve generated with synthetic
ATP. The cytosolic volume of 106 cells was roughly equivalent to 1 µl cell water. Data points
represent averages of two replicates.
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Figure 3-8. AICART knockdown recapitulates effects of pemetrexed in HCT116 cells.
siRNA knockdown (KD) of AICART mimics the effects of pemetrexed on (A) AMPKα
phosphorylation and (B) ZMP accumulation in HCT116 cells. Cells were exposed to siRNA for
24 hours and harvested after 72 hours. Where indicated, cells were treated with 100 µM AICAR
for the last 4 hours of incubation. In (A), 20 µg of total protein was loaded into each lane. In
(B), error bars represent standard deviations from two biological and two technical replicates.
* Represents measurements below the detection limit of the HPLC (<0.001 µM).
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mTORC1 inhibition by pemetrexed is dependent on AMPK activity
AMPK both directly and indirectly inhibits mTORC1 through phosphorylation of Raptor
and TSC2, respectively (Figure 3-1) (195, 196). The effect of pemetrexed on AMPK-dependent
Raptor phosphorylation was determined in HCT116 cells. In response to pemetrexed, striking
hyperphosphorylation of Raptor S792 was measured (Figure 3-9). Phosphorylation status of the
downstream target of mTORC1, S6K1, was used as an indicator of effects on mTORC1 activity.
Pemetrexed robustly inhibited S6K1 phosphorylation by mTORC1 at T389 (Figure 3-9).
Together, these data suggested that pemetrexed was inhibiting mTORC1 signaling through
effects on AMPK. In support of these findings, a competitive inhibitor of the AMPKα ATPbinding site, compound C (272), blocked the hypophosphorylation of S6K1 T389 induced by
pemetrexed (Figure 3-10). This implied that mTORC1 inhibition by pemetrexed depended on
the catalytic activity of AMPK. While the primary target of compound C is AMPK, off-target
effects of compound C likely complicate the specificity of this inhibitor as a chemical probe for
signaling events mediated by AMPK.

To definitively link pemetrexed-induced mTORC1

inhibition to AMPK activation, the effects of pemetrexed on mTORC1 signaling were
determined in HCT116 cells transiently transfected with siRNA pools to AMPKα1 (Figure 311). Interestingly, AMPKα1 knockdown had a significant cytotoxic effect in HCT116 cells,
suggesting that disruption of the balance of AMPK signaling either by activation or inhibition
might be a justified avenue of therapeutic intervention. Knockdown of AMPKα1 prevented the
hyperphosphorylation of Raptor at S792 and the hypophosphorylation of S6K1 at T389 induced
by pemetrexed (Figure 3-11B). These effects were measured even in the presence of elevated
ZMP levels, indicating that pemetrexed was still inhibiting AICART in these cells (Figure 3-
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Figure 3-9. Downstream effects of pemetrexed-induced activation of AMPK on mTORC1
signaling. Immunoblots on HCT116 cells treated with pemetrexed for 15 hours were probed for
p-S792 of the Raptor subunit of the mTORC1 complex and for p-T389 of S6K1 as described in
the Methods section. Total protein (20 µg) was loaded into each lane.
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Figure 3-10. Inhibition of mTORC1 signaling by pemetrexed is dependent on AMPK
activity. The AMPKα inhibitor, compound C (1 µM), blocks the effects of pemetrexed on
mTORC1 signaling following 15 hour exposure to both agents in HCT116 cells. All treatments
contained 0.1% DMSO and 5.6 µM thymidine. Total protein (20 µg) was loaded into each lane.
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Figure 3-11. Pemetrexed inhibits mTORC1 through activation of AMPKα1 in HCT116
cells. (A) Depletion of AMPKα1 by siRNA knockdown in HCT116 cells 48 hours after
transfection (B) blocks the effects of pemetrexed on mTORC1 signaling. siRNA pools were
added to HCT116 cells for 72 hour with 1 µM pemetrexed and 5.6 µM thymidine present during
the last 15 hours. Total protein (20 µg) was loaded into each lane. The bottom panel indicates
that ZMP still accumulated in siRNA-treated cells, as expected, and results are presented as
averages ± standard deviations from two biological and two technical replicates.
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11B). Importantly, knockdown of AMPKα1 depleted all AMPKα detectable by western blot
with an antibody that recognized both α1 and α2 isoforms of AMPK (Figure 3-11A), further
indicating that AMPKα2 was not expressed in HCT116 cells. We therefore concluded that the
pemetrexed-induced accumulation of ZMP behind an AICART block activated AMPK, signaling
downstream through Raptor phosphorylation to hinder the kinase activity of the mTORC1
complex (Figure 3-1). Additionally, AMPK signaling through TSC likely contributes to the
observed mTORC1 inhibition by pemetrexed, and it will be important to determine the extent of
inhibition through this axis in comparison to the direct effect on Raptor.

LKB1 is not required for AMPK activation in response to pemetrexed
The tumor suppressor gene product, LKB1, is the predominant upstream kinase of
AMPKα T172 in most cells (181-183). Phosphorylation of AMPKα T172 has been shown to be
requisite for the kinase activity of the trimer (167, 168), and genetic deletion of LKB1 renders
cells insensitive to several agents that function through AMPK activation. Since loss-of-function
mutations in LKB1 occur with high frequency in primary non-small cell lung carcinomas (Figure
3-2) (185), and pemetrexed is clinically indicated for the treatment of NSCLC, we sought to
determine whether the effects of pemetrexed on signaling through AMPK would be affected by
loss of LKB1.
In a screen of carcinoma cell lines for the secondary growth-inhibitory effect of
pemetrexed, we identified several cell lines that had loss-of-function mutations in LKB1, the
human H460 NSCLC, A549 lung carcinoma, and Hela cervical carcinoma (Figure 3-12).
Somewhat surprisingly, these cell lines were all sensitive to pemetrexed. The degree of
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Figure 3-12. Sensitivity of carcinoma cells to pemetrexed with thymidine and to
rapamycin. Cells were exposed to 1 µM pemetrexed and 5.6 µM thymidine or to 25 nM
rapamycin for 72 hour. Growth was assessed by Coulter counting. Cell line genotypes were
determined from the Sanger Institute Cancer Cell Line Project Consortium website
(http://www.sanger.ac.uk/genetics/CGP/CellLines/) and are listed as mutant (M) for LKB1,
PI3K, and KRAS. Mutancy for LKB1 indicates loss of function, while PI3K and KRAS
mutations confer hyperactivity. Cultures were set up in triplicate, and error bars are
representative of standard deviation from triplicate measurements.
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sensitivity to pemetrexed, however, could not be predicted by LKB1 mutation status alone, as
H460 was the second most sensitive cell line in our screen, A549 fell in the middle, and Hela
was among the least sensitive. We chose two cell lines for further investigation, H460 and Hela,
and confirmed that these cells lacked LKB1 expression by western blot (Figure 3-13A). H460
has a premature stop at codon 37, the most common loss-of-function mutation in LKB1 (292),
and Hela has a biallelic deletion of the gene (293). Cell growth in the presence of several
concentrations of pemetrexed with thymidine showed that both cell lines were indeed sensitive to
pemetrexed (Figure 3-13B).

Compared to HCT116 cells, which express wild type LKB1,

pemetrexed was 10-fold less potent at inhibiting growth in H460 and Hela cells (Figure 3-13).
Interestingly, the effect of proliferation of Hela cells plateaued at approximately 60% growth
inhibition, even at high concentrations of pemetrexed, while H460 had a similar growth
inhibitory effect as HCT116 at high concentrations. We do not yet understand this effect.
To determine whether inhibition of mTORC1 signaling was preserved in LKB1-null
carcinomas treated with pemetrexed, we used S6K1 T389 phosphorylation as a marker for
mTORC1 activity. To our surprise, S6K1 T389 was hypophosphorylated in both H460 and Hela
cells, proving that LKB1 was not necessary for the inhibitory effect of pemetrexed on mTORC1
(Figure 3-14). HCT116 cells were carried as a positive control through this experiment, and total
protein lysates from all three cell lines were loaded onto the same gels, allowing for quantitative
comparisons to be made across samples. Interestingly, S6K1 expression was significantly higher
in HCT116 than in H460, and Hela had very weak expression of S6K1. Because of this, the
exposure level for these blots was dependent on expression in Hela. Therefore, HCT116 total
and phosphorylated S6K1 was overexposed, as was H460 phosphorylated S6K1. While a clear
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Figure 3-13. Sensitivity of LKB1-null cell lines to growth inhibition by pemetrexed. (A)
LKB1 expression was assessed by immunoblot. Total protein (20 µg) was loaded into each lane.
(B) Growth was determined by Coulter counting after 72 hour exposure to 1 µM pemetrexed in
the presence of 5.6 µM thymidine. Cultures were set up in triplicate, and error bars are
representative of standard deviation from triplicate measurements.
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Figure 3-14. Signaling downstream of mTORC1 is inhibited in LKB1-null cells following
pemetrexed treatment. Cells were exposed to 1 µM pemetrexed and 5.6 µM thymidine for 15
hours. Immunoblots were done on equivalent amounts of total protein, assayed by the Bradford
method. Total protein (20 µg) was loaded into each lane. Blots were exposed to the level at
which HELA S6K1 was detectable, resulting in overexposure of H460 and HCT116.
Hypophosphorylation is also detectable by the pronounced mobility shift in the total S6K1 blot
in pemetrexed-treated lanes.
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diminution in S6K1 T389 phosphorylation was measured in all three cell lines, the degree of
hypophosphorylation of S6K1 T389 correlated with the degree of sensitivity to pemetrexed (i.e.,
HCT116 being the most sensitive and Hela the least). Regardless, this result indicated that
pemetrexed-mediated mTORC1 inhibition was indeed maintained in the absence of LKB1.
In HCT116 cells, we used chemical (compound C) and genetic (AMPKα1 siRNA
knockdown) approaches to determine whether the effects of pemetrexed on mTORC1 activity
were mediated through AMPK activation. By both criteria, they were. Likewise, in H460 cells,
blocking the catalytic activity of AMPK with compound C ablated the inhibitory effect of
pemetrexed on S6K1 T389 phosphorylation (Figure 3-15). This confirmed that pemetrexedmediated mTORC1 inhibition was mediated by AMPK activation in the absence of LKB1.
Unlike what was seen in HCT116, compound C induced S6K1 T389 hypophosphorylation in the
absence of pemetrexed in H460 cells, an effect not completely understood at this time.
In LKB1-null cell lines, enhanced phosphorylation of AMPKα T172 did not always
correspond with AMPK activity. For example, in H460 cells, hyperphosphorylation of AMPKα
T172 in response to pemetrexed treatment was not detectable, because this residue was already
hyperphosphorylated in the absence of treatment (Figure 3-16). However, in addition to the
above-mentioned result with S6K1 T389 phosphorylation, several observations discussed later in
this chapter clearly indicated that AMPK was activated by pemetrexed exposure. 1) The direct
target of AMPK, acetyl CoA carboxylase (ACC), was hyperphosphorylated at S79 in H460 and
Hela cells (Figure 3-17). ACC catalyzes the committed reaction of de novo fatty acid synthesis,
the conversion of acetyl CoA to malonyl CoA. Phosphorylation of ACC at S79 by AMPK
inhibits the activity of this enzyme (198). 2) Eukaryotic elongation factor 2 (eEF2), the substrate
for the direct AMPK target eEF2 kinase, was also hyperphosphorylated at T56 in H460 and Hela
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Figure 3-15. Inhibition of mTORC1 signaling by pemetrexed is dependent on AMPK
activity, even in the absence of LKB1. The AMPKα inhibitor, compound C (1 µM), blocks the
effects of pemetrexed on mTORC1 signaling in the H460 LKB1-null human non-small cell lung
carcinoma cell line following 15 hour exposure to both agents. All treatments contained 0.1%
DMSO and 5.6 µM thymidine. Total protein (20 µg) was loaded into each lane.
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Figure 3-16. Differential effects of AMPKα T172 phosphorylation in response to
pemetrexed across cell lines. Cells were exposed to 1 µM pemetrexed and 5.6 µM thymidine
or to 250 µM AICAR for 15 hours. Total protein was isolated, quantified, and subjected to
immunoblot analysis as described in the Methods section. Total protein (20 µg) was loaded into
each lane. H460 blot on the right was overexposed to allow for detection of HELA.
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Figure 3-17. Differential effects on acetyl-CoA carboxylase S-79 phosphorylation in
response to pemetrexed across cell lines. Cells were exposed to 1 µM pemetrexed and 5.6 µM
thymidine or to 250 µM AICAR for 15 hours. Total protein was isolated, quantified, and
subjected to immunoblot analysis as described in the Methods section. Total protein (20 µg) was
loaded into each lane. H460 blot on the right was overexposed to allow for detection of HELA.
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Figure 3-18. Phosphorylation of eukaryotic elongation factor 2 at T56 is augmented in
response to pemetrexed in cells of wild type (HCT116) and –null (H460, HELA) LKB1
status following pemetrexed treatment. Cells were exposed to 1 µM pemetrexed and 5.6 µM
thymidine for 15 hours. Total protein was isolated, quantified, and subjected to immunoblot
analysis as described in the Methods section. Total protein (20 µg) was loaded into each lane.
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cells (Figure 3-18).

Phosphorylation of eEF2 kinase by AMPK promotes eEF2 kinase to

transmit an inhibitory phosphorylation signal to eEF2 by targeting T56 on this essential
translation elongation factor (197). AMPK in untreated H460 cells was inactive by these criteria.
The inactivity of AMPK that was extensively phosphorylated at T172 in untreated H460 cells led
to the conclusion that T172 phosphorylation was necessary, but not sufficient for AMPK
activation in these cells, and our data suggested that AMPK activation only occurred following
accumulation of ZMP either after pemetrexed or AICAR treatment (Figures 3-16 through 3-18).
The effect of pemetrexed on AMPKα T172 phosphorylation in Hela cells was somewhat
different. Hyperphosphorylation of AMPKα T172 was measured in Hela cells treated with
pemetrexed, but not with AICAR (Figure 3-16). The inability of AICAR to activate AMPK in
Hela cells has indeed been reported by others (182). Surprisingly, we measured no accumulation
of ZMP in AICAR-treated Hela cells (data not shown). This suggested that Hela cells might
have lost adenosine kinase function, preventing the conversion of AICAR to ZMP. This finding
warrants further study.

Feedback suppression of AKT is relieved following pemetrexed-induced mTORC1 inhibition
The original purpose of the following experiments was simply to characterize the
dynamics of mTORC1 inhibition by pemetrexed. We somewhat naively hypothesized that we
would see a pattern of AMPK activation that coincided with downstream inhibition of mTORC1
signaling, measured by phosphorylation status of S6K1 and 4E-BP1. Signaling events along the
AMPK-mTORC1 axis were measured as a function of time following pemetrexed and thymidine
treatment in HCT116 cells.

A 48-hour signaling time course was chosen based on the time

course of ZMP accumulation measured in these cells. In response to pemetrexed, AMPKα
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became hyperphosphorylated at T172 by 15 hours and this phosphorylation persisted for an
interval coincident with expansion of the ZMP pool (Figure 3-19). It therefore appeared that the
presence of this expanded ZMP pool was sufficient to trigger AMPKα hyperphosphorylation for
an extended period of time.
Initially, a burst in mTORC1 signaling was measured at the 7-hour time point, supported
by both hyperphosphorylation of 4E-BP1 and S6K1 (Figure 3-20A and 3-21).

This was

especially apparent from a mobility shift observed on immunoblots of total 4E-BP1 (Figure 320A). Since 4E-BP1 has 4 phosphorylation sites sensitive to mTORC1, a substantial shift in size
can be seen when probing for total protein.

The hyperphosphorylated form runs at

approximately 22 kDa on a 12.5% polyacrylamide gel, while the unphosphorylated form runs at
approximately 17 kDa (Figure 3-20A). At time 0 (or in untreated cells) total 4E-BP1 looked like
a smear across this size range, indicating a mixture of phosphorylated forms. However, at the 7hour time point, there was a clear mobility shift to the higher phosphorylated form, and this was
confirmed by measuring hyperphosphorylation of 4E-BP1 T70.

The mechanism by which

mTORC1 signaling ramped up before being shut down is unknown to us, as is the therapeutic
relevance of this interesting phenomenon.
Inhibition of 4E-BP1 phosphorylation peaked by 15 hours, but recovered slowly, as
indicated by western blots probed with phospho-specific antibody and, particularly, by a pan 4EBP1 antibody (Figure 3-20A). While only a very low percentage of this protein ran at the
position of p-4E-BP1 (pan 4E-BP1 blot, Figure 3-20A), there was a substantial expansion of the
cellular content of unphosphorylated 4E-BP1 after pemetrexed treatment in HCT116 cells. This
suggests that 4E-BP1 was either being overexpressed or that the protein was not susceptible to
turnover in its unphosphorylated form following pemetrexed treatment.
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Because

unphosphorylated 4E-BP1 is known to tightly bind to eIF4E-capped mRNA complexes,
preventing the binding of eIF4G and the initiation of cap-dependent translation (Figure 3-3), we
hypothesized that CAP-bound 4E-BP1 was stabilized. We measured the binding of 4E-BP1 to
eIF4E-cap complexes in extracts of pemetrexed-treated cells. The binding of 4E-BP1 to eIF4Ebound 7-methyl-GTP-beads was enhanced by pemetrexed and was maintained for at least 24
hours after treatment (Figure 3-20B), indicating a prolonged presence of active inhibitor of capdependent translation.

In contrast, the binding of 4E-BP1 to cap complexes promoted by

rapamycin was less than seen with pemetrexed and diminished at longer times (12 hr) after
treatment (Figure 3-20B), as previously shown by others (294).
To our surprise, the time-course of pemetrexed effects on S6K1 phosphorylation (Figure
3-21) indicated that S6K1 phosphorylation was initially inhibited by 15 hours, but that
hypophosphorylation of S6K1 was transient and partially recovered by 48 hours (Figure 3-21).
As in HCT116 cells, hypophosphorylation of S6K1 was transient in H460, peaking at 15-24
hours and partially recovering by 48 hours, suggesting that the negative feedback controls on
mTORC1 signaling are also functional in H460 cells, which lack LKB1 (Figure 3-21). Important
to note is that the recovery of S6K1 phosphorylation occurred in spite of continued
phosphorylation of AMPKα T172 and expansion of the ZMP pool (Figure 3-19 and 3-21),
suggesting that an event dominant over continued AMPK activity was being activated.
We sought to determine whether the partial escape from mTORC1 inhibition following
pemetrexed was caused by relief of feedback suppression of PI3K and AKT signaling (Figure 31). The phosphorylation and stability of IRS-1 was determined with an antibody directed against
total IRS-1 protein. As S6K1 became hypophosphorylated at T389, an increased level of IRS-1
was observed (Figure 3-22), presumably signifying expression and stabilization of this protein
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Figure 3-19. ZMP accumulation and AMPK activation as a function of time in HCT116
cells exposed to pemetrexed. For Immunoblotting, cells were exposed to 1 µM pemetrexed and
5.6 µM thymidine for the indicated times. Total protein was isolated, quantified, and subjected
to immunoblot analysis as described in the Methods section. Total protein (20 µg) was loaded
into each lane. For ZMP measurements, cells were exposed to 1 µM pemetrexed and 5.6 µM
thymidine for 0, 4, 7, 15, 24, and 48 hours. Acid-soluble extracts were analyzed by HPLC as
described in the Methods section. The area units under HPLC peaks corresponding to ZMP were
converted to moles using the equation derived from a standard curve generated with synthetic
ZMP. The cytosolic volume of 106 cells was roughly equivalent to 1 µl cell water. Error bars
are representative of standard deviation from two biological and two technical replicates.
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Figure 3-20. Repression of mTORC1 signaling to 4E-BP1 is maintained over time
following pemetrexed treatment in HCT116 cells. (A) Cells were exposed to 1 µM
pemetrexed and 5.6 µM thymidine for the indicated times. Total protein was isolated,
quantified, and subjected to immunoblot analysis as described in the Methods section. Total
protein (20 µg) was loaded into each lane. (B) Cells were exposed to 1 µM pemetrexed and 5.6
µM thymidine or 25 µM rapamycin for the indicated times. Thymidine and DMSO controls
were exposed for 24 hours. Cell lysates (500 µg) were incubated with m7GTP-Sepharose beads
and subjected to immunoblot analysis as described in the Methods section. Sepharoseprecipitated protein (350 µg) was loaded into each lane probed with 4E-BP1 antibody, and 150
µg sepharose-precipitated protein was loaded into each lane probed with eIF4E antibody.
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Figure 3-21. Repression of mTORC1 signaling to S6K1 partially recovers over time
following pemetrexed treatment in HCT116 and H460 cells. Cells were exposed to 1 µM
pemetrexed and 5.6 µM thymidine for the indicated times. Total protein was isolated,
quantified, and subjected to immunoblot analysis as described in the Methods section. Total
protein (20 µg) was loaded into each lane.
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Figure 3-22. Recovery of mTORC1 signaling in response to pemetrexed is concurrent with
release of feedback inhibition of PI3K and AKT in HCT116 cells. Cells were exposed to 1
µM pemetrexed and 5.6 µM thymidine for the indicated times. Total protein was isolated,
quantified, and subjected to immunoblot analysis as described in the Methods section. Total
protein (20 µg) was loaded into each lane.
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(264). Enhanced phosphorylation of AKT on S473 was also observed coincident with recovery
of pemetrexed-mediated inhibition of S6K1 in HCT116 cells (Figure 3-22).

Therefore, it

appeared that the partial recovery of S6K1 T389 phosphorylation (Fig 4B) was a result of
enhanced AKT activity, at least partially reactivating mTORC1. Importantly, reactivation of
mTORC1 is not seen following rapamycin treatment since there is a direct block of mTORC1.
This is a somewhat obvious, yet important distinction between direct mTORC1 inhibition and
inhibition of mTORC1 indirectly through AMPK activation.
In support of this mechanism of feedback hyperactivity of AKT being the cause of
transient S6K1 inhibition following pemetrexed, treatment of HCT116 cells with the pan-AKT
competitive inhibitor GSK690693 prolonged the inhibitory effect of pemetrexed on S6K1-T389
phosphorylation (Figure 3-23).

Additionally, colony formation experiments with this

combination indicated that the cytotoxicity of AICART inhibition by pemetrexed was enhanced
by exposure to the AKT inhibitor (Figure 3-24). Moreover, an additive cytotoxic effect in
HCT116 and H460 cells was measured by clonogenic survival when pemetrexed was combined
with the celecoxib-derived PDK1 inhibitor OSU-03012 (Figure 3-25). Collectively, these drugs
not only served as tools to identify AKT as a mediator of this rebound effect on mTORC1
signaling, they also suggest that combining pemetrexed with agents that inhibit PI3K signaling is
likely a clinically relevant combination strategy

The effects of AMPK activation by pemetrexed extend beyond mTORC1 inhibition
Our studies thus far have primarily focused on the effects of pemetrexed as an mTORC1
inhibitor. However, the downstream consequences of AMPK activation are well known to
extend beyond inhibition of mTOR signaling (Table 3-1). This is illustrated in a comparison of
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Figure 3-23. AKT reactivation mediates recovery of mTORC1 signaling after pemetrexed
treatment in HCT116 cells. Cells were exposed to 1 µM pemetrexed and the pan AKT
inhibitor GSK690693 (100 nM) in the presence of 5.6 µM thymidine for the indicated times.
Total protein was isolated, quantified, and subjected to immunoblot analysis as described in the
Methods section. Total protein (20 µg) was loaded into each lane.
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Figure 3-24. The cytotoxicity of pemetrexed in HCT116 cells is enhanced in combination
with GSK690693. Clonogenic survival assays were performed as described in the Methods
section. Cells were exposed to 0-10 µM combinations of pemetrexed and GSK690693 for 72
hours. Survival plates representative of additivity are shown in the top panel and enumerations
of these colonies are shown in the bottom panel. Cultures were set up in triplicate, and error bars
are representative of standard deviation from triplicate measurements.
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Figure 3-25. The cytotoxicity of pemetrexed in (A) HCT116 and (B) H460 is enhanced in
combination with OSU-03012. Clonogenic survival assays were performed as described in the
Methods section. Cells were exposed to 0-10 µM combinations of pemetrexed and OSU-03012
for 72 hours. Colony number was counted manually, and representative combinations showing
additivity are depicted relative to control colony formation in the presence of vehicle (0.1%
DMSO). Cultures were set up in triplicate, and error bars are representative of standard
deviation from triplicate measurements.
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growth inhibitory effects of pemetrexed and thymidine with rapamycin (Figure 3-12). The
sensitivity of all ten of these cell lines to pemetrexed and to a concentration of rapamycin that
would cause complete and prolonged inhibition of mTORC1 (25 nM) were not identical nor even
correlated, with most cell lines demonstrating higher sensitivity to AMPK activation by
pemetrexed than to direct inhibition of mTOR (Figure 3-12).

We highlight that similar

sensitivity (or lack-there-of) to rapamycin and its analogs in several of these cell lines was also
reported elsewhere (295). From this experiment, we concluded that the secondary effects of
pemetrexed causing growth inhibition were due to the downstream signaling from multiple
effects of AMPK activation rather than solely to inhibition of mTORC1.
Striking to us was the drastic difference in sensitivity to pemetrexed and rapamycin in
HCT116 cells (Figure 3-12).

Rapamycin is thought to elicit its antiproliferative effects

exclusively through mTOR inhibition, which perturbs ribosome biogenesis and CAP-dependent
translation, processes essential for protein synthesis. We therefore attempted to determine the
effects of pemetrexed and rapamycin on global protein synthesis in these cells. We pulse-labeled
HCT116 cells with 35S-methionine following an exposure to pemetrexed or rapamycin that was
sufficient to inhibit mTORC1 signaling.

The rate of protein synthesis (measured by

35

S-

methionine incorporation) in these cells following drug exposure was indeed reflective of the
growth inhibitory effects of these drugs (Figure 3-26). While rapamycin had an insignificant
effect on the rate of protein synthesis in HCT116 cells compared to its vehicle control,
pemetrexed inhibited the rate of protein synthesis by greater than 50% in these cells (Figure 326). This degree of protein synthesis inhibition was in agreement with reported inhibition
following AICAR treatment (296). This finding therefore confirmed that mTORC1-dependent
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Figure 3-26. Global translational effects of pemetrexed and rapamycin in HCT116 cells.
HCT116 cells were treated with pemetrexed or rapamycin for 24 hours before being pulselabeled with 35S-methionine as described in the Methods section. Error bars are representative of
standard deviation from triplicate measurements. * Represents p < 0.05 as determined by a
student’s T-test.
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and -independent factors downstream of AMPK activation by pemetrexed were
contributing to this diminution in protein synthesis in HCT116 cells.
We then questioned whether the differential effect of pemetrexed and rapamycin on
protein synthesis could be explained by other signaling events mediated by AMPK. AMPK has
been shown to directly target eEF2 kinase (197). Activation of eEF2 kinase transmits an
inhibitory phosphorylation signal to eEF2 by targeting T56 on this essential translation
elongation factor. Indeed, eEF2 was hyperphosphorylated at T56 in response to pemetrexed
(Figure 3-18). We extended these findings to LKB1-null H460 and HELA cells, which also
showed increased phosphorylation in response to pemetrexed. This not only confirmed our
findings in HCT116 cells, it also gave further support that AMPK signaling mediated by
pemetrexed was preserved in the absence of LKB1 (Figure 3-13 and 3-18). Interestingly, when
we compared phosphorylation status of eEF2 at T56 (Figure 3-18) across these three cell lines,
we observed a high basal level of T56 phosphorylation in untreated HCT116 cells in the absence
of detectable phosphorylation of AMPKα T172 (Figure 3-16). This result suggested that either
another kinase was responsible for these phosphorylation events, or that AMPK had a basal level
of kinase activity in untreated cells that was sufficient to target eEF2 kinase, but not sufficient to
propagate inhibitory signals to mTORC1. It is important to note that the basal activity of AMPK
in HCT116 cells measured by our in vitro kinase assay (Figure 3-6) was not 0. Therefore, it is
likely that this latter hypothesis may explain the kinase activity observed in the absence of a
stimulus.
The first identified substrate of AMPK was acetyl CoA carboxylase (ACC), which
catalyzes the committed step of de novo fatty acid synthesis, the conversion of acetyl CoA to
malonyl CoA (198). Phosphorylation of ACC at S79 by AMPK inhibits the activity of this
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enzyme, thus perturbing de novo lipid synthesis. Indeed, the preferred in vitro substrate for
AMPK in kinase assays is the SAMS peptide, which encompasses S79 of ACC and surrounding
residues (155). In LKB1-null H460 and Hela cells, ACC was hyperphosphorylated at S79 in
response to pemetrexed and AICAR (Figure 3-17). Surprisingly, it was difficult to detect
increases in phosphorylation of ACC S79 in HCT116 cells. In a direct comparison with H460
lysates, it was determined that, like eEF2, ACC S79 in HCT116 cells was hyperphosphorylated
in untreated cells (Figure 3-17). Hyperphosphorylation of ACC S79 under basal conditions was
also reported by others (169), and this result questioned whether another kinase was indeed
responsible for phosphorylation of ACC.

As mentioned above, our data also suggests an

alternative hypothesis. The activity of AMPK measured in the absence of an allosteric stimulus
may be sufficient to directly target both ACC and eEF2 kinase, but insufficient to target the
mTORC1 signaling axis.

166

DISCUSSION
Mutant hyperactivity of the PI3K-AKT and RAS-MAPK signaling pathways, both
converging on mTORC1, are a common phenotype in human carcinomas, and are thought to be
causal of uncontrolled cell growth and proliferation in the absence of environmental stimuli
(158). Operating as a negative regulator of aberrant signaling within these pathways, AMPK is
activated in response to diminished ATP, limiting the energy-consuming processes of protein
and lipid metabolism, and promoting the energy-generating process of carbohydrate metabolism,
to maintain cellular energy homeostasis (Figure 3-1) (157). In this chapter, we show that
AICART inhibition by antifolates stimulates AMPK activity following accumulation of the de
novo purine synthesis intermediate, ZMP. This demonstrates a novel therapeutic intervention to
prevent aberrant proliferation in tumors with genetic defects in these pro-survival pathways.
Activation of AMPK in human carcinoma cells following AICART inhibition by pemetrexed
elicits mTORC1-dependent and -independent effects on key controlling elements of translational
initiation and elongation as well as lipid metabolism. Additionally, we identified a potential
limitation to mTORC1 inhibition through this mechanism, the release of feedback inhibition of
AKT signaling. This suggested a rational therapeutic strategy in which pemetrexed might be
effectively combined with inhibitors of upstream signaling components of the PI3K-AKT or
RAS-MAPK signaling pathways to limit rebound hyperactivity of mTORC1. However, we note
that the effects of AMPK activation by pemetrexed extend beyond mTORC1 signaling, placing
AICART inhibitors in a class distinct from rapamycin and its analogs.
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The requirements for AMPK activation may be cell and substrate-specific
In vitro, ZMP mimics the allosteric effects of AMP on the activity of AMPK following
binding to CBS motifs in the γ subunit (132, 297). ZMP or AMP binding to the γ subunit is
thought to allosterically stimulate the kinase activity of the α subunit both directly through
conformational restraint of an autoinhibitory peptide on the α subunit and by protecting AMPKα
T172 from dephosphorylation (170, 179, 180). In HCT116 cells, these dual allosteric effects of
ZMP appear to contribute to the enhanced kinase activity of AMPK necessary for mTORC1
inhibition (Figure 3-6 and 3-9). Following pemetrexed-mediated ZMP accumulation in HCT116
cells, T172 is maintained in a phosphorylated state, the proposed autoinhibitory domain of
AMPKα is presumably restrained, and the kinase is inhibitory towards mTORC1 signaling.
However, AMPK activity was easily measurable in immunoprecipitates of untreated HCT116
cells (Figure 3-6).
mTORC1,

the

While this basal AMPK activity did not translate inhibitory signals to

mTORC1-independent

targets

of

AMPK,

ACC

and

eEF2,

were

hyperphosphorylated in HCT116 cells (Figure 3-17 and 3-18) in the absence of detectable T172
phosphorylation or an expanded ZMP pool (Figure 3-16 and 2-16). This suggests that either
AMPK displays substrate-specificity, requiring enhanced levels of activity for certain targets, or
that another kinase phosphorylates ACC and eEF2 in untreated HCT116 cells. Indeed, others
have observed phosphorylation of ACC in cells with no detectable AMPKα T172
phosphorylation (169). The mechanism of the differential phosphorylation in HCT116 cells of
mTORC1-independent targets, ACC and eEF2, and of mTORC1-related AMPK targets remains
to be elucidated.
The interpretation of signaling events following pemetrexed treatment in cells lacking
LKB1 added to the apparent complexity of AMPK activation. In H460 cells, AMPKα T172 was
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hyperphosphorylated in the absence of stimulation (Figure 3-16). However, neither ACC nor
eEF2 were hyperphosphorylated under these conditions, and S6K1 T389 was not
hypophosphorylated (Figure 3-14, 3-17 and 3-18). Only after pemetrexed or AICAR treatment
were these targets affected. This suggested that allosteric binding of ZMP to the AMPKγ subunit
in H460 cells is required to release autoinhibition of the α subunit, but not to induce a
conformational shift necessary to protect AMPKα T172 from phosphatases. Presumably, this
residue is already protected. CAMKKβ or Tak1 are candidate alternative upstream kinases
responsible for AMPKα T172 phosphorylation in these cells. It is possible that these upstream
kinases are inhibiting phosphatase activity towards this residue or that H460 cells simply lack the
T172 phosphatase. We therefore concluded that T172 phosphorylation alone is insufficient to
fully activate the kinase activity of AMPKα in H460 cells. In accord, an in vitro measurement of
AMPKα1 kinase activity in untreated H460 cells showed no basal kinase activity compared to
basal activity in HCT116 (data not shown), a finding consistent with our signaling results.
In Hela cells, AMPK responded to pemetrexed in a manner similar to HCT116. Basal
phosphorylation of AMPKα T172 was very low (compared to H460) (Figure 3-16), and became
hyperphosphorylated in response to pemetrexed.

Presumably, T172 was protected from

phosphatase activity by ZMP, amplifying the influence of another kinase such as Tak1 or
CAMKKβ. Like HCT116 cells, there did appear to be basal kinase activity of AMPK towards
ACC and eEF2, but not towards the mTORC1-dependent target, S6K1, which was only affected
in the presence of pemetrexed (Figure 3-14, 3-17 and 3-18).
While AMPKα T172 phosphorylation was observed in Hela cells treated with
pemetrexed, phosphorylation was not measured following AICAR treatment (Figure 3-16). The
inability of AICAR to activate AMPK in Hela cells has been reported by others (182). In these
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studies, not only did AICAR fail to stimulate the kinase, but also the downstream effects of
AMPK activation were not observed in Hela cells treated with AICAR. The authors concluded
that AMPK required LKB1 for activation by ZMP.

However, our data refutes this, as

pemetrexed-mediated ZMP accumulation stimulates the kinase.

Importantly, we found no

accumulation of ZMP in AICAR-treated HeLa cells, suggesting a loss of adenosine kinase
activity in these cells. In comparison, ZMP was easily measurable in pemetrexed-treated Hela
cells (Table 2-3).

The lack of ZMP accumulation in Hela following AICAR treatment is

interesting, and further study is warranted to permit proper interpretation of prior studies.
Of interest to us was the observation that ZMP induced by pemetrexed stimulated AMPK
activity in cells that lost LKB1 function (Figures 3-13 through 3-18), in spite of the fact that the
experimental support for LKB1 as the principal kinase for AMPKα T172 phosphorylation is
strong (181-183). In H460 cells, the AMPKα subunit is hyperphosphorylated at T172 under
basal conditions by a kinase other than LKB1, suggesting a lack of T172 phosphatase activity in
these cells. As described above, AMPK is not catalytically active under these conditions but
becomes active following the accumulation of ZMP. Central to the proper interpretation of these
findings is the elucidation of the upstream kinase responsible for phosphorylating AMPKα T172
in H460 cells.
Based on previous literature, it could be hypothesized that CAMKKβ is the alternate
upstream kinase in cells that lack LKB1 (188-190). We could test this by measuring AMPKα
T172 phosphorylation in H460 cells following treatment with CAMKKβ siRNA or the
pharmacological inhibitor STO-609. Indeed, the observation that CAMKKβ siRNA and STO609 treatment blocked AMPKα T172 phosphorylation has been previously made in Hela cells,
also lacking LKB1 (189).

Importantly, studies have shown that while CAMKKα activity
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depends on a rise in intracellular calcium, CAMKKβ is constitutively active, although activity
does increase in the presence of calcium (287, 298). Therefore, it is not unreasonable to think
that CAMKKβ could substitute for LKB1 as the AMPKα T172 kinase.

Antifolate activation of AMPK by ZMP-independent mechanisms
The studies presented in this chapter definitively prove that AMPK is activated by
pemetrexed in response to accumulation of ZMP. However, AMPK is also sensitive to changes
in the AMP:ATP ratio as well as to increased intracellular calcium (157). This suggests that
other antifolates, classically recognized to deplete nucleotide pools, may have AMPK-activating
effects. In response to pemetrexed, the concentration of ATP and GTP do not diminish (Figure
3-7) (143). This is important, because a depletion of cellular ATP would stimulate AMPK. This
was indeed the case with the GART inhibitor (6R)-DDATHF. A.C. Racanelli in our lab showed
that AMPK was activated in response to (6R)-DDATHF, an effect reversed by addition of the
salvage nucleotide inosine (Racanelli AC, Ph.D. dissertation 2009, Figure 4-8). In comparison to
pemetrexed, (6R)-DDATHF depletes both cellular ATP and GTP (46). Based on in vitro studies
with rat liver AMPK, AMP is a more efficient allosteric activator of AMPK than ZMP (132).
This would suggest that depletion of ATP by (6R)-DDATHF might be a more effective means of
AMPK activation than ZMP accumulation following pemetrexed treatment. However, when
A.C. Racanelli compared the effects of AICAR, LCA and (6R)-DDATHF on inhibition of
mTORC1 signaling, she surprisingly showed a more effective blockade in response to the ZMPmimetic and the AICART inhibitor than to GART inhibition (Racanelli AC, Ph.D. dissertation
2009, Figure 4-6). This therefore suggests that AMPK activation using an AICART inhibitor
would be more advantageous than through GART inhibition.
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It is not understood why purine pools are not depleted in response to pemetrexed
treatment. Given the fact that ZMP pools are expanded in response to pemetrexed to a much
greater extent than siRNA knockdown of AICART by approximately 95%, we expect that
pemetrexed induced a strong inhibitory effect on AICART, which would hypothetically diminish
de novo purine synthesis (Table 2-2 and 2-3). I hypothesize that de novo ATP synthesis is
indeed diminished, but ATP pools are maintained as a result of AMPK activity towards effectors
of carbohydrate metabolism (Table 3-1). As next-generation AICART inhibitors are discovered,
it will be important to determine the extent of ATP depletion in response to these treatments, as a
combination of ZMP accumulation and ATP depletion in response to significant AICART
inhibition may have an additive effect on AMPK activity.
The finding that AMPK activity can be modulated by intracellular calcium in the absence
of alterations to the AMP:ATP ratio is extremely interesting (188-190).

The effects of

methotrexate on calcium homeostasis were recently studied in rat hepatocytes (299). Cytosolic
calcium in response to methotrexate was elevated, and it was determined that the antifolate
enhanced calcium release from the endoplasmic reticulum in a manner similar to IP3 rather than
promoting extracellular calcium uptake. The effects of pemetrexed on intracellular calcium
homeostasis are unknown. However, if pemetrexed also enhanced cytosolic calcium, this would
present an alternative explanation for the AMPK-activating effect of pemetrexed in LKB1-null
cells. It may also add to the explanation of why pemetrexed, but not AICAR, is able to activate
AMPK in Hela cells. It would also be interesting to determine whether the therapeutic effect of
pemetrexed could be potentiated with a calcium ionophore. Importantly, if this proposed effect
on calcium homeostasis was independent of effects on folate metabolism, it may help explain
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why the growth-inhibitory effects of pemetrexed could not be completely rescued by thymidine
and hypoxanthine in HCT116 cells (Figure 2-10B).

Diverse potential clinical utility of AICART inhibitors
The finding that the effects of pemetrexed extend beyond folate metabolism to control
signaling pathways disrupted in cancer suggests that AICART inhibitors may have therapeutic
efficacy in a variety of clinical conditions. The utility of structural analogs of rapamycin for
cancer therapeutics has recently been demonstrated by the activity of temsirolimus and
everolimus for renal cell carcinoma (300, 301). Based on our results, we would predict that the
clinical effectiveness of AICART inhibitors would show overlap with rapalogs.

A direct

inhibitor of mTOR such as rapamycin, binds to a site adjacent to the kinase domain of mTORC1
as a complex with FKBP12, and inhibits mTORC1 activity at low nanomolar concentrations
(259). Prolonged rapamycin exposure has also been reported to inhibit mTORC2 signaling, but
the effects of rapamycin are generally taken as due to inhibition of mTORC1 (232). In contrast,
AICART inhibitors activate AMPK and inhibit mTORC1 by enhancing two physiological
control systems, the phosphorylation of the Raptor subunit of mTORC1 at S792, which prevents
or inhibits the formation of a complex between mTOR and Raptor, and phosphorylation of the
TSC2 subunit of the tuberous sclerosis complex, an effect which promotes the GTPase activity
of Rheb, preventing activation of mTORC1 (195, 196). Pemetrexed-induced accumulation of
ZMP does not appear to inhibit the mTORC2 complex, as judged by the enhanced
phosphorylation of AKT seen in Figure 3-22.
The pronounced effect of AICART inhibitors on mTORC1 signaling suggests these
agents may have therapeutic efficacy in the treatment of tuberous sclerosis complex disorder.
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TSC is caused by mutations in the TSC1 and TSC2 genes, and results in a multi-system disorder
plagued by benign hamartomas of the brain, kidney, skin, heart, and lungs (302). TSC patients
often present with mental retardation, epilepsy, autism, renal angiomyolipomas, and pulmonary
lymphangioleiomyomatosis (LAM). The identification that the TSC GTPase activating protein
functioned as an upstream regulator of mTORC1 signaling suggested that rapamycin and its
analogs may be an effective therapeutic approach to controlling the symptoms of TSC disorder,
for which there were no effective therapeutics. The efficacy of rapamycin and its analogs in
clinical trials for TSC patients has been promising, and tumor regression as well as a diminution
in neurological effects of the disease has been documented (303). However, symptoms and
tumors returned upon removal of the drug. Patients were treated with rapamycin continuously
for up to 9 months, however, the long-term effects of continuous rapamycin exposure are
unknown.
It is likely that AICART inhibitors would also be beneficial to TSC patients. It will be
important to test this hypothesis in mouse models of TSC. It would also be expected that
removal of an AICART inhibitor would allow TSC symptoms to return. Therefore, studies of
chronic AICART inhibitor administration in comparison to chronic rapalog treatment are
warranted to determine whether there is any advantage to long-term administration of one over
the other. The kinetics of antifolates may make them more favorable for chronic administration
than rapamycin, which has a short half-life and would have to be given quite frequently. On the
contrary, pemetrexed polyglutamates are retained intracellularly following plasma clearance, and
therefore, the drug is given once every 21 days in a 10-minute infusion (73). Pemetrexed is also
well tolerated, and is approved for maintenance therapy of NSCLC (80), suggesting long-term
administration may be possible without overt toxicity. However, the progressive nature of
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NSCLC would likely not provide the clinical data necessary to deem pemetrexed safe for chronic
administration over the time scale needed for TSC therapy.
Although AMPK phosphorylation of TSC2 and Raptor exerts a strong inhibition on
mTORC1 and downstream targets critical to protein and lipid synthesis, a number of other
targets are controlled by AMPK that are not mediated by mTORC1 (Table 3-1) (157). It would
be expected that pemetrexed-induced activation of AMPK would also affect these other direct
targets of this kinase, and that the overall effects of AICART inhibition would have components
additional to the effects seen with rapamycin analogs. This would afford AICART inhibitors a
therapeutic advantage over direct mTORC1 inhibitors, and might extend the utility of AICART
inhibitors towards diseases and conditions of metabolic origin. Indeed, we show that targets for
AMPK whose phosphorylation is not mediated by mTORC1, such as ACC and eEF2, are
affected by pemetrexed (Figures 3-17 and 3-18). The multiple effects of AMPK on lipid
synthesis suggest AICART inhibitors should be tested as therapeutics for disorders of lipid
metabolism, such as hypercholesterolemia and obesity. As described above, AMPK directly
inhibits ACC, which catalyzes the committed reaction of de novo fatty acid synthesis, converting
acetyl CoA to malonyl CoA (Figure 3-27). Additionally, AMPK directly inhibits HMG CoA
reductase (Table 3-1), a key enzyme of de novo cholesterol biosynthesis that is the target of the
statin class of cholesterol-lowering drugs. Most recently, the sterol regulatory-element binding
proteins (SREBPs) were identified as downstream targets of mTORC1 (304).

These

transcription factors are essential for the expression of multiple enzymes of de novo fatty acid
and cholesterol biosynthesis (Figure 3-27). Indeed, we have shown that pemetrexed inhibits the
nuclear localization of SREBP1 (Figure 3-28), but this effect is likely sensitive to unknown
variables, as the result was difficult to repeat.
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Figure 3-27. De novo lipid and cholesterol biosynthesis. Horton JD et al. J. Clin. Invest.
109(9): 1125-1131 (2002) (305)
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Figure 3-28. Pemetrexed inhibits nuclear localization of the SREBP-1 transcription factor.
HCT116 cells were treated with 1 µM pemetrexed and 5.6 µM thymidine for 24 hours. Total
protein was isolated, quantified, and subjected to immunoblot analysis as described in the
Methods section. Total protein (20 µg) was loaded into each lane. Nuclear SREBP-1 (65 kDa)
is a cleavage product from the full-length species (100 kDa), which is bound to the endoplasmic
reticulum membrane. This SREBP-1 antibody detects both cytosolic (membrane-bound)
SREBP-1 as well as cleaved (nuclear) SREBP-1.
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Diminishing the influence of AKT on AMPK-mediated mTORC1 inhibition
Whereas AMPK inhibits mTORC1 through phosphorylation of TSC2 and the Raptor
subunit of mTORC1, AKT opposes each of these effects. AKT indirectly inhibits the GTPase
activity of the mTORC1 effector Rheb (196, 306, 307), likely through phosphorylation of
multiple residues including S939 and T1462 on the human TSC2 subunit (246, 247), while
AMPK phosphorylation of TSC2 S1387 and T1271 are requisite for mTORC1 inhibition in
response to energy stress (196). AKT also activates mTORC1 by phosphorylating the PRAS40
subunit of mTORC1 at T246, promoting the dissociation of inhibitory PRAS40 from mTORC1
(245), whereas the phosphorylation of Raptor S792 by AMPK results in inhibition of the kinase
activity of mTORC1 (195).
A question of significance is whether the effect of AMPK or that of AKT would
dominate at each of these two nodes of signal integration. The events we observed during
recovery from pemetrexed-induced inhibition of mTORC1 signaling give some insight into this
interaction. We show that, in spite of continued activation of AMPK in response to pemetrexed,
the inhibition of S6K1 phosphorylation is partially relieved, apparently by activation of the
opposing influences of AKT on TSC2 and mTORC1 (Figure 3-21). However, the recovery of
4E-BP1 was less marked than was the recovery of phosphorylation of S6K1, and residence of
4E-BP1 at a synthetic m7GTP-sepharose substrate remained following rebound hyperactivity
(Figure 3-20).

This suggests that rebound hyperactivity of AKT may present a differential

influence on mTORC1 activity towards its substrates. Of course, it is the unphosphorylated form
of 4E-BP1 that is central to inhibition of protein synthesis, and that species remained markedly
accumulated after pemetrexed treatment.
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Others have reported that the stimulation of AKT activity following rapamycin
suppression of S6K1 activity did not prevent suppression of S6K1 phosphorylation nor did it
interfere with growth suppression by everolimus (Lane HA 2009 8. Ludwig DL 2006 66). This
is expected, as rapamycin is directly blocking mTORC1. We note that the relief of feedback
induced stimulation of AKT after pemetrexed treatment also did not prevent complete growth
suppression of HCT116 cells after 72 hours (Figure 2-16), although though recovery of S6K1
phosphorylation was evident by 24 hours (Figure 3-21). At the moment, we do not understand
why the secondary effects of pemetrexed are not reversed by this hyperactivated AKT.
However, our results do suggest therapeutic efficacy in limiting rebound hyperactivity of
mTORC1 signaling to S6K1 (Figure 3-23 through 3-25). Indeed, we show that inhibition of
clonogenic survival in response to pemetrexed can be enhanced by inhibiting AKT, either
directly with the competitive inhibitor GSK690693 (Figure 3-24), or indirectly by inhibiting the
AKT T308 kinase, PDK1, with OSU-03012 (Figure 3-25). Interestingly, PDK1 inhibition would
affect both AKT and S6K1 directly, providing a dual mechanism of controlling rebound
hyperactivity (See Figure 3-1).
The realization that the efficacy of rapamycin and its analogs was potentially limited by
rebound hyperactivity of AKT has stimulated drug discovery efforts to circumvent this issue.
One promising approach is the development of competitive inhibitors of the mTOR catalytic
subunit (308-311). This approach would in effect target both mTORC1 and mTORC2, as they
share the same mTOR catalytic subunit. Blocking mTORC1 would inhibit the downstream
targets S6K1 and 4EBP1, and simultaneously blocking mTORC2 would inhibit AKT and
prevent the mTORC2-stimulating effect of S6K1 inhibition. Although these competitive mTOR
inhibitors will perturb AKT signaling, they do not directly target hyperactive PI3K. Therefore,
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another approach was the discovery of dual competitive inhibitors of mTOR and PI3K. These
compounds have been developed and are already being tested against hematological
malignancies (312-314). These compounds are proving to be more effective anti-cancer agents
than the rapalogs, and it would be very interesting to determine whether additivity can be seen
with these compounds in combination with AICART inhibitors.

Molecular genetics of tumor sensitivity to AMPK activation
Genetic abnormalities in elements of the PI3K-AKT, RAS-MAPK, and AMPK signaling
networks are frequently observed in biopsies of primary human tumors (158, 315, 316). In lung
tumors, KRAS was activated in 35% of biopsies, LKB1 was deficient in 23%, and PI3K was
activated in 8%; loss of PTEN was a rare occurrence in NSCLC, although it is common in other
tumor types, such as prostate and colon cancers (158). PI3K hyperactivating mutations are also
common events in colon, breast, prostate, and ovarian carcinomas (317). Determination of how
these genetic signatures of tumors affect the sensitivity to AICART inhibitors is a question of
importance, and may aid in the ability to screen patients to predict response to a particular
treatment regimen.
To our surprise, LKB1 mutations did not confer resistance to the downstream effects of
AMPK activation by pemetrexed in the two LKB1-null cell lines we studied (Figure 3-13). Even
in the absence of LKB1, AMPK is clearly activated in response to pemetrexed (Figure 3-14
through 3-18). In addition to LKB1 mutations, KRAS is frequently hyperactivated in primary
NSCLC and cell lines derived from these tumors (316). KRAS propagates signaling to ERK and
RSK, both of which phosphorylate and inhibits TSC2, similarly to AKT (158). Carcinomas with
hyperactive mTOR signaling have been predicted to be more sensitive to rapamycin because of
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an increased dependence on mTOR signaling for survival and proliferation (219). It remains to
be seen whether mutations in KRAS correlates with hypersensitivity to pemetrexed.
Interestingly, HCT116 cells were the least sensitive to growth inhibition by rapamycin but the
most sensitive to the secondary effect of pemetrexed. Indeed, cell lines with hyperactive PI3K
and KRAS (HCT116 and H460) were the most sensitive in our screen (Figure 3-12). It would be
worthwhile to extend this observation to other double mutant cell lines to determine whether
these two genetic signatures could serve as biomarkers to predict tumor sensitivity to
pemetrexed.
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CHAPTER 4
DIFFERENTIAL THERAPEUTIC OUTCOMES OF FOLATE-DEPENDENT TARGET
INHIBITION BY PEMETREXED

The discovery that pemetrexed was an AMPK-activating agent that elicited a strong
inhibitory effect on mTORC1 signaling prompted us to question how this newly-discovered
mechanism of action was contributing to the overall therapeutic effect of the drug. While the
cytotoxic therapeutic consequences of thymidylate synthase inhibition via induction of apoptosis
have been well documented, the therapeutic effects of AICART inhibition as they pertain to
AMPK activation and mTORC1 inhibition remained undefined. The overall cytotoxic effect of
pemetrexed has been studied, but the individual contribution of each target of pemetrexed has
not been explored.

We therefore sought to understand how TS and AICART inhibition

contributed both individually and in synchrony to the therapeutics of pemetrexed.

The cytotoxicity associated with TS inhibition is apoptotic and S-phase-specific
As described in Chapter 2, the cytotoxic effect of TS inhibition results from both a
diminution of TTP as well as accumulation of dUTP, causing ineffective cycles of excision and
repair that ultimately lead to DNA strand breaks and induction of apoptotic cell death. (98).
Therefore, the cytotoxicity associated with TS inhibition is likely S-phase specific (318). From a
time course of CCRF-CEM cell cycle profiles following exposure to pemetrexed, it was
demonstrated that cells accumulated at the G1/S border by 12-24 hours, followed by
synchronous entry into S-phase (319). By 36 hours, the cell population was mostly accumulated
in S-phase, assessed by both flow cytometry and 5-bromo-2-deoxyuridine incorporation, and a
significant population was present at a sub-G1 peak, indicative of apoptosis (320). By 48 hours,
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the majority of the cell population was apoptotic, supported by the presence of significant DNA
fragmentation (319). Interestingly, using thymidine to reverse the effects of raltitrexed, it was
demonstrated by clonogenic survival that the cytotoxicity associated with TS inhibition was
completely reversible if thymidine was supplemented in media containing inhibitor within the
first 24 hours of drug exposure (321). This indicated that the cellular events contributing to
irreversible commitment to apoptosis following TS inhibition did not occur within the first 24
hours of drug treatment, consistent with the time of entry into S-phase following pemetrexed
treatment.

Therapeutic effects of AICART inhibition
From our studies in Chapter 3 detailing the cellular signaling events that ensued
following AICART inhibition, we hypothesized that the therapeutic consequences of AICART
inhibition would be similar to effects mediated by an AMPK activating agent such as AICAR or
an mTORC1 inhibitor such as rapamycin. One of the most widely recognized consequences of
AMPK activation and mTORC1 inhibition is the induction of macroautophagy (herein referred
to as autophagy). This coordinated process of cellular self-digestion is paradoxically essential
for cellular survival, but deleterious if deregulated (322). Autophagy is an adaptive mechanism
to cellular starvation in which cytoplasmic contents including misfolded, aggregated, and longlived proteins, as well as damaged or unneeded organelles are degraded through the lysosomal
machinery and recycled for carbon sources necessary for nutrient metabolism (323). Autophagy
operates at a low basal level in most cells and is upregulated in response to nutrient or energy
starvation, the withdrawal of growth factors, or when the energetic demands of a cell are
elevated.
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Autophagy occurs in several distinct phases that are tightly controlled by more than 20
evolutionarily conserved proteins encoded by autophagy genes (ATG’s) (322).

A

serine/threonine kinase complex consisting of the ATG-gene products ULK1, FIP200, and
ATG13 induces the autophagy cascade. The process begins with the nucleation and expansion
of a phagophore isolation membrane, which likely buds from the endoplasmic reticulum.

A

class III PI3K complex consisting of Vsp15, Vsp34, Atg14, and Beclin1 mediates phagophore
nucleation, and the ATG12 ubiquitin-like conjugation system promotes phagophore expansion.
The phagophore engulfs cytosolic components and upon closure is then referred to as an
autophagosome. The ATG12 complex also catalyzes the cleavage and lipid conjugation of LC3I to form LC3-II, promoting the stable association of LC3-II with the autophagosome. Once
LC3-II binds the autophagosome, this double-membraned vescicle fuses with a lysosome to form
an autolysosome, where the inner membrane and captured contents are degraded. Membrane
permeases then release the degraded contents back into the cytosol (322, 324).
mTORC1 is a key negative regulator of autophagy, inhibiting this catabolic process when
nutrients and growth factors are abundant (325, 326). It was recently discovered that mTORC1
regulates autophagy by inhibiting the initiating step in the cascade (327-329).

mTORC1

phosphorylates both ULK1 and ATG13, which perturbs the association of this multiprotein
complex and inhibits its kinase activity. In support of this finding, rapamycin enhanced the
kinase activity of ULK1 and promoted the association of this initiation complex with isolation
membranes. In contrast, AMPK activation promotes autophagy (330). While the mechanism of
activation is likely mediated partially through mTORC1 inhibition, novel mechanisms by which
AMPK can directly stimulate the autophagy cascade by signaling to ULK1 are being elucidated
(Shaw RJ, conference communication).
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Both AMPK-activating agents as well as mTORC1 inhibitors have been shown to induce
cell cycle arrest at the G1/S phase boundary. Among other processes, progress from G1 to S
phase of the cell cycle requires phosphorylation of the retinoblastoma protein (Rb) by the
CDK4/6-cyclin D complex, which releases transcription factors necessary to enhance synthesis
of S-phase specific target genes. The cyclin-dependent kinase inhibitor, p21, whose mRNA
expression is induced by p53, promotes G1 arrest by preventing CDK complexes from
phosphorylating Rb (331-333). Studies have shown that the AMPK-activating agent metformin
diminished the expression of cyclin D1 and causes hypophosphorylation of Rb in several
prostate carcinoma cell lines (334). Additionally, studies in the HepG2 hepatocellular carcinoma
cell line demonstrated that AICAR induced a G1/S checkpoint arrest that corresponded with
pronounced stabilization of p53 concomitant with S15 phosphorylation as well as enhanced
expression of p21 (335). Rapamycin has also been shown to induce a G1/S arrest, however, p53
is not stabilized, nor is p21 expression enhanced in response to drug (336-340). This would
suggest that the effect of AMPK activation on p53 stabilization is independent of mTORC1
inhibition. Indeed, it has been shown in vitro that AMPK can phosphorylate p53 on S15, a
posttranslational modification that contributes to p53 stability by perturbing its interaction with
MDM2 (209, 341-343).
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MATERIALS AND METHODS
Chemicals and reagents
Propidium iodide staining solution (#P3566), RNAse A (#12091-021), and Acridine
Orange vital dye (#A3568) were from Invitrogen (Carlsbad, CA). All other reagents were from
Fisher Scientific (Waltham, MA) or Sigma Aldrich (St. Louis, MO) and were of the highest
available purity.

DNA content/Cell Cycle Analysis
Tissue culture dishes (10 mm) were seeded with 106 cells and allowed to adhere
overnight. Following drug treatments, wells were washed once with PBS, trypsinized, and
counted electronically using a Z1 Coulter Particle Counter (Beckman Coulter Brea, CA). One
million cells were transferred to a new tube, pelleted by centrifugation at 1,000 rpm for 5
minutes, and resuspended in 1 ml propidium iodide staining solution (75 µg/ml propidium
iodide, 0.1% Triton X-100, 10 µg/ml RNAse A, and 32 mM sodium citrate). Samples were
vortexed and placed at 4°C overnight to maximize staining. Prior to analysis, samples were
filtered through 35 µM nylon mesh. DNA content was analyzed with a Beckman CoulterEPICS
Elite ESP (Enhanced Sorting Performance) multilaser flow cytometer in the Flow Cytometry and
Imaging Shared Resource Facility at VCU.

Acridine Orange Staining
Cells were seeded in 6-well plates at a density of 105 cells/well and allowed to attach
overnight. Following drug treatments, cells were washed once with PBS before being incubated
with Acridine Orange vital dye (1 µg/ml in media) for 15 minutes at 37°C. Cells were washed
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again with PBS, and staining was visualized within 1 hour on an inverted fluorescence
microscope at a wavelength of 480-520 nm.
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RESULTS
Pemetrexed is both a cytotoxic and antiproliferative therapeutic agent
The cytotoxicity associated with thymidylate synthase inhibition is well documented
(Figure 2-1) (321). Indeed, pemetrexed is a potent cytotoxic agent in tumor cell lines and in vivo
(344). However, the relative contribution of thymidylate synthase inhibition and AICART
inhibition to the therapeutics of pemetrexed is not known.

To address this question, we

performed clonogenic survival assays in the presence and absence of the growth rescue agents
thymidine and hypoxanthine to isolate the effects of pemetrexed on each target individually. In
the absence of rescue agents, pemetrexed had a pronounced cytotoxic effect in both HCT116 and
H460 cells (Figure 4-1 and 4-2). The toxicity window of pemetrexed in both cell lines was fairly
broad, between 0.01 and 10 µM following a 72 hour drug treatment. When this experiment was
performed in media supplemented with thymidine to rescue the effect of thymidylate synthase
inhibition, the cytotoxic effect of pemetrexed was completely rescued in HCT116 and H460
cells. Upon closer examination (Figure 4-3 and 4-4), it became apparent that although colony
number remained the same, colony size was dramatically smaller. This was our first indication
that the secondary effect of pemetrexed (AICART inhibition) was antiproliferative, not
cytotoxic. Indeed, when both thymidine and hypoxanthine were supplemented in the media, the
cytotoxic and antiproliferative effects of pemetrexed were completely rescued, even at high
doses (Figure 4-1 and 4-2).
To confirm that AICART inhibition by pemetrexed was antiproliferative, we performed a
similar experiment with LCA, whose effects we suspected were mediated primarily through
AICART inhibition and secondarily through inhibition of thymidylate synthase (Figure 2-21).
Compared to pemetrexed, LCA was 10-fold less potent at inducing cytotoxicity in
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Figure 4-1. The cytotoxic effect of pemetrexed in HCT116 cells is rescued in the presence
of thymidine and a preformed purine. Clonogenic survival assays were done as described in
the Methods section on HCT116 cells exposed to the indicated concentrations of pemetrexed for
72 hours. In rescue conditions, 5.6 µM thymidine and 32 µM hypoxanthine were used, and
remained present in culture media throughout the duration of the experiment. Enumerations of
these colonies in the absence of rescue agents are depicted in the graph. Cultures were set up in
triplicate, and data points are representative of an average of triplicate measurements.
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Figure 4-2. The cytotoxic effect of pemetrexed in H460 cells is rescued in the presence of
thymidine and a preformed purine. Clonogenic survival assays were done as described in the
Methods section on H460 cells exposed to the indicated concentrations of pemetrexed for 72
hours. In rescue conditions, 5.6 µM thymidine and 32 µM hypoxanthine were used, and
remained present in culture media throughout the duration of the experiment. Enumerations of
these colonies in the absence of rescue agents are depicted in the graph. Cultures were set up in
triplicate, and data points are representative of an average of triplicate measurements.
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Figure 4-3. The effect of pemetrexed in the presence of thymidine is antiproliferative to
HCT116 cells. Clonogenic survival assays (A) were done as described in the Methods section
on HCT116 cells exposed to 1 µM pemetrexed and 5.6 µM thymidine for 72 hours.
Enumerations of these colonies are depicted in (B). Cultures were set up in triplicate, and
enumerations are representative of an average of triplicate measurements.
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Figure 4-4. The effect of pemetrexed in the presence of thymidine is antiproliferative to
H460 cells. Clonogenic survival assays (A) were done as described in the Methods section on
H460 cells exposed to 1 µM pemetrexed and 5.6 µM thymidine for 72 hours. Enumerations of
these colonies are depicted in (B). Cultures were set up in triplicate, and enumerations are
representative of an average of triplicate measurements.

192

the absence of rescue agents in both HCT116 and H460 cells (Figure 4-5). Importantly, addition
of thymidine to culture medium had no effect on the clonogenic survival of either HCT116 or
H460 cells in the presence of LCA (Figure 4-5). This result confirmed that the primary target of
LCA was not thymidylate synthase. It was interesting to us that LCA retained its cytotoxic
effect in the presence of thymidine. This suggested that either LCA had additional targets
beyond AICART and thymidylate synthase, that potent AICART inhibition was indeed cytotoxic
in and of itself, or that prolonged growth inhibition was suppressing colony formation.
The antiproliferative effect of pemetrexed in the presence of thymidine was extremely
interesting to us and had potential therapeutic importance. We therefore sought to determine
how the secondary effect of pemetrexed augmented passage through the cell cycle. Initially,
HCT116 cells were treated with pemetrexed in the presence and absence of thymidine for 24
hours, and DNA content of propidium iodide-stained cells was analyzed by flow cytometry. In
the presence of pemetrexed, a clear accumulation of HCT116 cells in S-phase of the cell cycle
was measured (Figure 4-6). This was likely indicative of thymidylate synthase inhibition (318).
However, when the effect of thymidylate synthase inhibition was alleviated with extracellular
thymidine, it appeared that pemetrexed was arresting cells at the G1/S boundary (Figure 4-6).
Over the course of a 24 hours treatment with pemetrexed and thymidine in HCT116 cells, the
approximate % distribution of cells in G1:S:G2 changed from 41:18:36 to 55:15:26.

We

performed flow cytometry as a function of time in H460 cells treated with pemetrexed and
thymidine or LCA. Indeed, we saw pronounced accumulation of cells at the G1/S checkpoint
with a clear diminution of cells in G2/M in response to each of these treatments (Figure 4-7).
Importantly, G1/S arrest was measured in the absence of thymidine in LCA-treated cells, further
confirming that thymidylate synthase was not a primary target for this compound.
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The cytotoxicity of pemetrexed requires both an apoptotic and autophagic response
The primary cell death mechanism induced by thymidylate synthase inhibition is
apoptosis (98). Indeed, pemetrexed has been shown to strongly induce apoptosis in cultures of
human tumor cell lines (319). We therefore questioned whether the effect of AICART inhibition
by pemetrexed was contributing to the apoptosis induced by the drug. We hypothesized that
AICART inhibition would induce autophagy, as there is strong evidence linking mTORC1
signaling to the suppression of autophagy and AMPK signaling to autophagy induction (325,
326, 330). We first queried whether autophagy was induced subsequent to AICART inhibition.
We stained LCA-treated HCT116 and H460 cells with the acridine orange, a vital dye that stains
neutral compartments green and acidic compartments orange (Figure 4-8). The rationale for this
method was the identification of lysosomal compartments, whose formation is upregulated when
the autophagic cascade is induced. Clearly, LCA increased the orange staining pattern in both
cell lines, and this punctate staining pattern was indicative of an autophagic response.
A more specific indicator of autophagy comes from measuring the sequestration cleaved
LC3 to autophagosomes, which then fuse to the lysosome. We collaborated with Dr. Margaret
Park, a post-doctoral fellow in Dr. Paul Dent’s lab in the Massey Cancer Center (VCU) to
measure LC3 localization to lysosomes. Dr. Park transfected H460 cells with a GFP-tagged LC3
construct, treated cells with pemetrexed in the presence and absence of thymidine, and measured
green foci in these cells, indicative of association of LC3 with lysosomes. We observed
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Figure 4-5. The antiproliferative effect of LCA is not rescued in the presence of thymidine.
Clonogenic survival assays were done as described in the Methods section on HCT116 and H460
cells exposed to the indicated concentrations of LCA for 72 hours. In rescue conditions, 5.6 µM
thymidine was used, and remained present in culture media throughout the duration of the
experiment.
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Figure 4-6. Cell cycle analysis of HCT116 cells following pemetrexed exposure indicates a
shift from S-phase accumulation to G1/S arrest in the presence of thymidine. HCT116 cells
were exposed to 1 µM pemetrexed and 5.6 µM thymidine for 24 hours. DNA content was
measured by propidium iodide incorporation as described in the Methods section.
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Figure 4-7. Cell cycle analysis of H460 cells following pemetrexed and thymidine or LCA
exposure indicates a G1/S arrest in these cells. Cells were exposed to 1 µM pemetrexed and
5.6 µM thymidine for the indicated times. DNA content was measured by propidium iodide
incorporation as described in the Methods section.
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Figure 4-8. Acidic vesicles are more prominent in HCT116 and H460 cells treated with
LCA. HCT116 and H460 cells were treated with 1 µM LCA for 24 hours before being stained
with the vital dye Acridine Orange and visualized under an inverted fluorescence microscope as
described in the Methods section.
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significant LC3 localization to lysosomes in these cells (Figure 4-9). This not only indicated to
us that pemetrexed was inducing autophagy, it also showed that this effect was independent of
thymidylate synthase inhibition, as it was occurring in the presence and absence of thymidine
(Figure 4-9). This effect also occurred in HCT116 cells, although to a lesser extent.
Importantly, our clonogenic survival data indicated that in the absence of thymidylate
synthase inhibition, no cell death was being induced (Figure 4-3 and 4-4). Therefore, we drew
the conclusion that autophagy alone was not sufficient to induce cell death in response to
pemetrexed. But was autophagy contributing to the apoptotic effect in response to thymidylate
synthase inhibition? To test this, we ablated the autophagic response to pemetrexed and queried
what happened to the apoptotic response. To ablate autophagy, we used both chemical and
genetic means. Chemically, we treated H460 cells with 3-methyladenine, a class III PI3K
inhibitor that prevents autophagosome formation (345). Genetically, we directly knocked down
Beclin-1 with siRNA. We determined that the apoptotic effect of pemetrexed was severely
blunted in the absence of autophagy (Figure 4-10).

It appeared that the cytotoxicity of

pemetrexed resulted from a combined effect of apoptosis induced by thymidylate synthase
inhibition and autophagy induced by AICART inhibition.
prevented the cytotoxicity of the drug.
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Importantly, loss of either one

Figure 4-9. LC3-GFP staining pattern following pemetrexed treatment indicates a
commitment to autophagy that is independent of thymidylate synthase inhibition. H460
human non-small cell lung cancer cells were transfected with an LC3-GFP construct and were
treated with the indicated concentrations of pemetrexed and 5.6 µM thymidine 24 hours later for
24 hours. Cells were then visualized under an inverted fluorescence microscope for LC3 foci
formation, indicative of association with autophagolysosomes. Experiment performed by Dr.
Margaret Park (Dent Lab, VCU).
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Figure 4-10. The apoptotic effect of pemetrexed is ablated in the absence of autophagy.
H460 cells were exposed to (A) 3-MA for 4 hours or (B) Beclin 1 siRNA for 24 hours before
being exposed to the indicated concentration of pemetrexed for 24 hours. Apoptosis was
measured by Annexin V/propidium iodide staining, analyzed by flow cytometry. Measurements
are representative of cells scoring positive for both Annexin V and propidium iodide.
Experiment performed by Dr. Margaret Park (Dent Lab, VCU). Error bars are
representative of standard deviation from two biological and three technical replicates.
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DISCUSSION
In this chapter, we determined that AICART inhibition by pemetrexed was cytostatic, not
cytotoxic (Figure 4-3 and 4-4). Furthermore, we showed that this antiproliferative AMPKmediated effect of the drug arrested cells at the G1/S boundary (Figure 4-6 and 4-7). AICART
inhibition induced an autophagic response, likely as a result of AMPK activation and mTORC1
inhibition (Figure 4-8 and 4-9).

Although autophagy alone did not induce cell death, its

induction was essential for the overall cytotoxic effect of pemetrexed (Figure 4-10). From these
studies, we propose that the efficacy of pemetrexed against non-small cell lung cancer and
mesothelioma is reflective of its combined activity as a thymidylate synthase inhibitor as well as
an AMPK-activating agent.

A complex interplay between autophagy and apoptosis
The cellular consequences of autophagy induction are not straightforward, and are likely
context-dependent. In situations of stress or nutrient deprivation, autophagy is suggested to play
a pro-survival role, recycling cytoplasmic debris for energy (346). On the other hand, autophagy
induction under conditions of nutrient sufficiency are damaging to the cell. In this context,
autophagy has been classified as a distinct mode of programmed cell death. The finding that
pemetrexed induced autophagy in response to AICART inhibition (Figure 4-8 and 4-9), led us to
question whether autophagy was contributing to or protecting cells from the cytotoxic effect of
pemetrexed.

That AICART inhibition was cytostatic, not cytotoxic (Figure 4-3 and 4-4)

suggested that autophagy was not promoting cell death in response to pemetrexed. However,
inhibition of autophagy by genetic and pharmacological means protected pemetrexed-treated
cells from cell death by apoptosis (Figure 4-10). These findings led to the conclusion that the
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overall cytotoxic effect of the drug requires both an autophagic and apoptotic response from
combined inhibition of AICART and thymidylate synthase, respectively, and that ablation of
either programmed cell death mechanism perturbs the cytotoxic effect of pemetrexed (Figure 411).
From a biological standpoint, our data suggests that the processes of apoptosis and
autophagy are inter-related. The coordinate control and crosstalk between these two cell death
mechanisms has been an important topic of recent study, and the conclusions, like autophagy
itself, are not straightforward. In certain instances, autophagy and apoptosis have been shown to
be mutually exclusive modes of cell death that could be activated by similar stimuli. For
instance, inhibition of apoptosis with the pan caspase inhibitor Z-VAD.fmk induced autophagic
cell death in mouse fibrosarcoma and human T-cell lymphoma cells (347). Additionally, the
topoisomerase II poision and common apoptosis-inducing agent, etoposide, induced pronounced
autophagic cell death in MEF’s from bax-/- -bak-/- double-knockout mice, resistant to apoptotic
stimuli (348). It would be very interesting to determine whether bax-/- -bak-/- double-knockout
MEF’s responded similarly to pemetrexed. In a reciprocal fashion, inhibition of autophagy has
been shown to potentiate the apoptotic response. Under conditions of nutrient starvation, in
which autophagy has been shown to play a cytoprotective role, apoptosis was induced following
siRNA knockdown targeting mRNA from several autophagy genes including Beclin 1 (349).
Studies have also shown that autophagy and apoptosis work coordinately to induce cell
death. Induction of autophagy by overexpression of ULK1 (the mammalian homolog of ATG1
in Drosophila melanogaster and S. cerevisiae) induced apoptotic cell death in Drosophila (350).
A point of integration between these two pathways may be the interaction between the antiapoptotic protein, Bcl-2, and Beclin 1. Under conditions of starvation in yeast and mammalian

203

Figure 4-11. A proposed model for the involvement of apoptosis and autophagy in the
induction of cell death by pemetrexed.
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cells, binding of Bcl-2 to Beclin 1 inhibited autophagy (351). Moreover, starvation of cells
expressing a mutant form of Beclin 1, unable to bind to Bcl-2, promoted autophagic cell death.
Therefore, Beclin 1 may promote apoptosis by sequestering Bcl-2. This finding is of relevance
to our studies, as knockdown of Beclin 1 in pemetrexed-treated H460 cells diminished the
apoptotic response to the drug (Figure 4-10). I hypothesize that as a consequence of Beclin 1
knockdown, Bcl-2 is released to prevent the release of cytochrome C from the mitochondria,
inhibiting apoptosis. Thus, our interpretation of the effects of ablation of autophagy by Beclin 1
knockdown in pemetrexed-treated cells may be complicated by this anti-apoptotic effect. To
circumvent this potential complication, it would be advantageous to repeat this experiment
targeting ULK1 with siRNA rather than Beclin 1.

Comparison of pemetrexed and raltitrexed illustrates the significance of a secondary target
Based on kinetic parameters, it could be rationalized that pemetrexed and raltitrexed
would have similar therapeutic effects. Both drugs are potent thymidylate synthase inhibitors as
pentaglutamates (Ki ~ 1.0 nM) and have similar kinetic properties in terms of RFC transport (Km
~ 5 µM) and FPGS polyglutamation (Km ~ 0.8 µM) (54, 57, 352). However, raltitrexed is
several orders of magnitude more cytotoxic to tumors in culture and in humans (353, 354). This
finding was also confirmed by clonogenic survival assays presented in this dissertation (Figure
2-1 and 4-2). This effect may be partially due to enhanced transport of pemetrexed by the PCFT
(58-61). Additionally, pemetrexed has proven effective in treating tumors resistant to raltitrexed
(143), further illustrating the importance of thymidylate synthase-independent effects of the
drug.
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The cytotoxicity associated with thymidylate synthase inhibition occurs following
cellular entry into S-phase, where futile cycles of excision-repair of misincorporated dUTP into
DNA lead to strand breaks and induction of apoptosis (98, 318). In this chapter, we discovered
that in addition to the cytotoxic effect of thymidylate synthase inhibition, pemetrexed also
generates an antiproliferative effect consequent of AICART inhibition, arresting cells at the G1/S
cell cycle checkpoint (Figure 4-6 and 4-7). This does not occur following raltitrexed treatment,
as the cytotoxic effect is completely reversed by addition of thymidine even at higher
concentrations of drug (Figure 2-1). Therefore, it is hypothesized that the AICART effect of
pemetrexed limits the cytotoxicity associated with thymidylate synthase inhibition by hindering
the cellular traverse into S-phase. From our studies in Chapter 2, we showed that hypoxanthine
dose-dependently diminished ZMP accumulation in response to pemetrexed treatment across
concentrations of hypoxanthine that incrementally rescued growth inhibition (Figure 2-18).
Therefore, hypoxanthine may be diminishing the G1/S arrest induced by AMPK activation in
pemetrexed-treated cells, and enhancing S-phase entry, where the cytotoxic effects of
thymidylate synthase are seen.

Regardless, the enhanced clinical efficacy of pemetrexed

compared to raltitrexed suggests benefit to combining the cytotoxic thymidylate synthase effect
with the antiproliferative AMPK-activating effects subsequent to AICART inhibition, even
though the toxicity associated with thymidylate synthase inhibition is diminished.

Does p53 influence the therapeutic outcome of AICART inhibition?
Greater than 50% of human cancers harbor mutations in the tumor suppressor p53,
making it the most frequently mutated gene in human malignancies (355). Activation of this
transcription factor has been shown to induce apoptosis, cell cycle arrest, and senescence under

206

certain conditions (356). Importantly, the therapeutic consequences of mTORC1 inhibitors and
AMPK-activating agents have shown differential sensitivities to p53 in wild type and mutant
tumors. The growth of HCT116 p53-/- tumor xenografts in nude mice was significantly more
inhibited in response to metformin and AICAR treatment than HCT116 p53+/+ tumor xenografts
(357). This differential effect was concomitant with enhanced apoptosis in HCT116 p53-/- cells,
but autophagy induced by both treatments was ablated in the absence of p53. If p53 is indeed
essential to the induction of autophagy in response to AMPK activation, our studies would
paradoxically predict that p53-/- cells would not die by apoptosis in response to pemetrexed.
Clonogenic survival assays in p53 isogenic HCT116 and MEFs would be a straightforward way
to begin addressing this hypothesis.
Upon glucose starvation, MEFs have been shown to arrest at the G1/S cell cycle
checkpoint, an effect dependent on AMPK activation, but independent of mTORC1 inhibition
(209). Growth arrest in response to glucose starvation also required p53, and loss of p53
conferred MEFs sensitive to apoptosis in the absence of glucose. This suggests that the cell
cycle arrest induced by p53 in response to AMPK activation is cytoprotective. It will be
important to determine the cell cycle response to pemetrexed and thymidine in the absence of
p53. This data would suggest that cells would no longer arrest at the G1/S checkpoint, which
may enhance the cytotoxicity of thymidylate synthase inhibition by pemetrexed. However,
several experiments done in our lab suggest that loss of p53 does not enhance the cytotoxicity of
pemetrexed and thymidine treatment. S. Agarwal in our lab compared the growth inhibitory
effect of pemetrexed and thymidine in p53 isogenic HCT116 and MEFs, and showed that growth
inhibition was not enhanced in the absence of p53 in either of these cell types. Additionally, S.
M. Anderson performed clonogenic survival assays in p53 isogenic HCT116 cells exposed to
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pemetrexed and thymidine for 24 hours, and did not see any toxicity in the absence of p53. In
both genetic backgrounds, the secondary effect was antiproliferative. We do not understand why
the cellular effects of AMPK activation in the absence of p53 reported by Jones et al are not
recapitulated with pemetrexed and thymidine treatment.
An important (but overlooked) result presented by Jones et al showed that expression of
the p53 target gene, p21, was not stimulated in response to AMPK activation (209). Binding of
two moles of p21 to G1/S-specific cyclin/cyclin-dependent kinase complexes inhibits their
activity, and thus prevents traverse through this cell cycle checkpoint. The observation that p21
expression was not induced following pemetrexed-mediated stabilization of p53 was also made
by C.L. Heyer in our lab, suggesting that p53 is not directed to the p21 promoter following
AMPK activation. If the G1/S arrest induced by pemetrexed requires p53, it will be important to
understand how p53 induces this arrest independent of p21 induction. Other p53 target genes,
that interact with cyclin/cyclin-dependent kinase complexes, such as GADD45, have been shown
to be upregulated in response to DNA damage-induced p53 stabilization, and would be
candidates to begin elucidating this mechanism (358).
AMPK activation was also shown to correlate with stabilization of p53 and
phosphorylation of S15, a mark thought to stabilize p53 by disrupting the interaction with
Mdm2, and prime p53 for further posttranslational modifications that influence its activity (341,
342). The sequence surrounding S15 of human p53 is similar to the sequence surrounding S79
of human ACC, and AMPKα1 immunoprecipitated from glucose-deprived cells were able to
phosphorylate a GST-p53 fusion protein containing the N-terminal sequence (residues 1-98) of
p53 (209, 343). Of significance, mTORC1 activates a S15 phosphatase (359), suggesting an
AMPK-mTORC1 feedback loop to regulate this important posttranslational modification.
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Additionally, the p53 target genes, Sestrin 1 and 2, have been shown to stimulate AMPK activity
(360). This may serve as a positive feedback loop to keep p53 stabilized, since AMPK activation
by Sestrins would promote p53 S15 phosphorylation both directly as well as through inhibition
of mTORC1 signaling. If Sestrin gene expression is induced following pemetrexed treatment,
this would amplify the AMPK-activating effect, and would define an important role of p53 in the
therapeutics of AICART inhibitors. The complex regulation of p53 in response to AMPK
activation thus illustrates the importance of elucidating how p53 influences the therapeutic
response to this new class of AMPK-activating agents.
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CHAPTER 5
PERSPECTIVES

The clinical response of MPM and NSCLC to pemetrexed, atypical for a thymidylate
synthase inhibitor, suggested that secondary effects of the drug were of significant therapeutic
importance. In this dissertation, a novel mechanism of pemetrexed action was discovered,
stemming from inhibition of AICART, the second folate-dependent enzyme of de novo purine
synthesis.

The metabolic block imposed by AICART inhibition resulted in the intracellular

accumulation of the reaction substrate and AMP-mimetic, ZMP. Consequently, we identified
pemetrexed to be a potent activator of AMPK, central to the regulation of cellular energy
homeostasis. The molecular and therapeutic consequences of AICART inhibition and AMPK
activation by pemetrexed were studied, with particular focus on perturbation of the PI3K-AKTmTOR signaling cascade. Mutations in key regulators of this pathway promote hyperactive
signaling in the absence of growth stimuli, uncoupling nutrient supply from the demands of
proliferation and survival. AMPK negatively regulates PI3K-AKT-mTOR signaling through
several mechanisms, and thus represents a promising cancer therapeutic target to regain control
over hyperactivity along this signaling axis. These studies suggest that the therapeutics of
antifolates extend beyond classical effects of folate-dependent target inhibition, and raise several
questions of considerable importance whose answers will likely influence the development of
next-generation antifolates as molecularly-targeted agents.
Are the secondary effects of pemetrexed demonstrated in cell culture relevant in the
clinical setting? Our hypothesis suggests that the efficacy of pemetrexed in MPM and NSCLC
is a result of the AMPK-activating effects of the drug. The implications of AMPK activation by
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pemetrexed in humans are of significant importance for the implementation of rational
combination therapeutic strategies, biomarker screening for clinical responsiveness, as well as
for the development of next-generation antifolates targeting AICART. Therefore, it is essential
to quickly determine whether this effect of pemetrexed is clinically relevant. To determine
whether pemetrexed inhibits AICART in vivo, a non-invasive and fairly straightforward
approach would be HPLC or liquid chromatography-mass spectrometry (LCMS) analysis of
human blood and urine for ZMP and the membrane-permeable metabolites, AICAR and AICA.
Protocols for extraction and quantification of these metabolites from bodily fluids are well
established, and importantly, basal levels are often undetectable (129, 149). The concentrations
of pemetrexed that cause ZMP accumulation in cell culture (0.03-1 µM) (Fig 16, 21) are
maintained in the serum of patients for more than 48 hours (144), and the cellular effects of
pemetrexed on AMPK signaling arise within the first 15 hours of exposure (Fig 42). This would
suggest sampling blood or urine 24 hours following drug dosing as an optimal starting point for
analysis. Additionally, exposure as a single agent, either in the maintenance or second-line
setting, would be most favorable to avoid potential complications in interpretation from exposure
to pemetrexed in combination with platinums.
Does targeted AICART inhibition/AMPK-activation represent an efficacious cancer
therapeutic strategy, and could it fit into rational combination therapeutics regimens targeting
PI3K-AKT-mTOR signaling? With the far-reaching effects of AMPK on processes essential to
cellular proliferation and survival, therapeutic activation of AMPK represents a promising cancer
therapeutic strategy.

However, the observation that AICART inhibition by pemetrexed is

cytostatic, not cytotoxic suggests that the answer to this question is not as straightforward as one
might think. Will all AICART inhibitors be cytostatic? Would permanently preventing the
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outgrowth of a tumor rather than eradicating it be an acceptable and effective outcome of cancer
therapy? The discovery and study of novel AICART inhibitors will help answer some of these
important questions. Indeed, clonogenic survival assays with LCA, whose primary target is
likely AICART, suggest that not all AICART inhibitors are cytostatic (Figure 4-5). While LCA
likely has a weak TS effect, in the presence and absence of TdR, the antifolate is an impressive
inhibitor of clonogenic survival compared to pemetrexed with TdR (Figure 4-1 and 4-2).
Interestingly, while the cytotoxicity of pemetrexed requires both the apoptotic thymidylate
synthase effect and the autophagic AICART effect, our clonogenic survival data suggests this is
not the case with LCA. This may be due to differential potencies of pemetrexed and LCA as
AICART inhibitors, or LCA may have other TS-independent targets. A more detailed analysis
of the interplay between these two modes of programmed cell death in response to pemetrexed is
warranted, and will ultimately be necessary to fully exploit the AICART effect.
The susceptibility of mTORC1 inhibition by pemetrexed to feedback activation of AKT
would suggest combining AICART inhibitors with direct or indirect inhibitors of PI3K, AKT,
mTORC2, or PDK1 to enhance the effect of AICART inhibition. Indeed, combination strategies
to diffuse negative feedback effects are already being implemented with the development of dual
inhibitors of mTORC1/mTORC2, S6K1/AKT, and mTORC1/PI3K (361).

That caloric

restriction and exercise, both implicated in reducing cancer risk, are physiological activators of
AMPK, suggests that low doses of AMPK-activating agents combined with an exercise regimen
and a controlled diet may be synergistic in the treatment of cancer. Indeed, dose-dependent
caloric restriction in mice has shown AMPK activation and mTORC1 inhibition (362), and mice
fed high fat diets had decreased AMPK activity and increased mTORC1 signaling (363).

212

Can the utility of AICART inhibitors/AMPK-activating agents be extended to other
diseases and conditions? That AMPK-activating agents have diverse cellular metabolic effects
suggests that AICART inhibitors could be developed as therapeutics for conditions extending
beyond cancer.

One obvious utility would be for the management of Tuberous Sclerosis

Complex. Phase II clinical studies with rapamycin analogs as single agents have shown a
remarkable response in the regression of hamartomas in TSC patients (364, 365). However, the
short half-life of rapamycin requires daily dosing, and the condition progressed quickly
following termination of treatment (364). Antifolates have favorable kinetic profiles in terms of
transport and polyglutamation, trapping and enhancing the target potency of these compounds.
For this reason, pemetrexed is given once every 21 days, and although the parent drug is cleared
from systemic circulation fairly rapidly, metabolites are retained intracellularly for extended
periods of time (56). Additionally, our data suggests that pemetrexed may be effective in
treating Peutz-Jeghers syndrome, as pemetrexed was able to activate AMPK and elicit inhibitory
effects on mTORC1 in the absence of LKB1.

This is supported by studies showing that

rapamycin was efficacious in treating a mouse model of Peutz-Jeghers syndrome, in which a
single allele of LKB1 was knocked out (366). The effects of AMPK on the promotion of
carbohydrate metabolism and inhibition of lipid synthesis are well documented as well. This
would suggest that AICART inhibitors should be tested for their anti-diabetic and
cholesterol/fatty acid-lowering effects. Interestingly, metformin use correlates with a decreased
incidence of cancer (277, 278), suggesting that AICART inhibitors may have a similar
therapeutic profile.
Do tumor genetics predict sensitivity to AICART inhibitors/AMPK-activating agents? It
is often stated in the mTOR signaling field that tumors harboring mutations that drive mTORC1
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signaling are hypersensitive to rapamycin, as they rely more heavily on mTORC1 signaling for
growth and proliferation (219). This hypothesis is indeed supported by mouse models with
PTEN, TSC, and AKT mutations, which all respond strongly to rapamycin. Patient sensitivity to
AMPK-activating agents might similarly be predicted based on an individual’s mutation profile
along the PI3K-AKT-mTOR signaling axis. In our limited screen of carcinoma cell lines, the
most sensitive cell types were those with hyperactive mutations in PI3K and KRAS. A more
extensive study of genetic predictors of AMPK-sensitivity is warranted to determine whether
specific mutations correlate with tumor sensitivity. Our screen also demonstrated that additional
markers of sensitivity to AMPK-activating agents beyond mTORC1 signaling are of interest, as
there was no correlation between sensitivity to pemetrexed and rapamycin.

This suggests

additional benefits of AMPK activation that extend beyond mTORC1 signaling. Analysis of
signaling events mediated by AMPK to mTORC1-independent metabolic processes in response
to AICART inhibitors is essential to the future development of this class of AMPK-activating
agents, and will likely uncover more sensitive biomarkers to predict responsiveness to these
agents.
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